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Thesis Summary 
Cationic liposomes have been extensively explored for their efficacy in delivering 
nucleic acids, by offering the ability to protect plasmid DNA against degradation, 
promote gene expression and, in the case of DNA vaccines, induce both humoural and 
cellular immune responses. DNA vaccines may also offer advantages in terms of safety, 
but they are less effective and need an adjuvant to enhance their immunogenicity. 
Therefore, cationic liposomes can be utilised as delivery systems and/or adjuvants for 
DNA vaccines to stimulate stronger immune responses. 
To explore the role of liposomal systems within plasmid DNA delivery, parameters such 
as the effect of lipid composition, method of liposome preparation and presence of 
electrolytes in the formulation were investigated in characterisation studies, in vitro 
transfection studies and in vivo biodistribution and immunisation studies. Liposomes 
composed of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine  (DOPE) in combination 
with 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or 1,2-stearoyl-3-
trimethylammonium-propane (DSTAP) were prepared by the lipid hydration method 
and hydrated in aqueous media with or without presence of electrolytes. Whilst the in 
vitro transfection efficiency of all liposomes resulted to be higher than Lipofectin, 
DSTAP-based liposomes showed significantly higher transfection efficiency than 
DOTAP-based formulations. Furthermore, upon intramuscular injection of liposomal 
DNA vaccines, DSTAP-based liposomes showed a significantly stronger depot effect at 
the injection site. This could explain the result of heterologous immunisation studies, 
which revealed DSTAP-based liposomal vaccines induce stronger immune responses 
compared to DOTAP-based formulations. Previous studies have shown that having 
more liposomally associated antigen at the injection site would lead to more drainage of 
them into the local lymph nodes. Consequently, this would lead to more antigens being 
presented to antigen presenting cells, which are circulating in lymph nodes, and this 
would initiate a stronger immune response. Finally, in a comparative study, liposomes 
composed of dimethyldioctadecylammonium bromide (DDA) in combination with 
DOPE or immunostimulatory molecule of trehalose 6,6-dibehenate (TDB) were 
prepared and investigated in vitro and in vivo. Results showed that although DDA:TDB 
is not able to transfect the cells efficiently in vitro, this formulation induces stronger 
immunity compared to DDA:DOPE due to the immunostimulatory effects of TDB.  
This study demonstrated, while the presence of electrolytes did not improve immune 
responses, small unilamellar vesicle (SUV) liposomes induced stronger humoural 
immune responses compared to dehydration rehydration vesicle (DRV) liposomes. 
Moreover, lipid composition was shown to play a key role in in vitro and in vivo 
behaviour of the formulations, as saturated cationic lipids provided stronger immune 
responses compared to unsaturated lipids. Finally, heterologous prime/boost 
immunisation promoted significantly stronger immune responses compared to 
homologous vaccination of DNA vaccines, however, a single immunisation of subunit 
vaccine provoked comparable levels of immune response to the heterologous regimen, 
suggesting more immune efficiency for subunit vaccines compared to DNA vaccines.  
Keywords: lipoplex, gene delivery, transfection, depot effect, heterologous regimen 
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1.1.Vaccines 
The World Health Organisation have noted that the two public health interventions that 
have the greatest impact on the World’s health are clean water and vaccines (Andre et 
al., 2008). The aim of a vaccine is to exploit the natural defence mechanisms of a body’s 
immune system to promote long term immunological protection against establishment 
of an infection. Vaccines can be prepared in a range of formats, including live attenuated 
forms of a virus (e.g. rubella or measles vaccine) or live attenuated bacteria (e.g. BCG 
vaccine). Alternatively, inactivated preparations of the virus or bacteria can be used (e.g. 
influenza vaccine). A third class of vaccines includes those prepared from extracts of 
pathogens or detoxified exotoxins (e.g. Tenanus toxoid vaccine). 
1.1.1. Historic evolution of vaccines 
The impact of vaccination is most clearly demonstrated in the eradication of Smallpox, 
thanks to the development of a vaccine based on the early work of Edward Jenner 
(Jenner, 1798). The earliest evidence of smallpox has been found on the mummified 
body of Pharaoh Ramses V of Egypt, who died over 3000 years ago (Hopkins, 1980; Li 
et al., 2007). Medical writings from ancient India (1500 B.C.) and China (1122 B.C.) (Li 
et al., 2007) show the presence of smallpox in that region. Rhazes, a Persian physician, 
was the first to publish a written account attempting to distinguish the measles from 
smallpox in “fi al-Judari wa al-Hasbah” (“A Treatise on the Smallpox and Measles”) in 
9th century A.D. (Cohen, 2008; Otri et al., 2008; Rhazes, 910). Smallpox was described 
as an acute infectious disease with a mortality rate of at least 30 % (Stewart and Devlin, 
2006). Recovery was seen to be accompanied with long-life immunity against the 
disease (Li et al., 2007).  It has been reported that a procedure called inoculation (also 
known as variolation) was possibly first performed by Asians to prevent smallpox. This 
technique involved nasal administration of dried powders of smallpox scabs or 
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scratching the recovered materials from smallpox lesions into the skin of a non-infected 
patient (Hilleman, 2000; Maurer et al., 2003). This method decreased the rate of 
smallpox infection, but still was a threat, as the virus could become active despite being 
in these dried formats and cause smallpox infection (Stewart and Devlin, 2006).  
Inoculation was introduced to UK in 1721, and its successful treatment led to an 
extensive acceptance across the Europe and USA (Riedel, 2005; Stewart and Devlin, 
2006). This method was introduced to Edward Jenner who was born in Gloucestershire, 
England in 1749, as he was inoculated in his childhood (Stewart and Devlin, 2006). As 
a practitioner, he used the same method for his patients. He was also aware of the fact 
that milkmaids who caught cowpox from their cows were protected against smallpox. 
Therefore, in 1796, he inoculated his gardener’s son James Phipps with cowpox from a 
local milkmaid and afterwards exposed James to smallpox. Successfully, James showed 
immunity against smallpox (Hilleman, 2000; Jenner, 1798; Riedel, 2005) and this was 
start of vaccinology and immunology. The term vaccine was derived from use of the 
term “cowpox” (Latin “variolæ vaccinæ”, adapted from the Latin “vaccïne-us, from 
“vacca” cow). 
It took 80 years for another vaccine to be discovered. In 1885 Louis Pasteur introduced 
rabies vaccine, which was the first live attenuated vaccine (Nicolle, 1961; Pearce, 2002). 
Moreover, the nineteenth century had other fundamental events regarding immunology, 
such as proving of the germ theory of disease, commencing of the sciences of 
microbiology and immunology, discovery of large numbers of bacteria due to the great 
work of Koch and his colleagues, and by the end of the century viruses were discovered 
as a new class of microbes (Artenstein, 2009; Hilleman, 1998, 1999, 2000; Plotkin, 
2005). The understanding and knowledge of such systems continued to the 20th century, 
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with the discovery of more vaccines such as toxoid, cholera, typhoid, tuberculosis, 
plague, yellow fever, influenza, polio and many more bacterial and viral vaccines 
(Hilleman, 2000; Norrby, 2007). Besides discovery of the vaccines, understanding of the 
role of antibodies in immune responses, concepts of humoural and cellular immune 
systems and different vaccinations have increased (Hilleman, 2000; Plotkin, 2005).  
However, despite huge improvements in vaccinology in the last century, there remains 
the urgent need for new vaccines to be developed for both existing uncontrolled diseases 
(e.g. HIV, TB and malaria) and new diseases like tumour associated diseases. To 
achieve this goal, large amounts of research is in progress across the globe and World 
Health Organisation (WHO) have encouraged governments to invest more in vaccine 
technology (Taylor et al., 2009). 
1.1.2. Overview of immunological concepts 
The immune system is responsible for protecting the host from pathogens, including 
external microbes and viruses or autoimmune syndrome and mutation. To do so, the 
immune system, which is composed of biological structures and processes, should be 
activated at the right time and respond effectively (Schijns, 2000). To achieve this, the 
immune system is divided into innate and adaptive (acquired) systems, although there 
are many crossover reactions between the two systems. 
1.1.2.1. Innate immune system 
The innate immune system is described as the first line of immune defence against the 
pathogen. The response of the innate immune system is non-specific and rapid, and its 
duration of action is short, therefore the host will not be protected (immunised) against 
future infection with the same pathogen (Medzhitov, 2007; Storni et al., 2005). In 
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addition, failure of this system can lead to the development of autoimmune diseases 
(Rifkin et al., 2005). This response includes mechanisms such as fever, mucosal 
secretions, chemical mediators and phagocytic cells. The innate immune system senses 
the pathogen through receptors called pattern recognition receptors (PRRs). The targets 
of PRRs are named pathogen-associated molecular patterns (PAMPs) (Hashimoto et al., 
1988), particularly when there are bacterial or fungal PAMPS. For viral pathogens 
instead, the main target of PRRs are viral nucleic acids, because all viral components 
are developed within host cells. In the presence of pathogens, the macrophages and 
dendritic cells (DCs) are responsible for eliminate of the intruders by phagocytosis. This 
is followed by antigen presentation, which triggers the adaptive immune system. The 
pathogen or antigen uptake has three main pathways: initially, antigen presenting cells 
(APCs) submerge the microorganisms, then phagocytes recognise the pathogen surface 
for the PRRs and finally phagocytic cells take up the soluble substances by 
macropinocytosis (Sallusto et al., 1995).  
There are different classes of PRRs and the best characterised class is called Toll-like 
receptors (TLRs). They are known to evoke inflammatory and antimicrobial responses 
(Medzhitov, 2007) and their stimulation results the production of important mediators 
of innate immunity such as IL-6, IL-12, IL-18 and IFN-α and IFN-γ. It is also reported 
that TLRs signal through two main intracellular pathways, including MyD88-dependant 
(TLRs 2,4,5 and 9) and MyD88-independent (TLRs 3 and 4). It is shown that signalling 
via both pathways has a synergistic impact on their ability to produce pro-inflammatory 
cytokines in mice (Kawai et al., 1999; Milicic et al., 2012). Based on their cellular 
localisation, TLRs can be divided into plasma membrane (TLRs 1, 2, 4, 5 and 6) and 
intracellular counterparts (TLRs 3, 7, 8 and 9) (Milicic et al., 2012; O'Hagan and De 
Gregorio, 2009).  
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1.1.2.2. Adaptive immune system 
In contrast to the innate immune system, the adaptive (acquired) immune system is 
specific with long-term effect, however, it does not respond quickly. This system is 
mediated by two types of antigen receptors, called T-cell and B-cell receptors. Two types 
of lymphocytes that express antigen receptors are conventional and innate-like 
lymphocytes. Conventional lymphocytes include conventional T cells and B cells. 
Innate like lymphocytes on the other hand consist of B1 cells, marginal zone B cells, 
natural-killer T cells and subsets of γδ T cells. Being taken up by APCs, antigens are 
delivered to the lymph nodes or spleen, so they will be recognised by conventional 
lymphocytes, which circulate through the lymph nodes (Bendelac et al., 2001; 
Medzhitov, 2007). 
Conventional T cells have two types: T-helper (Th) cells and cytotoxic T cells. The 
former cells are marked by the co-receptor CD4+ on the cell surface and the latter ones 
express CD8+. In fact, recognition of the antigen in association with major 
histocompatibility complex (MHC) II molecules can lead to activation of CD4+ T cells 
and differentiation to Th1 and Th2 (Pierre et al., 1997; Seder and Hill, 2000). CD8+ 
cells, in contrast are activated by MHC I molecules. A group of TLRs, which is located 
in intracellular counterparts (TLRs 3, 7, 8 and 9) can enhance antigen presentation rate 
by DCs and through the MHC I pathway. This process results in the increase of CD8+ T 
cell responses (Edwards et al., 2002; Schubert et al., 2000; Seder and Hill, 2000). 
Conventional B cells can recognise any antigen by binding to the epitopes (a specific 
three-dimensional molecular determinant). However, the innate-like B cells (B1 cells) 
emerge in peripheral cavities and produce IgM antibodies against bacterial pathogens. 
More differentiation of B cells to naïve B cells leads to expression of IgD. Naïve B cells 
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circulate in lymph nodes, spleen and mucosa-associated lymphoid tissues (MALT) to 
encounter possible antigens (Bendelac et al., 2001; Medzhitov, 2007; Storni et al., 2005). 
When a microbial antigen such as lipids, glycolipids and formylpeptides are presented 
by non-classical MHC molecules, innate-like T cells are responsible for their recognition 
and this would be enough to signal the presence of infection (Janeway et al., 1988). 
1.1.2.3. Innate control of adaptive immune responses  
It was discussed that some PRRs such as TLRs are responsible for the induction of 
adaptive immune responses by specialised signals for conventional lymphocytes. 
Therefore, an association between the antigens recognised by lymphocytes and the 
PAMPs recognised by TLRs is the basic principle of innate control of adaptive 
immunity (Janeway, 1989).  
This process for T cells is initiated by DCs recognising the pathogen. The DCs then take 
up the pathogen by phagocytosis and antigenic peptides of pathogens are presented by 
MHC I or II molecules at the DC cell surface (Blander and Medzhitov, 2006). DCs also 
become activated by TLRs, so they produce cytokines and express cell-surface signals. 
DCs migrate to lymph nodes and present the antigen and cytokines to the T cells, which 
leads to the activation of T cells and differentiation of them to Th1 and Th2 by 
interference of CD4+ (Banchereau and Steinman, 1998; Seder and Hill, 2000). For B 
cells, co-engagement of B cell receptor and a TLR can establish a direct association 
between the antigen and a PAMP (Medzhitov, 2007).  
T cells can differentiate into different subsets, including Th1, Th2 and Th17 cells 
(Reinhardt et al., 2006). Th1 cells produce IFN-γ and also induce B cells to produce 
antibodies of the IgG2 subclass (Medzhitov, 2007; Seder and Hill, 2000). Th1 cells 
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represent a class of immune responses called cell mediated or cellular immune 
responses. Th2 responses can produce IL-4, IL-5 and IL-13. IL-4 is also involved in 
production of antibodies of the IgE subclass from B cells (Nelms et al., 1999; Stetson et 
al., 2004). Th2 cells represent humoural immune responses. Th17 cells produce IL-17, 
which induces haematopoietic cell types and is involved in protection against bacteria 
and fungi (LeibundGut-Landmann et al., 2007; Weaver et al., 2007). Differentiation of 
T cells is mostly due to the production of cytokines by antigen presenting cells in 
response to the TLR activation, so the whole process is controlled and initiated by the 
innate immune system. It has been reported that TLR activity induces IL-12 production; 
this causes differentiation of Th1 cells from Th cells. In addition, IL-6 can induce a 
TLR, as part of a differentiation process of Th cells to Th17. A similar route is 
predictable for Th2 cell generation (Medzhitov, 2007; Seder and Hill, 2000; Stetson et 
al., 2004). Since MHC class II molecules are responsible for CD4+ T cells activity, CD8+ 
T cells are induced by MHC class I molecules. CD8+ T cells are responsible for 
production of cytokines such as IFN-γ and tumour necrosis factor (TNF-α) (Seder and 
Hill, 2000). Interestingly, it has been shown that innate immunity induces the activity of 
adaptive immunity and the latter has impact on performance of the former (Banchereau 
and Steinman, 1998; Medzhitov, 2007). TLRs from the innate immune system activate 
the adaptive immunity and induce production of T cells, thus T cells produce 
appropriate cytokine which activates a particular route of the innate immune system. 
For example, Th1 and Th2 cells activate macrophages and eosinophils, respectively 
(Reinhardt et al., 2006). 
1.1.2.4. Immunisation  
The main purpose of vaccination is to protect the patient from the recurrence of the 
infection in future exposures of the host cells and the pathogens. This has been called 
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immunisation and is provided through immunological memory, which is the specific 
consequence of the adaptive immune system. Immunological memory is the ability of 
the immune system to respond more effectively to pathogens that have been exposed 
before, and using memory B cells and T cells, it induces a strong response against the 
pathogen (Storni et al., 2005). When the immune system successfully removes the 
antigens from the system, it enters the phase of memory development (Zinkernagel, 
2002). 
Differentiation of naïve B lymphocytes into the memory B lymphocytes is triggered by 
CD4+ Th cells through CD40 ligation. This process starts at the final phase of primary 
immune response and takes place in germinal centres, where the naïve B cells 
experience clonal expansion, somatic hypermutation, affinity maturation and possibly 
isotype switch during the adaptive immune response. B cells that survive and did not 
differentiate to plasma cells, change to memory B cells (Arpin et al., 1997; Gray et al., 
1994a; Gray et al., 1994b).  
The mechanism of generation of memory T cells has not been completely understood, 
although, it has been described that upon exposure of the antigen to naïve T cells in 
lymph node and spleen, T cells become activated and divided. T cell expansion 
proceeds over the course of a week and leads to a remarkable increase in the number of 
antigen reactive T cells and, after reaching to the optimum level, this falls back to a level 
which is notably higher than initial levels (100 to 1000 fold higher). T cells are now 
called memory T cells and have two subsets: central memory T cells and effector 
memory T cells (Sallusto et al., 1999). Central memory T cells express CCR7 for 
recirculation through secondary lymphoid tissues such as splenic T zone, lymph nodes 
and peyer’s patch (Moser, 2003). These central memory T cells are long-lived in the 
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absence of antigen and are able to face systemic pathogenic infections. In contrast, 
effector memory T cells are dependant of antigen presentation and they are short-lived 
(Opferman et al., 1999). This process is stimulated by production of cytokines and 
interaction of accessory molecules on the APC (Garside et al., 1998; McCullough and 
Summerfield, 2005; Sallusto et al., 1999).  
In summary, upon encounter of antigen to the host cell, the innate immune system 
reacts to the antigen and triggers the adaptive immune system. This activates different 
signalling cascades leading to activation of effector T cells and finally removal of the 
antigens. In the last phase of defensive reactions against antigen, memory B and T cells 
will be generated and circulate in the lymphatic system to protect the body from 
secondary infection. At this stage, the body is immunised from the infection by 
microorganism and this type of immunity is called active immunity. Vaccination 
technology can provide this immunity using killed or attenuated live microorganisms, or 
its subunits thereof, to trigger the immune system and provide long time immunity. A 
key consideration on all this is that upon secondary and subsequent responses of 
immune system, responses are only mediated by memory cells and not by naïve cells, so 
the ability of the vaccine to promote memory responses should be at the centre of 
attention in designing a vaccine. 
1.1.3. Types of vaccines 
As mentioned traditional vaccines are categorised into three main groups: live 
attenuated vaccines, inactivated vaccines and subunit vaccines. However, there are 
more types of vaccines such as peptide vaccines and DNA vaccines.  
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Attenuated vaccines are produced via the induction of physical or chemical changes to 
the microorganism so that its pathogenic effect weakens and, as a result, will be safe for 
the vaccine recipient (Perrie, 2006). These microorganisms are able to infect target cells 
but the infection is mild and the replication of the microorganisms is limited. These 
vaccine are able to stimulate both humoural and cell mediated immune responses; 
however, because of the risk of reversion to a more pathogenic state, this type of 
vaccines cannot be considered for use in immunosuppressed patients (Chambers et al., 
2004; Perrie, 2006). Some important vaccines of this group are polio, Bacillus Calmette-
Guerin (BCG), measles, mumps, rubella combination vaccine (MMR) and influenza 
virus vaccine (Arvin and Greenberg, 2006; Harper et al., 2003; Nichol et al., 1999; 
Wareing and Tannock, 2001).  
Inactivated or killed vaccines contain microorganisms, which have been inactivated by 
heat or chemicals and are unable to replicate or produce toxins, so while these vaccines 
are not infectious they can retain their immunogenicity (Perrie, 2006). The main 
advantage of this group of vaccines is their safety. However, these vaccines are less 
effective than live attenuated vaccines and they fail to produce cellular immune 
responses (Black et al., 2010; Mackett and Williamson, 1995). Examples of vaccines 
from this group are cholera, hepatitis A and polio vaccines (Fiore et al., 2006; Perrie, 
2006). 
Subunit vaccines consist of small parts of the organism such as cellular extracts, parts of 
cells, a surface antigens that are highly purified and reproducible (Perrie, 2006). They 
induce strong immune responses and are not able to revert to the infectious format. 
Important developed vaccines of this group are influenza and Hepatitis B virus vaccines 
(Mischler and Metcalfe, 2002; Perrie et al., 2008). DNA recombinant technology 
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facilitated the production of subunit vaccines. For instance, hepatitis B vaccine is now 
manufactured using biotechnology as it cloned in yeast; however, in the past it used to 
be purified from the blood of hepatitis B carrier patients (Edlich et al., 2003; Perrie, 
2006). Although subunit vaccines have less adverse effects compared to live attenuated 
and inactivated vaccines, they are less immunogenic and require adjuvants to promote 
the immune response to the antigen. In addition, since the duration of immune response 
initiated by subunit vaccines is short, several boosts are needed to achieve the protection 
(Bramwell and Perrie, 2005b; Perrie, 2006; Perrie et al., 2008).  
There are some microorganisms that produce toxins to cause the disease. Inactivated 
forms of toxins are called toxoids, which can also be used in vaccines. The most 
common toxoids are tetanus and diphtheria vaccines. Whilst used as a vaccine in their 
own right, toxoids can also be used to increase immunogenicity of the other vaccines; 
for example Haemophilus influenza type b (Hib) vaccine contains polysaccharide unit 
from the bacterium conjugated to diphtheria or tetanus toxoid (Perrie, 2006). 
1.1.4. Challenges in using traditional vaccines 
Since their invention, vaccines have been among the most attractive and successful ways 
of prevention of infectious disease and cancers. They have eradicated many pathogens 
all over the world such as smallpox, tetanus, diphtheria and measles (Gregoriadis, 1998; 
Perrie et al., 2007). However, there are still some untreated viruses such as human 
immune deficiency virus (HIV), herpes simplex virus (HSV), and influenza virus or 
recurred diseases such as tuberculosis (TB), which traditional vaccines have yet to 
eradicate. (Andersen, 2007; Fairman et al., 2009; Hong et al., 2010; Tirabassi et al., 
2011; Toda et al., 1997). Furthermore, there is a large amount of research currently in 
progress on discovering vaccines to have a therapeutic or prophylactic effect on cancers 
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or autoimmune diseases, which need a new generation of vaccines. So far, only two 
prophylactic cancer vaccines have been approved by FDA which are hepapitis B (HB) 
vaccine and Gardsil™	  that	  prevent	   the	   infection	  with	  HBV	  and	  human	  papillomavirus	  (HPV)	  respectively	  (Giarelli,	  2007).	  These	  viruses	  are	  believed	  to	  be	  the	  leading	  causes	  of	   liver	   cancer	  and	  cervical	   cancer	   respectively	   (Hamdy	  et	   al.,	   2011).	  Cancer vaccine-
based immunotherapy is shown as a novel therapeutic strategy for cancer treatment. A 
recent study (Wang et al., 2012a) demonstrated that use of TLR 3 agonists as an 
adjuvant in combination with cationic liposomes such as DOTAP could enhance 
vaccine-induced tumour-specific cytotoxic T lymphocyte (CTL) response and IFN-γ 
production. Particulate vaccine delivery systems have been shown to be effective for 
therapeutic cancer vaccination, as they are capable of stimulating CD8+ T cell 
immunity, which enhances the activation of cytotoxic lymphocytes that can kill cancer 
cells (Foged et al., 2012).  
Concerns about safety of vaccines and their adverse effects give some challenges for 
traditional vaccines. This becomes a more problematic issue in a developed 
environment where disease incidence is much less than a developing or undeveloped 
society. For instance, concerns over the safety of the MMR vaccine has led to a 10% 
reduction in vaccine uptake across the UK and 20% just in London (Fitzpatrick, 2004; 
Perrie, 2006). Whilst uptake is now improving, as the HSCIC’s NHS Immunisation 
Statistics England, 2011-12 has reported, MMR vaccine uptake is still below the 
required 95% as it has reached to 91.2% in 2011-12 (HSCIC, 2012). Most of the licensed 
vaccines, whether live attenuated or inactivated, have shown rare but serious adverse 
effects. These adverse responses include headache, nausea, encephalitis, neurological 
reactions and even death (Bramwell and Perrie, 2005a; Huang et al., 2004). Based on 
this, and as a part of Immunisation Safety Priority Project (ISPP) launched in 1999 by 
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WHO (Duclos and Hofmann, 2001), the main focus of vaccine research is in the 
development of a new generation of vaccines using highly purified proteins or synthetic 
peptides. However, to have a highly potent and immunogenic vaccine, these antigens 
should be delivered along with adjuvants (Chen et al., 2002; Kenney and Edelman, 
2003; Moser et al., 2003). 
Given the fact that licenced adjuvants such as Alum and squalene-oil-water emulsion 
(MF59) are not suitable for the new generation of vaccines as they only generate 
humoural immune responses (Holten-Andersen et al., 2004), suggests there remains a 
need to develop new adjuvant systems or delivery vehicles which are focused on subunit 
and DNA vaccines (Gregoriadis, 1998; Henriksen-Lacey et al., 2011c; Perrie et al., 
2007; Perrie et al., 2008).  
1.1.5. DNA vaccines 
The concept of DNA vaccination is based on the fundamental experiment by Wolff et 
al; (1990), which showed that intramuscular inoculation of plasmid DNA (pDNA) 
resulted in expression of its encoded protein. They showed upon direct injection of 
antigen-encoding plasmid DNA and its uptake by cells, the DNA can enter into the 
nucleus and transfect the cell. The expressed antigens trigger the immune system of the 
host, similar to the way that foreign antigens do, so DNA injection can induce 
protective humoural and cell mediated immunity (Gregoriadis, 1998; Tang et al., 1992; 
Ulmer et al., 1993).  
DNA vaccines have several advantages over conventional immunisation. ‘Naked’ DNA 
vaccines are inexpensive and easy to produce, due to one step cloning of target coding 
sequence into plasmid vectors; they are also more temperature stable than live vaccines 
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(Chen and Huang, 2005; Gregoriadis et al., 2002; Li et al., 2012). In addition, 
expression of the antigens inside the live cell gives the advantage of presenting the 
antigens in the same condition as in a viral infection, but without being infectious; so 
antigenic structure includes all the important post-translational modifications that are 
the same as the native protein. Furthermore, DNA vaccines are able to stimulate Th1 
and Th2 CD4+ and CD8+ T cells as well as B cells and induce both humoural and 
cellular immune responses, and were reported to achieve this without use of 
conventional adjuvants (Li et al., 2012; Liu, 2011; Wahren, 1996). Indeed, several 
studies in 1990s showed the promising immunogenic characteristics of naked DNA 
tested on a variety of different animal models of infectious disease, including rabies 
(Lodmell et al., 1998), influenza virus (Ulmer et al., 1993), malaria, (Becker et al., 1998; 
Sedegah et al., 1994), HIV (Donnelly et al., 1997), tuberculosis (Tascon et al., 1996) and 
herpes simplex virus (Manickan et al., 1995).   
Following the encouraging results of DNA vaccines, these formulations have been 
tested in several human clinical trials (Levine, 2010; Liu, 2011; Liu and Ulmer, 2005). 
Overall results showed an acceptable safety but disappointingly low immune response 
for the DNA only vaccines. However, this technology had a successful profile in animal 
vaccination, with four licenced DNA vaccines (Liu, 2011). The latest was Oncept™	  (Merial,	   Lyon,	   France)	   approved in 2010, which was an immunotherapeutic DNA 
vaccine as a therapy for malignant melanoma in dogs (Li et al., 2012; Liu, 2011). 
Despite poor human clinical trial results, considering the successful development of 
DNA vaccines for veterinary use and advantages of this type of vaccine over traditional 
vaccines has led to the development of new strategies for vaccination, such as 
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prime/boost vaccination and enhancing the delivery method of plasmid DNA using 
different kinds of vectors such as viral, bacterial and liposomal systems. 
1.1.6. Delivery of nucleic acids 
Although it has been shown that direct injection of naked DNA allows transgene 
expression in muscle (Vassaux et al., 2006), in most cases naked DNA molecules are 
not able to enter cells efficiently due to their large size, negative charge and the nuclease 
mediated degradation in systemic blood stream (Al-Dosari and Gao, 2009). Therefore, a 
delivery vehicle (vector) is needed to carry the gene into the target cell to save the gene 
from the above dangers. There are two classic categories for gene vectors: biological and 
non-biological systems. As shown in Table 1.1, biological systems or viral vectors are 
viruses or bacteria, which mediate gene transfer (El-Aneed, 2004; Vassaux et al., 2006). 
Non-viral delivery systems include physical and chemical methods (Al-Dosari and Gao, 
2009; Mae et al., 2009) (Table 1.1). 
Viral vectors provide a high efficiency, although, there remains concerns about inducing 
toxicity and immunogenic reactions. In fact, there has been a fatality reported by 
adenoviral vector gene therapy (Marshall, 1999). Therefore, non-viral vectors are under 
more attention to reach the ideal vector (Whitehead et al., 2009), which should have 
stability, high efficiency, minimal toxicity, and unrestricted size limitation for nucleotide 
acid and easy preparation with up -scaling capacity and low cost (Lul and Haung, 
2003). 
Particulate delivery systems are categorised among non-viral gene delivery systems and 
are limited to those delivery systems that use non-living components for the purpose of 
carrier systems (Bramwell and Perrie, 2005a). Particulate delivery systems have been 
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used for delivery of protein and peptide and DNA and mainly for vaccination purposes. 
Several particulate delivery systems have been introduced for DNA delivery, such as 
gold nanoparticles (Fynan et al., 1993), polymers such as poly(lactide-co-glycolide) 
PLGA (Jones et al., 1997) and chitosan (Mumper et al., 1995) and liposomes (Allison 
and Gregoriadis, 1974).  
Table 1.1. Different gene transfer systems (Al-Dosari and Gao, 2009; El-Aneed, 2004; Galanis et al., 2001; 
Mae et al., 2009; Vassaux et al., 2006). 
Biological Gene Transfer 
Systems 
 
Bacterial Vectors Salmonella, E.Coli, Shigella, Yersinia, 
Listeria. 
Viral Vectors 
Retrovirus, Adenovirus, Adeno-
associated Virus, Herpes simplex Virus, 
Epstein-Barr Virus, Poxivirus, 
Newcastle Disease Virus, 
Non-biological Gene 
Transfer Systems 
Physical Methods 
Needle/Jet Injection, Hydrodynamic 
Gene Transfer, Gene Gun, 
Electroporation, Sonoporation. 
Chemical Methods 
Cationic Lipids, Cationic Peptides, 
Cationic Polymers, Cell Penetrating 
Peptides, Inorganic Nanoparticles 
   
 
Liposomes were first identified as being effective immunological adjuvants for 
diphtheria toxoid (DT) by Alison and Gregoriadis (1974) and, since then, liposomes 
have attracted extensive attention as adjuvant systems for DNA and subunit protein 
vaccines (Gregoriadis, 1998). Adjuvants are substances which are able to enhance a 
specific immune response and increase humoural and cell mediated immunity to the 
antigen compared to the free antigen (O'Hagan et al., 2001). Opposite to other 
adjuvants, liposomes are found to be safer with no local or systemic toxicity. Liposomes 
also do not produce allergic reactions or any other side effects (Gregoriadis et al., 1999).  
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1.2. Liposomes  
Liposomes were first described by Bangham et al., 1965 while studying cell membranes. 
They are vesicular structures consisting of hydrated bilayers, which form when lipids 
(generally phospholipids) are dispersed in water (Bangham et al., 1965). In 1970s 
Gregoriadis (1974) proposed a new drug delivery system using liposomes. Subsequently, 
Felgner et al. (1987) demonstrated the use of cationic liposomes to promote gene 
expression in vitro. Since these early studies, numerous investigations have been 
performed in this area, with, for example, Karmali and Chaudhuri (2007) showing 
DNA mediates high levels of transgene expression in vivo after incorporation into 
cationic liposomal systems. A key component of these systems is the cationic lipid and 
several studies have been performed on the effect of cationic lipids on nucleic acid 
delivery, and many achievements have been obtained, such as inn the use of DNA 
vaccines (Perrie et al., 2002), improving in vivo lung transfection efficacy (Majeti et al., 
2004), hepatocyte-selective gene transfection by using galactosylated cationic liposomes 
(Fumoto et al., 2004), and development of folate-conjugated cationic lipid-based 
transfection complexes which cause in vivo transgene expression in mice tumours 
(Hofland et al., 2002). 
1.2.1. Liposome morphology 
Lipids are amphiphilic and have a polar head and a non-polar fatty acid chain. They 
form a closed structure in aqueous media, called liposomes. The polar heads, when 
exposed to the water, form a single layer of lipid, with the non-polar parts form, in the 
second layer of the bilayer structure shielded have the water, that will form liposomes. 
Because of their structure, liposomes can carry both hydrophilic and lipophilic drug 
molecules. Hydrophilic drugs can be localised in the aqueous phase and lipophilic and 
amphiphilic drugs can be included in the lipid bilayers (Muller-Goymann, 2004).  
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Liposomes can be classified by their structural properties. The main types are listed and 
their characteristics are outlined in the Table 1.2 followed by a schematic representation 
in Figure 1.1. 
Table 1.2: Size and number of lipid bilayers of different categories of liposomes. (Rongen et al., 1997) 
 
        Figure 1.1: Schematic representations of five types of liposomes.  
 
1.2.2. Liposome preparation methods 
There are many different methods for the preparation of liposomes, depending on the 
type of vesicle formation (Kirby and Gregoriadis, 1984; Lasch et al., 2003; Rongen et 
al., 1997). 
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1.2.2.1. Hydration method 
In this method, a mixture of lipids are dissolved in an organic solvent such as methanol 
or chloroform. The solvent is then removed by rotary evaporation at reduced pressure. 
The dried film of lipids, which has been deposited onto the wall of a round-bottom flask, 
is hydrated and shaken to give a milky suspension of equilibrated MLV (Kirby and 
Gregoriadis, 1984; Lasch et al., 2003) (Figure1.2). 
 
Figure1.2: Schematic representation of hydration method of liposome preparation 
 
1.2.2.2. Ultrasonication method 
In the ultrasonication method, the aqueous lipid dispersion, which has been prepared 
with hydration method, will be sonicated. Sonication can be performed by bath 
sonication or probe sonication. The resulting liposomes will be SUV. It should be 
considered that in the case of probe sonication, the vial of the sample must be put in ice 
or a water bath to avoid localised overheating (Lasch et al., 2003). However, in the case 
of low Tc lipids, liposome suspensions are more effectively reduced in size when they are 
sonicated at temperatures above Tc. 
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1.2.2.3. Dehydration- rehydration method 
This method begins with SUV mixed with the drug to be entrapped, after which they are 
freeze-dried. Then, the vesicles are rehydrated under controlled conditions and larger 
vesicles are formed, which are DRV and it gives a high encapsulation efficiency of the 
drug (Kirby and Gregoriadis, 1984) (Figure 1.3). 
 
Figure 1.3: Schematic representation of the dehydration-rehydration method. In brief, MLV prepared 
according to the lipid hydration method outlined above was sonicated to produce SUV. These SUV were 
mixed with the antigen, frozen at -70 °C	  and	   freeze-­‐dried	  overnight.	  Controlled	   rehydration	  of	   the	  dried	  powder	  led	  to	  the	  formation	  of	  antigen	  containing	  DRV	  vesicles. 
 
1.2.2.4. Reverse-phase evaporation method 
The procedure starts by adding the drug to the mixture of dissolved lipid in an organic 
solvent. Then an emulsion will be gained by vortexing. Rotary evaporating and 
removing the organic solvent results in formation of a gel and by shaking of the gel or 
continuing the rotary evaporator the gel will change to a dispersion of large liposomes 
which are reverse-phase evaporation vesicles. These liposomes may be LUV or MLV in 
morphologies, depending on the water and organic phase ratio (Lasch et al., 2003; 
Rongen et al., 1997). 
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1.2.2.5. Ether evaporation method 
Ether vaporisation or solvent injection method is another method of liposome 
preparation. In this method, after dissolving lipids in organic solvent, the resulting 
mixture is injected slowly into an aqueous phase. By this method, large unilamellar 
vesicles will be produced with a high entrapment efficiency (Rongen et al., 1997). 
1.2.2.6. Freeze-thaw extrusion method 
This method is based on repeated cycles of quick freezing of liposome dispersion in 
liquid nitrogen and thawing in warm water. The liposome dispersion is first formed by 
the film method. The final vesicles are MVV or LUV with a high entrapment ratio 
(Rongen et al., 1997).  
1.2.2.7. Detergent removal method 
One of the most important methods for detergent depletion is detergent dialyses 
method. In this method, an aqueous solution of drug is added to the mixture of lipids in 
an organic solvent. After forming the film and removal of the organic solvent, a 
detergent is added to solubilise the lipids and this will form a lipid-detergent micelle. 
Subsequent removal of the detergent by dialyses will cause formation of liposomes 
(Rongen et al., 1997). There are other methods of detergent removal instead of dialyses 
such as dilution, gel filtration and adsorption (Lasch et al., 2003). 
1.2.3. Cationic liposomal systems 
Cationic lipids were first introduced for gene therapy by Flegner and his colleagues in 
1987, they used N-(1-[2,3-dioleyloxy]propyl)-N,N,N-trimethylammonium chloride 
(DOTMA) to deliver DNA and RNA into animals and human cell lines (Felgner et al., 
1987). 
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1.2.3.1. Cationic lipid structure 
Cationic lipids are amphiphilic molecules, which are positively charged and have a 
cationic polar head group (e.g. an amine) and a hydrophobic domain (generally alkyl 
chains or cholesterol). A linker connects the polar head group to the non-polar tail. 
There are several cationic lipids that have been used in gene delivery, such as DOTAP, 
DC-Cholesterol, and DSTAP (Lonez et al., 2008). Each of the three domains of a 
cationic lipid plays a role in the quality of gene delivery by affecting the cellular toxicity, 
transfection efficiency and stability of the lipoplex.  
1.2.3.2. DNA liposome complex- lipoplex 
A lipoplex is a complex of a cationic liposome and a polynucleotide like DNA. The 
positive charge of the amine head group of the cationic lipid and negative charge of 
phosphate in nucleic acid cause an interaction between them, thus forming the lipoplex 
(Figure 1.4). At this stage, the cationic lipid wrapped around the nucleic acid and the 
lipoplex will be in its highest stable condition, as all potential interaction sites are 
blocked and the tendency of adjacent complexes to further undergo extensive lipid 
mixing has largely ceased (Wasungu and Hoekstra, 2006). The size of the lipoplex is 
thought to be in a range of 80-400 nm; however, this varies and can depend upon 
cationic lipid/DNA ratio, type of lipids used and method of preparation. 
1.2.3.3. Mechanism of delivery to the cells and transfection 
The aim of liposomal mediated gene transfer is to have the DNA or other 
polynucleotides inside the cell where it should be translated to a protein or peptide. 
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Figure 1.4: Schematic representation of lipoplex formation. 
 
The lipoplex surface has a positive charge and these charges will make an electrostatic 
interaction with negative charges of cell surfaces. This is the first step of the transfection 
process after making the lipoplex. Due to their cationic nature, incubation of lipoplexes 
with cultured cells promotes internalisation of the lipoplexes through the vesicular 
pathway and then the DNA can be released in the cytoplasm. Some fractions of released 
DNA will be trafficked to the cell nucleus, followed by transcription and translation of it 
to the protein (Figure 1.5). Internalisation pathways of lipoplexes are mainly three 
endocytotic routes: 1) clathrin-mediated endocytosis, 2) caveolae-mediated endocytosis, 
3) macropinocytosis. Of these, the most common pathway for lipoplexes is clathrin-
mediated endocytosis, as caveolae is mostly for polyplexes and macropinocytosis is still 
a potential entry, which is poorly characterised (Uyechi-O'Brien and Szoka, 2003; 
Wasungu and Hoekstra, 2006). A crucial point in transfection is DNA escape from the 
endosome, because as much as it stays there, the chance of plasmid degradation 
increases. The ability of lipoplexes to move into hexagonal phase is helpful here. In 
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contrast, adenovirus, which is a well-known vector for gene delivery, solves this 
problem by lysis of the endosomal membrane structure. Lipoplexes do not have such an 
enzyme, but some interactions occur between the inverted hexagonal layer of the 
lipoplex and the endosomal layer of the cell membrane. In fact, there will be a 
competition between the DNA and the negatively charged endosomal membrane lipids 
to interact with the cationic lipids of lipoplexes, thus the DNA will release to the cytosol 
(Xu and Szoka, 1996). DNA entrance to the nucleus relates to the size of DNA and also 
the time of transfection. Some studies show if transfection occurs in S or G2 expression 
will be 30-500 fold more than G1 (Lul and Haung, 2003; McNeil and Perrie, 2006). 
 
Figure 1.5: Proposed mechanisms of cationic lipoplex condensation and uptake. In brief, cationic 
liposomes are attracted by electrostatic interactions to the negative charges of DNA forming a lipoplex. 
Lipoplex binding to the cell surface followed by internalisation and then release of DNA from the lipoplex. 
DNA enters the nucleus and in the nucleus, RNA will be transcribed. 
1.2.3.4. Effect of helper lipid on transfection 
The theory of using helper or co-lipid comes from the origin research of Flegner et al, in 
1987. They demonstrated that the transfection activity of DOTMA when formulated 
with dioleoylphosphatidylethanolamine (DOPE) is more than when it is formulated 
with dioleoylphosphatidylcholine (DOPC). The reason is the effect of DOPE to 
promote the transition from lamellar phase to an inverted hexagonal phase (Uyechi-
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O'Brien and Szoka, 2003). The ability to achieve this is related to the structural 
attributes of the lipids used in lipoplexes. Cationic lipids are amphiphilic molecules and 
geometry of amphihile is an important property, which is related to the lipid application 
as a vector. When cationic lipids suspend in an aqueous phase, they can make different 
structural phases, such as micellar, lamellar and inverted hexagonal phases (Figure 1.6). 
 
 
 
Figure 1.6: Schematic representation of the phase structure of cationic lipids as a function of packing 
parameter (Adapted from Wasungu & Hoekstra, 2006). 
 
A factor known as the critical packing parameter (P) can determine which structure a 
particular cationic lipid will make. A critical packing parameter P= v/alc is defined as 
the ratio of the hydrocarbon volume (v) and the product of effective head-group area (a) 
and the critical length of the lipid tail (lc). In fact, (P) describes the ratio of the area 
occupied by the hydrophobic region versus that of the hydrophilic region. Therefore, 
when P>1 the area occupied by the hydrophobic chain is larger than that of hydrophilic 
head groups and the lipid will adopt the inverted hexagonal (HII) phase (Figure 1.6). 
This structural phase is a bilayer destabilising structure and it is essential for liposomal 
gene delivery to the cytosol (Israelachvili and Mitchell, 1975).  
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Figure 1.7: Cartoons of cationic lipids and helper lipids shown as a micelle, single composition and mixed 
composition liposomes, and in an inverted hexagonal phase. Proposed lipid mixing model of fusion of 
cationic liposome with a target, i.e., endosomal, membrane (Uyechi-O'Brien and Szoka, 2003). 
Helper lipids such as DOPE and cholesterol also promote conversion of the lamellar 
lipoplex phase into a non-lamellar structure. They are fusogenic and have strong 
destabilising effect towards bilayer lipids. These properties are the cause of transfection 
efficiency improvement by helper lipids, Figure 1.7 (Ciani et al., 2004). However, whilst 
this helper effect of DOPE has been shown to be effective in vitro, in vivo studies shows 
cholesterol is better than DOPE due to enhanced stability and transfection (Lul and 
Haung, 2003; McNeil and Perrie, 2006). 
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1.2.3.5. Transition temperature 
The phase transition temperature is described as required temperature to change the 
lipid physical state from gel phase to the liquid phase. In the gel phase, the hydrocarbon 
chains are fully extended and closely packed. However, in the liquid phase the 
hydrocarbon chains are randomly oriented and fluid. Hydrocarbon length, unsaturation, 
charge and head-group species are main factors that affect the phase transition 
temperature (Cevc, 1991; Tristram-Nagle and Nagle, 2004).  
Van der Waals forces are the most important bonds between the hydrocarbon chains 
and they are responsible for the in ordered state of hydrocarbon chains. As the 
hydrocarbon length is increased, van der Waals interactions become stronger, requiring 
more energy to disorder the ordered packing and, consequently, the phase transition 
temperature increases (Cevc, 1991). To form stable liposomes, the formulation should 
be prepared above the transition temperature (Tc) of the lipid.  
1.2.4. Langmuir monolayer studies 
A common idiom, ‘pouring oil on troubled water’, is a figurative way of suggesting that 
attempts are made to calm a contentious or problematic situation. This relates to the fact 
that a thin layer of oil can calm choppy water, a technique referred to as wave damping, 
where sailors poured oil onto the sea to prevent waves being formed. This method was 
first described by Aristotle and Plinius (Fulford, 1968). To achieve this effect, very little 
oil is required; it need only be a surface coating of 1 molecule thick, that is to say a 
monolayer. Marangoni effects are the basis of this wave damping effect produced by oil. 
The Marangoni effect is a phenomenon whereby movement of a liquid occurs due to 
local differences in the surface tension of the liquid (Kuroda et al., 2000). Sudden local 
increases in surface area lead to enhanced surface tension, resulting in a surface tension 
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gradient which, in turn, promotes contraction of that area and thus, further surface area 
growth is prohibited. 
Basically, the Marangoni flow opposes the flow associated with the wave action. 
Benjamin Franklin, having seen this phenomenon of wave calming behind ships on 
which the cooks used sea water to rinse the fat off dishes, undertook to scientifically 
investigate this further (Lyklema, 2000). On a lake near Clapham Common in London, 
Franklin noted that one teaspoon of oil was enough to calm several hundred square 
meters of the lake’s surface, with the wind having a much reduced effect on treated areas 
of the water surface compared to the untreated parts (Franklin et al., 1774). Later, John 
Shields carried out large-scale wave-damping experiments in Scotland and lodged a 
patent based on this in 1879 (Lyklema, 2000). Lord Rayleigh also followed this research 
area, and he noted that water surface tension could be lowered by contamination and oil 
films. Although he had no method of exactly measuring the thickness of the films, he 
estimated them to be monomolecular, with a thickness of 1–2 nm, and noted that by 
using such films, information on the size of molecules was obtainable (long before the 
existence of molecules was generally accepted) (Lyklema, 2000; Rayleigh, 1890, 1899). 
However, the first surface pressure versus area measurements (as they are now referred 
to) were reported by Agnes Pockels (Pockels, 1891) a German Scientist, who made a 
basic surface balance in her kitchen. Using this system, she was able to determine 
surface contamination as a function of the surface area for different oils, and further 
observed that by compressing monolayers below a certain area, the surface tension falls 
rapidly. Pockels methods were further developed by Irvine Langmuir with his film 
balance system, a method that still bears his name. 
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One of the advantages the Langmuir trough offered was that a direct measurement of 
the film pressure could be derived from the deflection of a movable float, separating the 
film from clean water. Using this trough, Langmuir studied monolayer lipids more 
systematically and confirmed that the films are monomolecular. He also showed that 
the molecules in these monolayers are orientated on the aqueous surface, with the 
hydrophilic portion of the surfactants in contact with the liquid, whilst the hydrophobic 
region of the surfactants is pointing up towards the air (Langmuir, 1917; Langmuir, 
1920).  
1.2.4.1. Information gained from monolayer studies 
From Figure 1.8, various phases of the monolayer are shown: as the concentration of 
the molecules at the surface is increased (i.e. the distance between the barriers is 
contracted) the monolayer changes from a very dilute ‘gaseous’ monolayer (G), where 
the molecules are far apart and there is low interfacial pressure, to a ‘liquid’ state. Often 
there are two liquid states: a ‘liquid expanded’ (LE) and a ‘liquid condensed’ (LC) 
monolayer, which are determined by the proximity and orientation of the surfactants 
(Figure 1.8B). Only a small reduction in the area is required to move the monolayer 
from the LC to the ‘solid’ (S) state. In this state, all the amphiphilic molecules are 
closely packed and the hydrophobic tails are aligned in parallel, with the area per 
molecule corresponding with the S-phase which is equal to the closed-packed molecular 
cross-sectional area (Lyklema, 2000). Further compression of the monolayer results in 
the monolayer collapsing (molecules breaking out of the monolayer, by forming 
micelles, or multilayers in the case of phospholipids, for example) which leads to a sharp 
break in the isotherm (Figure 1.8B).  
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Figure. 1.8: (A) Schematic example of isotherm, Π-A exhibiting a variety of phases which can occur. G: 
gaseous, LE: liquid expanded, LC: liquid condensed, and S: solid. Curves like this are typical for lipid 
monolayers. (B) Schematic representation of lipid packaging at the monolayer interface. Figure modified 
from (Lyklema, 2000). 
 
As is shown in Figure 1.8A, the transition between these phases is not always distinct 
and often more than one phase may be present. There is also a question as to the 
orientation of the surfactant tails in the gaseous phase: are they orientated flat on the 
interface (as in Figure 1.8Bi), or are their tails out into the nonaqueous phase (Figure 
1.8Bii and iii). It is thought that situation (ii) maybe entropically more favourable 
(Lyklema, 2000), but the overall molecular shape of the molecules in question would 
need to be considered and often option (iii) is used schematically to represent the 
general concept.  
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1.2.4.2. The use of monolayer studies in liposome research–example applications  
As extensively reported, liposomes are bilayer vesicles, first described by (Bangham et 
al., 1965) whilst studying cell membranes. They are vesicular structures consisting of 
hydrated bilayers, which form when phospholipids are dispersed in water (Bangham et 
al., 1965). Whilst there are very many reported variations on the theme (e.g. niosomes, 
virosomes, bilosomes, etc.), all have the same basic bilayer construction. Since their first 
description as a possible drug delivery system (Gregoriadis and Ryman, 1971), these 
constructs have been extensively investigated and there are now several liposome-based 
products clinically used. Given their structure, it is not surprising that monolayer studies 
of phospholipids and other surfactants are undertaken and the findings extrapolated to 
liposomal bilayers. Indeed, such studies can be highly informative, giving insights into 
areas such as bilayer lipid packaging configuration (Ali et al., 2010; Dynarowicz-Latka 
and Hac-Wydro, 2004), drug–lipid interactions (Ali et al., 2010) and liposome stability 
(Christensen et al., 2008; Demel et al., 1998; Lambruschini et al., 2000). However, since 
they are effectively half a membrane, monolayer studies are less suited to study certain 
aspects, such as trans-membrane processes, and consideration to this overall difference 
in morphology should always be borne in mind. 
1.3. Liposomal vaccines  
As mentioned earlier, liposomes are being used as vaccine adjuvants due to their 
immunogenic properties and their capability to induce both cellular and humoural 
immunity (Gregoriadis et al., 1999). It has been reported that the immunogenicity of 
liposomes originates from the presentation of the liposomes to antigen presenting cells 
(APCs) such as macrophages and dendritic cells (DCs) (Killion and Fidler, 1998; Rao 
and Alving, 2000). In addition, association of liposomes and antigen leads antigen to 
gain access to both MHC class I and II pathways in APCs (Rao and Alving, 2000; Zhou 
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and Huang, 1994a), therefore liposomal antigens can stimulate humoural and cellular 
immune systems. 
1.3.1. Role of cationic liposomes in enhancement of immunity 
In contrast to neutral or anionic liposomes, cationic liposomes can interact effectively 
with negatively charged molecules such as DNA, siRNA, proteins and peptides based 
on electrostatic interactions between the liposome cationic charge and anionic charge of 
the molecules (Bramwell and Perrie, 2005a; Felgner et al., 1987; Gregoriadis, 1998; 
Henriksen-Lacey et al., 2010c; Malone et al., 1989; McNeil and Perrie, 2006; Perrie et 
al., 2001; Perrie et al., 2008). 
It has been shown that adjuvant activity of cationic liposomes has resulted from the 
enhanced protection of the antigen, the ability to form a depot at the site of injection 
and efficient uptake by cells (Gregoriadis, 1994; Henriksen-Lacey et al., 2010b). 
Furthermore, the positive surface charge of the cationic lipids enhances the uptake of 
the liposome and entrapped antigen uptake by APCs and their presentation to the 
responder cells (Gregoriadis et al., 2002; Korsholm et al., 2007). In addition, cationic 
liposomes with the help of fusogenic lipids, such as DOPE and cholesterol, can 
destabilise the endosomes allowing the delivery of antigens into the cytoplasm of the 
APCs and promoting CD8+ CTL responses (Burger and Verkleij, 1990; McNeil and 
Perrie, 2006; Zhou and Huang, 1994a). It is also been reported that cationic liposomes 
have an impact on activation of cell signalling pathways through activation of MAP 
kinases, leading to the expression of co-stimulatory molecules (CD80 and CD86) and 
chemokines in dendritic cells (Iwaoka et al., 2006; Ouali et al., 2007; Tanaka et al., 
2008; Yan et al., 2007). Therefore, cationic liposomes have been investigated 
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extensively as an adjuvant for subunit antigens (Davidsen et al., 2005; Vangala et al., 
2006) or DNA vaccines (McNeil and Perrie, 2006). 
1.3.2. Subunit liposomal vaccines 
Subunit vaccines include highly purified peptides or protein antigens and are being 
investigated extensively due to their safety, reproducibility and low manufacturing cost 
compared with the conventional live attenuated or killed vaccines (Wilson-Welder et 
al., 2009). It has been shown that liposomes are able to protect small peptide/protein 
antigens from enzymatic breakdown by host cells (Gregoriadis, 1994; Gregoriadis et al., 
1999) and co-delivery of the subunit antigen and liposomes enhances the immunity 
(Christensen et al., 2012). It is shown that cationic lipids such as DDA or DC-Chol can 
be used as adjuvants for subunit protein vaccines (Andersen, 1994). For instance, DC-
Chol has been shown to be able to overcome the non-responsiveness to hepatitis B 
vaccine (Brunel et al., 1999) and induce high levels of antibody and cell factors. Cationic 
lipids have also been extensively investigated as adjuvant for tuberculosis-unit vaccines 
(Holten-Andersen et al., 2004), with a combination of DDA and monophosphoryl lipid 
A promoting elevated immune responses (Brandt et al., 2000; Holten-Andersen et al., 
2004). 
In addition, incorporation of trehalose 6,6’-dibehenate (TDB), which is a synthetic 
analogue of trehalose 6,6’-dimycolate (TDM) an immunostimulatory component of the 
mycobacteria cell wall (Olds et al., 1980; Pimm et al., 1979), with DDA, has shown an 
effective adjuvant activity, which enhances high level of immunity, compared to the 
DDA liposome formulation alone (Davidsen et al., 2005). To evaluate the potential of 
DDA:TDB formulations and fulfil the requirements for the clinical studies, several 
studies were performed on this formulation to investigate the impacts of vesicle size 
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(Henriksen-Lacey et al., 2011b), surface charge (Henriksen-Lacey et al., 2010c), depot 
formation (Henriksen-Lacey et al., 2010b), and pegylation of DDA:TDB (Kaur et al., 
2012a, b) on its immune response. Furthermore, DDA immunogenicity was compared 
with other cationic liposomes such as DOTAP and DC-Chol (Henriksen-Lacey et al., 
2011a). Also monolayer properties (Christensen et al., 2008) and morphological 
characteristics (Davidsen et al., 2005; Vangala et al., 2006) of DDA:TDB were studied. 
Recently, phase I clinical studies on this system in combination with Ag85B-ESAT-6 
antigen called CAF01, have been completed (ClinicalTrials.gov, 2012). The 
effectiveness of DDA:TDB is not only due to the immunogenic effects of DDA (Gall, 
1966) but is also owed to the effect of immunostimulant TDB. The mechanism of action 
of TDB is not fully understood, yet, can be related to the fact that TDB is a synthetic 
analogue of TDM that is part of Mycobacterium tuberculosis cell wall and has antigenic 
effect, therefore can activate the innate immune system. Given the high immunogenicity 
as TB vaccine, DDA:TDB was studied as an adjuvant for other antigens such as 
HBsAg, an antigen related to hepatitis B (Vangala et al., 2007) and the study showed 
high immune responses, suggesting further evaluation should be performed on its 
clinical potential. Moreover, CAF01 has been studyied in other disease models such as 
malaria, chlamydia and influenza (Agger et al., 2008; Christensen et al., 2010; Vangala 
et al., 2006). Multi parameter flow cytometry has determined the stage of memory and 
effector T cell differentiation based on the expression of selected cytokine combinations 
(Seder et al., 2008). Upon immunisation with DDA:TDB incorporated with Ag85B-
ESAT-6, central memory (IFN-γ+ TNF-α+ IL-2+ and TNF-α+ IL-2+) and effector 
memory (IFN-γ- TNF-α+) cells, which are essential for the development of long term 
immunity,  became activated (Christensen et al., 2010; Kamath et al., 2009). The 
liposomal system induced high level of IFN-γ	   and	   IgG2	   production	   (Davidsen	   et	   al.,	  2005;	  Henriksen-­‐Lacey	  et	  al.,	  2010b;	  Henriksen-­‐Lacey	  et	  al.,	  2010c),	  showing	  the	  effect	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of	  CAF01	  on	  enhancement	  of	  the	  Th-­‐1	  immune	  response.	  Although	  DDA	  does	  not	  act	  via	  TLRs,	   TDB	   activates	   NF-­‐κB	   through	   syk-­‐CARD9/Bcl10/Malt-­‐1	   intracellular	   pathway.	  This	  results	  in	  up-­‐regulation	  of	  co-­‐stimulatory	  molecules,	  including	  CD40	  and	  CD86	  on	  DCs	  (Kamath	  et	  al.,	  2009;	  Schoenen	  et	  al.,	  2010;	  Werninghaus	  et	  al.,	  2009).	  It	  is	  known	  that	  incorporation	  of	  other	  immunostimulatory	  molecules	  or	  adjuvants	  can	  change	  the	  mechanism	   of	   action	   of	   liposomal	   subunit	   vaccines	   (Henriksen-­‐Lacey	   et	   al.,	   2011c;	  Nordly	  et	  al.,	  2011).	  	  
In	  summary,	   there	  are	  MHC	  I	  and	  MHC	  II	  molecules	  which	  are	  on	  the	  surface	  of	  APCs	  and	   injected	   antigen	   can	   interact	   with	   them	   to	   induce	   immunity	   (Figure	   1.9).	   Upon	  interaction	   of	   the	   antigen,	   the	   MHC	   molecules	   will	   be	   transported	   via	   cytosol	   to	   be	  expressed	  on	   the	   surface	  of	  APC,	   thereafter	   the	  complex	  of	  MHC-­‐antigen	  will	   interact	  with	   T	   cell	   receptors	   (Madigan	   et	   al.,	   2000).	   It	   is	   believed	   that	   the	   type	   of	   MHC	  molecules	   involved	   is	   related	   to	   the	   source	   of	   protein	   antigen.	   In	   the	   case	   of	   subunit	  protein	  antigens,	  these	  antigens	  cannot	  be	  presented	  by	  MHC	  I	  molecules	  because	  they	  cannot	  reach	  to	  the	  cytosol	  of	  the	  target	  cell.	  Therefore,	  MHC	  II	  molecules	  present	  the	  subunit	  antigens	  to	  the	  Th1	  pathway	  by	  CD4+	  T	  cells,	  leading	  to	  induction	  of	  humoural	  immune	   responses	   (Spack	   and	   Sorgi,	   2001).	   This	   explains	  why	   free	   subunit	   antigens	  are	  not	  able	  to	  induce	  CTL	  immune	  response,	  which	  is	  activated	  by	  MHC	  class	  I	  antigen	  presentation.	   Hence,	   liposomal	   systems	   can	   induce	   the	   MHC	   I	   antigen	   presentation,	  resulting	  in	  release	  of	  Th1	  cytokines,	  which	  induces	  a	  strong	  cellular	  immune	  response	  for	  the	  subunit	  protein	  vaccines	  (Rao	  and	  Alving,	  2000;	  Spack	  and	  Sorgi,	  2001).	  
1.3.3. DNA liposomal vaccines 
Cationic liposomes, which are able to protect the plasmid DNA (Gregoriadis et al., 
1996), have been shown to be able to enhance the uptake of DNA vaccines by the APCs 
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(Gregoriadis, 1990; Gregoriadis et al., 1997). Two types of DNA liposomal vaccines 
that have shown more interest are DRV and SUV vesicles. For DRV systems, DNA is 
entrapped within the aqueous compartments between bilayers (Perrie et al., 2001), 
whereas SUV form lipoplexes.  
	  
Figure 1.9: Presentation of the essential steps of different concepts of adjuvant activity. (a) Facilitation of 
antigen transport, uptake and presentation by antigen-capturing and processing cells in the lymph node 
draining the vaccine injection site. (b) Repeated or prolonged release of antigen to lymphoid tissues (depot 
effect). (c) Signalling of release of PRRs activates innate immune cells to release cytokines necessary for 
upregulation of costimulatory molecules. (d) Danger signals from stressed or damaged tissues alert the 
antigen-presenting cells to upregulate costimulatory molecules. (e) Signalling by recombinant cytokines or 
costimulatory molecules mimics classical adjuvant activity. Adapted from (Schijns, 2000) 
It has been reported (Gregoriadis, 1990) that local injection of liposomal DNA vaccines 
leads to APCs infiltrating the injection site or the lymph nodes and uptake of the 
plasmid DNA. Consecutive studies have been performed using plasmid DNA of 
(pRc/CMV HBS) which encodes the S region of the hepatitis B surface antigen (HBsAg) 
(Gregoriadis et al., 1997; Perrie et al., 2001). Results showed a remarkably higher 
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antibody response when the animal (BALB/C mice) immunised with liposomal DNA 
vaccines (e.g., DOTAP or DC-Chol) rather than naked DNA. Cytokine production 
levels for IFN-γ and IL-4 showed the same trend and using dehydration rehydration 
method to prepare the liposomes led to an increase in the immune responses for DRV 
liposomes compared to MLV liposomal vaccines. These results revealed the capability 
of liposomal DNA vaccines to enhance both humoural and cellular immune responses 
(Gregoriadis et al., 1997). These studies are in agreement with the notion that liposomes 
facilitate the uptake of liposomal DNA vaccines by APCs in the lymphoid tissues. In 
addition, expression of transgene-encoded protein (green fluorescent protein (GFP)) was 
also reported by these studies. Oral administration of liposomal DNA vaccines studied 
by Perrie et al (Perrie et al., 2002) shows that DSPC DRV liposomes containing DNA 
induce immune responses via the oral route. Another study showed DOTAP-based 
formulations produce longer-lived immunity compared to DC-Chol (Perrie et al., 2003). 
DNA lipoplexes (SUV liposomes/DNA complexes) may use different strategies, such as 
the use of surface ligand for cell targeting. Some studies used mannosylated cholesterol 
derivative to target macrophage mannose receptors and showed higher in vitro 
transfection and in vivo gene expression compared to DC-Chol (Kawakami et al., 2000). 
Using RGD peptides (Anwer et al., 2004) and use of biodegradable PLA (Bramwell et 
al., 2002) in combination with lipoplexes are other approaches of DNA delivery using 
SUV liposomes, which caused enhanced production of Th1 and Th2 responses. 
Different mechanisms (Figure 1.10) have been proposed to explain the immunogenicity 
of DNA vaccines; it was reported earlier that DNA-encoded antigens are presented by 
somatic cells through their MHC class I pathway to CD8+ T cells (Figure 1.10a) (Davis 
et al., 1993). However, other studies show that myocytes are not efficient enough to 
produce such high immune responses via MHC class I pathways (Gregoriadis, 1998; 
Spier, 1996). These studies have proposed that the CTL responses induced by DNA 
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vaccines result from the transfer of antigenic material between the muscle cells and 
professional APC (Figure 1.10c) and also the plasmid is taken up directly by DCs at the 
local lymph nodes, which present the antigen to the CD8+ T cells (Figure 1.10b). 
 
Figure 1.10: Mechanism of antigen presentation for activation of T lymphocytes (CTL) following plasmid 
DNA immunisation. a) DNA encoded antigens are presented by myocytes through their MHC class I 
pathway to CD8+ T cells. b) DNA vaccination led to direct transfection of APCs. c) Cross-priming results 
from transfected myocytes being phagocytosed by APCs, which then present the antigen to T cells. Adopted 
from (Liu, 2003). 
The effect of liposomes on this mechanism is to offer protection of the plasmid DNA 
from degradation so more DNA can transfect the cell and, as a result, higher CTL 
responses will be induced (Gregoriadis, 1998; Liu, 2003). Furthermore, cationic 
liposomes can induce innate immune response upon the immunisation and initiate the 
humoural immunity. Finally, applying fusogenic lipids in the structure of cationic 
liposomes would destabilise the cell membrane and enhance the delivery of the plasmid 
DNA into the cell and eventually to the nucleus (McNeil and Perrie, 2006). 
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1.3.4. Prime/boost DNA vaccine strategies 
Prime/boost immunisation regimen has been defined as a vaccination strategy, which 
includes prime immunisation of plasmid DNA followed by the immunisation with the 
same antigen, which was encoded by the prime plasmid DNA. An early study 
(Schneider et al., 1998), has shown that DNA prime immunisation followed by a single 
protein boost of the same modified vaccina virus Ankara (MVA) antigen induced high 
levels of CD8+ T cells, and as a result, induced complete protection in challenges. Later 
studies (Carstens et al., 2011; Deshmukh et al., 2007; O'Hagan et al., 2004; Tirabassi et 
al., 2011; Vaine et al., 2010; Wang et al., 2008; Wierzbicki et al., 2002; Yang et al., 
2008) have also shown the resulting immune response to the heterologous vaccination 
can be significantly higher than  homologous plasmid DNA or protein vaccines (eg., 
DNA/DNA or protein/protein). This was also tried in human studies, which have 
shown high immune responses of prime-boost vaccination compared to homologous 
DNA vaccine regimens (Lu et al., 2008). Recent studies have also investigated 
heterologous regimens for influenza and HIV vaccines (Churchyard et al., 2011; De 
Rosa et al., 2011; Koblin et al., 2011; Ledgerwood et al., 2011), which are showing 
promising immune responses and are currently undergoing human clinical trials. 
The immunologic mechanisms behind the effectiveness of heterologous prime/boost 
strategies are not well understood, but it can be related to the lower antigen expression 
of DNA prime immunisation compared to protein vaccines, and this may preferentially 
prime T-helper cell responses, with the humoural response subsequently being boosted 
by the high dose protein boost (De Mare et al., 2008; Li et al., 2012). In fact, following 
the prime immunisation, the rate and efficacy of antigen recognition and immune 
response are increased, therefore with booster immunisation, these provided high 
affinity lymphocytes to be further developed in size and in the ability of epitope 
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recognition. This leads to an increase in the efficiency of the immune system 
(McCullough and Summerfield, 2005). 
1.4 Aims and objectives  
As described, liposomes have shown great potential as adjuvants and delivery systems 
for subunit antigen and plasmid DNA vaccines, through enhancing the immunogenicity 
of these molecules as well as effective and efficient delivery of them. It was also 
mentioned that different aspects such as cationic lipid composition, choice of helper 
lipid, vesicle size and surface charge of the liposome and method of liposome 
preparation impact on in vitro transfection, in vivo delivery and immunogenicity of the 
vaccines. Therefore, the aim of this thesis was to evaluate how differences in 
physicochemical characteristic properties of the liposome formulations correlate with 
their in vitro transfection efficiency, in vivo biodistribution and immunological function. 
To achieve this aim following objectives have been considered: 
Ø To investigate a range of cationic liposome-DNA formulations with different 
lipid/DNA +/- charge ratios and study the physicochemical characteristics of 
them. 
Ø To investigate the role of lipid structure on molecular packaging of the lipids. 
Ø To study the effect of the presence of electrolytes and lipid composition on 
physicochemical properties and in vitro transfection of the DNA liposomal 
formulations.  
Ø To evaluate the biodistribution of liposomes and their associated plasmid DNA 
with the aim to correlate these to their physicochemical properties and 
immunological function. 
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Ø To perform prime/boost immunisation experiments with selected cationic 
liposomal vaccines to evaluate the effect of cationic lipid composition, 
electrolytes and type of the liposomes on immunogenicity of the liposomal 
vaccines. 
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2.1. Materials 
 
Material Supplier 
1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) 
Avanti Polar Lipids, Alabaster, AL, USA 
1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-
glycerol) (DOPG) 
Avanti Polar Lipids, Alabaster, AL, USA 
1,2-dioleoyl-sn-glycero-3-
phsphoethanolamine (DOPE) 
Avanti Polar Lipids, Alabaster, AL, USA 
1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-
glycerol) (DSPG) 
Avanti Polar Lipids, Alabaster, AL, USA 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE) 
Avanti Polar Lipids, Alabaster, AL, USA 
1,2-stearoyl-3-trimethylammonium-propane 
(DSTAP) 
Avanti Polar Lipids, Alabaster, AL, USA 
125I (NaI in NaOH solution) Perkin Elmer, Waltham, MA, USA 
2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) 
Sigma-Aldrich, Poole, Dorset, UK 
32P-dATP Perkin Elmer, Waltham, MA, USA 
3H-Cholesterol Perkin Elmer, Waltham, MA, USA 
African green monkey kidney cells (COS-7) European collection of cell cultures 
(ECACC) (Salisbury, UK). 
Agarose Sigma-Aldrich, Poole, Dorset, UK 
Alhydrogel-2 % InvivoGen San Diego, CA, USA 
BALB/C mice Charles River, Margrate, UK 
Bicinchoninic acid (BCA) protein assay kit Sigma-Aldrich, Poole, Dorset, UK 
Boric acid Biomedicals, Inc. Ohio, USA 
Bromophenol blue Sigma-Aldrich, Poole, Dorset, UK 
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C57BL/5Jico Charles River, Margrate, UK 
CellTiter 96® AQueous One Solution Cell 
Proliferation Assay 
Promega, Madison, WI, USA 
Chloroform Fisher Scientific, Leicestershire, UK 
Citric acid Sigma-Aldrich, Poole, Dorset, UK 
Concanavalin A Sigma-Aldrich, Poole, Dorset, UK 
Delbecco’s Modified Eagles Medium 
(DMEM) 
Biosera, Leicestershire, UK 
Deoxyribonuclease I Sigma-Aldrich, Poole, Dorset, UK 
Dimethyldioctadecylammoniumbromide 
(DDA) 
Avanti Polar Lipids, Alabaster, AL, USA 
Distilled Water; DNase/RNase Free Gibco, Invitrogen, Paisley, UK 
DNA ladder (2-10 kb) Promega, Madison, WI, USA 
Ethanol Fisher Scientific, Leicestershire, UK 
Ethidium bromide Sigma-Aldrich, Poole, Dorset, UK 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Poole, Dorset, UK 
Foetal bovine serum (FBS) Biosera, Leicestershire, UK 
Illustra ProbeQuant G-50 Micro Column GE Healthcare, Amersham, UK: 
Goat anti-mouse IgG, IgG1, IgG2b AbD Serotec, Oxford, UK 
gWizTM Luciferase Genovac GmbH, Germany 
Heparin Sigma-Aldrich, Poole, Dorset, UK 
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) buffer solution 
Sigma-Aldrich, Poole, Dorset, UK 
Hydrogen Peroxide Sigma-Aldrich, Poole, Dorset, UK 
Iodogen pre-coated iodination tubes Pierce Biotechnology, Rockford, IL, 
USA 
L-glutamine/Penicillin-Streptomycin Biosera, Leicestershire, UK 
Chapter 2: Materials and Methods                                                                                                     D 
 
68 
LipofectinTM reagent Invitrogen Life Technologies, UK 
Loading buffer Promega, Madison, WI, USA 
luciferase assay system Promega, Madison, WI, USA 
Magnesium chloride Sigma-Aldrich, Poole, Dorset, UK 
Marvel milk Premier Int. Foods Ltd, Lincs, UK 
Methanol Fisher Scientific, Leicestershire, UK 
Mouse DuoSet capture ELISA IL-1ß, IL-2, 
IL-5, IL-6, IL-10, IFN-γ 
R & D Systems, Abingdon, UK 
Nick Translation kit GE Healthcare, Amersham, UK: 
Phosphate buffer saline tablets (PBS) Sigma-Aldrich, Poole, Dorset, UK 
PicoGreen reagent Invitrogen Life Technologies, UK 
Plasmid DNA (pRc/CMV HBS) Aldevron, Fargo, USA 
Pontamine blue (Chicago Sky Blue 6B) Sigma-Aldrich, Poole, Dorset, UK 
Potassium chloride Sigma-Aldrich, Poole, Dorset, UK 
Potassium phosphate Sigma-Aldrich, Poole, Dorset, UK 
Protease inhibitor cocktail  Sigma-Aldrich, Poole, Dorset, UK 
Reagent diluent R & D Systems, Abingdon, UK 
RPMI 1640 Biosera, Leicestershire, UK 
Sephadex™ G-75 Sigma-Aldrich, Poole, Dorset, UK 
Serum free and antibiotic free medium  
(Opti-MEM) 
Gibco, Invitrogen, Paisley, UK 
Sodium bicarbonate Sigma-Aldrich, Poole, Dorset, UK 
Sodium carbonate Sigma-Aldrich, Poole, Dorset, UK 
Sodium chloride Sigma-Aldrich, Poole, Dorset, UK 
Sodium dodecyl sulphate Sigma-Aldrich, Poole, Dorset, UK 
Sodium hydroxide Sigma-Aldrich, Poole, Dorset, UK 
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Sodium phosphate dibasic Sigma-Aldrich, Poole, Dorset, UK 
SolvableTM Perkin Elmer, Waltham, MA, USA 
Stop solution R & D Systems, Abingdon, UK 
Sucrose Sigma-Aldrich, Poole, Dorset, UK 
Substrate solution R & D Systems, Abingdon, UK 
Synthetic hepatitis B surface antigen 
(HbsAg) (ayw subtype) 
Aldevron, Fargo, USA 
Trehalose 6,6′-dibehenate (TDB) Avanti Polar Lipids, Alabaster, AL, USA 
Triton X – 100 Sigma-Aldrich, Poole, Dorset, UK 
Trizma-Base Sigma-Aldrich, Poole, Dorset, UK 
Trypan blue Sigma-Aldrich, Poole, Dorset, UK 
Trypsin/EDTA Gibco-Invitrogen, Carlsbad, CA, USA 
Tween-20 Sigma-Aldrich, Poole, Dorset, UK 
Ultima Gold Scintillation Fluid Perkin Elmer, Waltham, MA, USA 
 
2.2. Monolayer studies 
To investigate the surface pressure of monolayer lipids, Langmuir-Blodgett technique 
has been used. It is an automated controlled film balance apparatus (Figure 2.1) (KSV 
Langmuir Mini-trough, KSV Instruments Ltd., Helsinki, Finland) equipped with a 
platinum Wilhemy plate and placed on a vibration-free table. This instrument was used 
to collect the surface pressure-area isotherms. The size of the trough was 24225.0 mm2 
enclosing a total volume of about 220 mL; the subphase was filtered deionised water or 
PBS solution. The compounds were prepared at fixed total concentration of 1 mg/mL 
of lipid in chloroform. 20 µL of each solution was spread onto the air/water interface 
with a Hamilton micro-syringe, precise to ± 0.2 µL (Figure 2.2). The monolayer was left 
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for about 15 minutes to allow chloroform to evaporate. Then a constant compression 
with a rate of 10 mm/minute was performed on the molecules until the required surface 
pressure was attained. The temperature of the subphase was kept constant at 20 °C ± 1 
°C by use of an external water bath circulation system.  
 
 
Figure 2.1: Representation of Langmuir mini trough, kindly supplied by KSV.Ltd and modified.  
Different parts of the instrument: 1) Balance 2) Trough filled with clean subphase e.g. water 3) Movable 
barriers 4) Wilhelmy Plate (Reproduced with permission from (Moghaddam et al., 2011)). 
 
The following compounds were tested in this study in both deionised water and PBS 
subphases: DOPE, DOTAP, DSTAP, DSPE, DOPE:DOTAP, DOPE:DSTAP, 
DSPE:DOTAP, DSPE:DSTAP. DDA, DDA:TDB and DOPE:DDA were also studied 
in deionised water. Each experiment was compressed once and performed at least three 
times. To analyse the data KSV software (KSV Instruments Ltd., Helsinki, Finland) was 
used. 
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Figure 2.2: Spontaneous spreading of a liquid of surfactant molecules (adapted from (Lyklema, 2000)) 
 
2.3. Liposome preparation by lipid hydration method 
2.3.1. Production of multilamellar vesicles (MLV) 
All cationic liposomes were prepared by the lipid hydration method based on the work 
of Bangham (Bangham et al., 1965). To prepare the liposomes, the required amount of 
each lipid were taken and dissolved in an appropriate volume of stock solution of 
chloroform:methanol (9:1 v:v ratio) in a round bottom flask (RBF). The organic solvent 
was then evaporated and a thin film coated in RBF by using rotary evaporator. After 
flushing of the RBF with N2 to ensure complete remove of solvent, 1 mL of hydration 
phase (either distilled water, PBS or Tris buffer) was added to the RBF followed by 2 
minutes vortex and the contents kept 10 °C above transitional temperature (Tc) for 30 
minutes to form multilamellar vesicles (MLV) e.g. the Tc for DOPE, and DOTAP is 
below room temperature but it is 47 °C for DDA, 62.9 °C for DSTAP and 75 °C for 
DSPE (Davidsen et al., 2005; Regelin et al., 2000). 
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2.3.2. Production of small unilamellar vesicles (SUV) 
To produce small unilamellar vesicles (SUV), MLV were sonicated (Figure 2.3A) for 
approximately 2 minutes with a probe sonicator (Soniprep 150) with the power of 5 
amplitude microns using a probe tip with a diameter of approximately 4 mm. Since 
sonication tips tend to release titanium particles into the lipid suspension this was 
removed by centrifugation prior to use. Details of each liposome formulation are shown 
in Table 2.1.  
                 Table 2.1: Studied liposome formulations 
Liposome formulation Lipid ratio (µmol) Hydration medium 
DOPE:DOTAP (8:8) dH2O/Sucrose 
DOPE:DOTAP (8:8) PBS 
DOPE:DSTAP (8:8) dH2O/Sucrose 
DOPE:DSTAP (8:8) PBS 
DSPE:DOTAP (8:8) dH2O 
DSPE:DOTAP (8:8) PBS 
DDA:DOPE (8:8) dH2O/Sucrose 
DDA:TDB (8:1) Tris buffer 
 
For biodistribution and immunisation studies, to keep the isotonicity of the formulation 
in vivo, 10 % solution of sucrose was used as hydration media instead of dH2O in 
formulations. Also for DDA:TDB 10 % trehalose was added to the Tris buffer to have 
an isotonic buffer. 
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2.3.3. Production of dehydration-rehydration vesicles (DRV) 
To produce dehydration-rehydration vesicles (DRV) (Kirby and Gregoriadis, 1984), the 
empty SUV suspension was kept at -70 °C for one hour and then placed in freeze dryer 
over night with a shelf temperature of -20 °C. Controlled rehydration procedure was 
performed after complete freeze drying. Minimal amount of dH2O added to the lipid 
cake (100 µL per 16 µmoles lipid) and then vortexed for a short time (less than one 
minute), this stage repeated until the dry lipid was redispersed. The rehydrated 
formulation was kept at >Tc for 30 minutes to allow vesicle formation. When the 
suspension was diluted for further experiments, it was left to stand for 30 minutes before 
any experiment was carried out (Figure 2.3B). 
 
Figure 2.3: Liposomal preparations: A) Small unilamellar vesicles complexed with DNA (SUV-DNA), 
B)Preformed empty dehydration-rehydration vesicles complexed with DNA, (DRV-DNA). (insert 
illustrates flattened liposomal membrane in their dried state after freeze drying). 
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2.3.4. DNA lipoplex preparation 
Cationic liposome-DNA complexes were prepared by incubating either empty SUV or 
DRV (Figure 2.3) with the required amount of gWiz Luciferase or plasmid DNA 
(pRc/CMV HBS) for 30 minutes. Lipid films were hydrated in either dH2O, 10 % 
sucrose, PBS or for DDA:TDB in Tris buffer (10mM, pH 7.4).  
2.3.5. Protein-liposome complex preparation 
To produce protein-liposome complexes, empty SUV or DRV were incubated with the 
appropriate amount of protein for one hour at room temperature (RT).  
2.4. Determination of vesicle size 
The z-average diameter of lipoplexes was determined by dynamic light scattering using 
the photon correlation spectroscopy (PCS) technique measured on a Malvern Zetasizer 
Nano-ZS (Malvern Instruments Ltd., UK). Using the cuvettes supplied by Malvern, 20 
to 50 μL of the sample was diluted by the hydration phase up to 1.5 mL and the vesicle 
size was measured at 25 °C.	  
2.5. Measuring Zeta potential 
The zeta potential of the complexes was measured on Malvern Zetasizer Nano-ZS 
(Malvern Instruments Ltd., UK) at 25 °C in distilled water, PBS or Tris buffer as 
appropriate. To measure the zeta potential 100 µL of liposome suspension was diluted 
in 2 mL of its aqueous phase whether dH2O or 0.001 M PBS.  
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2.6. Evaluating antigen association  
The level of associated plasmid DNA within lipoplexes, as well as absorbed protein, 
associated the liposomes was determined based on following protocols:
2.6.1. Plasmid DNA association  
To measure the association of the DNA with liposomes, 25 µL	   of	   the	   liposome	  was	  removed	   and	   diluted	   to	   1	   mL	   with	   PBS.	   The	   diluted	   samples	   were	   centrifuged by 
OptimaTM Max-xp Ultra Centrifuge, (Beckman Coulter, USA) for one hour with the 
speed of 125,000 x g at 4 °C. Following to the centrifugation, the supernatant were 
collected and the pellets were resuspended in 1 mL PBS and the centrifuge repeated. 
Supernatants, which contain unassociated pDNA, were incubated with similar volume 
of fluorescent dye of PicoGreen® for 5 minutes at RT in a black 96 well plate (the plate 
was covered by foil to avoid photodegradation). The absorbance was read by 
SpectroMax Gemini EM (Molecular Device) plate reader with the excitation maximum 
at 495 nm and an emission peak at 525 nm. So the amount of free pDNA (washed 
pDNA) was quantified. To measure the liposome-associated pDNA, the liposome 
‘pellet’ was resuspended in PBS and exposed to 10	  µL of 10 % Triton X-100 with final 
concentration of 0.1 %. The mixture was shaken vigorously prior to addition of 
Picogreen® and then the absorbent was read to quantify the associated pDNA. 
Incorporation values of DNA with liposomes were calculated by following equation 
(including any dilution):  
Fluorescence of washed sample       x 100 % 
                                     Fluorescence of unwashed sample 
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2.6.2. Protein adsorption 
2.6.2.1. Radiolabelling of the proteins 
In order to determine the entrapment of protein in each liposomal vaccine formulation, 
radiolabelling was applied using 125I. The protein antigen HBsAg, was radiolabelled 
using the Iodo-gen® pre-coated iodination tubes. The protein antigen was diluted to 50 µL PBS buffer (0.01 M, Ph 7.4) and added to the pre-coated iodination tube following by 
addition of 125I equal to 3.7 MBq. The mixture was left for 45 to 60 minutes with 
swirling every 15 minutes to ensure complete exposure of protein and 125I to the 
iodination tube. The labelled antigen was separated from unlabelled antigen by applying 
the mixture of protein and 125I onto a 5 mL Sephadex G-75 gel column.  
To prepare the gel column, 2 g of the Sephadex G-75 was rehydrated in 30 mL of 
distilled water and stored in the fridge over the night. Then the swollen gel was packed 
to give a final gel volume of 5 mL. The gel was washed by 10 mL PBS to ensure PBS 
hydrated the whole gel column.  
Radioactivity of the samples was measured using a Cobra™ CPM Auto-Gamma® 
counter (Packard Instruments Company inc., IL, USA).  
2.6.2.2. Detection of the liposome-associated protein. 
To determine the presence of protein, bicinchoninic acid (BCA) assay was used; 25 µL 
of each sample was transferred to the wells of 96 well plate. 200 mL of BCA reagent 
(ratio of 50:1 for reagent A to B) was added to each well. Then the plate was incubated 
for half an hour in 37° C. This was followed by reading the absorbance at 562 nm by 
microplate reader (BioRad, model 680). The radioactivity and absorbance readings for 
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each 0.25 mL aliquot were plotted to confirm the presence of radiolabelled protein 
antigen.  
2.6.2.3. Quantification of liposome-adsorbed protein 
The aliquots containing the radiolabelled antigen were collected and the required 
amount was added to the liposome suspension. The mixture was left at RT for one 
hour. The radioactivity of each liposome formulation was measured using a Cobra™ 
CPM Auto-Gamma® counter (Packard Instruments Company inc., IL, USA). To 
separate the entrapped and unentrapped antigen, the liposome suspension was diluted 
by PBS to 3.9 mL and centrifuged for one hour at 4° C at 125,000 x g using a TL-100 
rotor on an OptimaTM Max-xp Ultra Centrifuge; Beckman Coulter, USA. The Pellet and 
supernatant were separated and after redispersing of the pellet in 1 mL of PBS, the 
radioactivity of them was measured on the gamma counter. The amount of entrapped 
antigen was calculated by dividing the radioactivity of the pellet by the radioactivity of 
the unwashed sample multiplied by 100 %: 
Radioactivity of washed sample            x 100 % 
                                      Radioactivity of unwashed sample 
 
2.7. Agarose gel electrophoresis 
Gel electrophoresis was used to determine the retention of plasmid DNA in the 
lipoplexes under various conditions. Agarose gel was prepared by dissolving the desired 
amount of Agarose powder in 1x Tris borate EDTA (TBE) buffer solution to reach to 1 
% concentration (w/v). 10 µL ethidium bromide (1 mg/mL) was also added to the 
solution and followed by heating the mixture in the microwave for 5 minutes. A clear 
and transparent solution was obtained and left to cool down to (50 to 60) °C and then 
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was poured in the tray. When the gel hardened the comb was taken off the gel, and the 
tray, which is filled with the gel, was placed in the chamber filled with pre-chilled 1x 
TBE buffer. Samples of DNA ladder, free DNA and liposome incorporated DNA 
suspensions were mixed with gel loading buffer (bromophenol blue, 0.05 % w/v; 
sodium dodecyl sulphate, 0.05 % w/v; EDTA, 0.1 M at pH 8) and subjected to agarose 
gel electrophoresis for 1 hour at 80 V. DNA visualisation of the gels was carried out by 
using UV SynGene Bio Imaging (SynGene,Cambridge, UK). 
2.8. Protection of DNA from degradation 
A vial of Deoxyribonuclease I (DNase I) reconstituted with 1 mL of cold sodium 
chloride (NaCl) (0.15 M) to prepare a standard solution of DNase I with a 
concentration of 2000 Kunitz units/mL. From this, aliquots of 60 µL were pipetted into 
vials and frozen at -20 °C for future use. 100 µL of naked DNA (10 µg) was taken and 
150 µL of magnesium chloride (MgCl2) (5 mM) was added to it. Samples were then 
incubated in the presence (i.e. positive test) or absence (i.e. negative test) of 100 units of 
DNase I (50 µL from the stock solution), at 37 °C for 10 minutes.  This protocol was 
repeated for the DNA lipoplex formulations. Adding 100 µL of EDTA (0.1 M; pH 8.0) 
after 10 minutes stopped the reaction. 8 µL from each sample was removed and 2.5 % 
w/v SDS was added (1:1 v/v), in order to rupture liposomes to release their contents. 
The samples (i.e. positive and negative tests, free and entrapped DNA and with and 
without SDS) were then subjected to a 0.8 % agarose gel for 1 hour at 80 V.    
2.9. DNA release studies 
DNA association within liposome formulations was determined as detailed in section 
2.6.1. Liposome preparations were then diluted to 15 mL with PBS and incubated in a 
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37 °C water bath with shaking. At various time points (0, 2, 4, 24, 48, 96, 192 hours), 
DNA association and release from liposome formulations was determined by removing 
1 mL sample from liposome suspension, which was subsequently replaced with 1 mL 
PBS, in order to maintain sink conditions. From this 1 mL sample the amount of DNA 
released was determined as detailed in section 2.6.1. 
2.10. In vitro studies 
2.10.1. Cell culture protocols 
2.10.1.1. Reviving the frozen COS-7 cell line 
To revive the frozen cell line, the ampoule was removed carefully from liquid nitrogen 
tank and kept in 37 °C water bath for 2 minutes, until cells defrosted. Under sterile 
conditions, the cell solution was removed from the ampoule and slowly pipetted into a 
75 cm2 cell culture flask containing 20 mL of Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10 % foetal bovine serum (FBS) and 1 % 
penicillin/streptomyocin/L-Glutamine (PSG), in order to dilute out the toxic effects of 
Dimethyl Sulfoxide (DMSO). Cells were incubated at 37 °C and 5 % CO2 under sterile 
conditions. 
2.10.1.2. Subculture of COS-7 cells 
In order to passage the cell lines, the previous media (DMEM) was removed and 5 mL 
of trypsin/EDTA added to the flask ensuring that all cells are covered. The cells were 
incubated at 37 °C and 5 % CO2 for 5 minutes. Cells were examined under an inverted 
microscope to ensure all cells have detached from the flask. 5 mL of fresh DMEM 
supplemented with 10 % FBS and 1 % PSG was added to the cell suspension to dilute 
the trypsin/EDTA solution, the cell suspension was then added to a 50 mL centrifuge 
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tube and subsequently centrifuged (Mistril 3000i) at 200 x g for 10 minutes at 15 °C. 
After centrifugation, within sterile conditions, the supernatant was carefully removed 
and the pellet resuspended in 10 mL DMEM/FBS/PSG. 1 mL of cell suspension is 
added to a 75 cm2 containing 19 mL DMEM and incubated at 37 °C and 5 % CO2 under 
sterile conditions. 
2.10.1.3. Cell quantification 
As explained in section 2.10.1.2 adherent COS-7 cells were brought into solution. Then 
200 µL of this cell suspension was removed and added to a microcentrifuge tube 
followed by addition of 200 µL of Trypan Blue. Using a haemocytometer, cell viability 
and cell counts were determined. To each side of the cover slip of the haemocytometer, 
10 µL of the Trypan Blue cell suspension was added and observed by inverted 
microscope. The bright cells (i.e. viable cells) were counted and from this the cells 
concentration was calculated (including dilutions), whereas the cells stained blue 
indicate non-viable cells. The following equation was used to calculate the cell number: 
No of cells/mL = number of cells per square x dilution factor x 104 
v no. cells per square is the average of 10 squares in the hemocytometer  
v Dilution factor is 2 if equal volumes of resuspended cells and tryphan blue are used  
v 104  is the multiplication factor related to the volume of the hemocytometer grid 
 
2.10.1.4. Cryopreservation 
Adherent cells were brought into suspension and quantified as explained in sections 
2.10.1.2 and 2.10.1.3. Cells were then centrifuged at 200 x g for 10 minutes at 15 °C and 
the pellet resuspended in FBS containing 10 % DMSO with a cell concentration of 4 x 
106 cells/mL. 1 mL aliquots of cell suspension were pipetted into cryopreservation 
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ampoules, and frozen at -70 °C overnight. The ampoules were then placed and stored in 
a liquid nitrogen storage container. 
2.10.2. Transfection studies 
2.10.2.1.  Cell preparation and plating for in vitro transfection  
Adherent COS-7 cells were brought into suspension and quantified as detailed in section 
2.10.1.2 and 2.10.1.3. The cell suspension was then centrifuged at 200 x g for 10 
minutes at 15°C and the pellet resuspended to a cell concentration of 1 x 105 cells/mL 
with supplemented DMEM. COS-7 cells were plated 24 hours prior to transfection, at a 
cell concentration of 1 x 105 cells/mL in 1 mL of medium in a 12-well plate and 
incubated overnight at 37 °C and 5 % CO2 under sterile conditions for 24 hours. 
2.10.2.2. DNA lipoplex preparation for in vitro transfection 
To perform in vitro studies, lipoplexes was prepared by diluting 17.5 µL of SUV solution 
(16 µmoles) to 0.35 mL with Opti-MEM, and then incubated for 40 minutes at room 
temperature. After incubation, 0.35 mL of Opti-MEM containing 3.5 µg plasmid DNA 
was added, mixed with liposome solution and incubated again for a further 15 minutes 
at room temperature. The resultant lipoplex mixture was then diluted to a final volume 
of 3.5 mL with Opti-MEM. The lipid/DNA charge ratio for in vitro study was +1.7/1.  
Prior to transfection, cells, which were incubated for 24 hours, were washed with 1 mL 
of Opti-MEM before lipoplexes were added to the cells. 1 mL of the lipoplex solution 
(0.0078 µmole total lipid content containing 1 µg plasmid DNA) was added to each 
well, each in triplicate. In addition, Lipofectin reagent and free DNA were added as 
positive and negative controls respectively. After 5 hours incubation at 37 °C in 5 % 
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CO2, the Opti-MEM medium was replaced with growth medium (DMEM) containing 
10 % FBS and the cells were incubated for 48 hours in the same condition. 
2.10.2.3. Luciferase assay 
Transfection efficiency of each formulation was determined using luciferase assay 
system. Luciferase was used as a reporter to assess the transcriptional activity in cells 
that are transfected with the DNA by producing light emission so the luciferase activity 
of the cell can be determined by detecting the produced light using a illuminometer. 
Therefore to determine the transfection efficiency of lipoplexes, transfected cells were 
exposed to 80 µL/well of lysis buffer and detached using cell scrapper. Detached cells 
spanned down at 12,000 x g for 15 seconds at room temperature and 10 µL of the 
supernatant was removed and pipetted onto a 96-well plate. To quantify the luciferase 
activity prior to addition of luciferase reagent, the plate was read using illuminometer 
(Spectra Max Gemini XPS, Molecular Probes) with 30 reads/well. Then luciferase 
assay reagent was added to the cells (100 µL/well) and the plate was read again. 
Measuring the amount of detected light for each sample, the transfection efficiency was 
reported as the percentage of the produced activity of each formulation to the 
Lipofectin™. 
2.10.3. Cytotoxicity study 
Cell preparation and plating procedure for cytotoxicity study is same as transfection as 
described in section 2.10.2.1 and 2.10.2.2 except that 100 µL of cells were pipetted into 
96 well plates before incubation for 24 hours. After 5 hours incubation, the medium was 
replaced by 100 µL of supplemented DMEM and incubated for 24 hours, then 20 µL of 
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3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H 
tetrazolium (MTS) reagent, (CellTiter 96® AQueous One Solution Cell Proliferation 
Assay, Promega) was added to each well. This protocol is based on the fact that cells 
bioreduce the MTS reagent into a red formazan product. Plates were incubated for 4 
hours at 37 °C, in a 5 % humid CO2 condition. After that the quantity of produced 
formazan was measured on microplate reader (Thermo Scientific Molecular Spectrum 
plate reader) at A490. The absorbance reading is directly proportional to the number of 
living cells in the medium. In this study cell viability is calculated by comparing the 
results to the positive control (i.e., cells and medium) and expressed as a percentage.
2.11. Biodistribution studies in mice 
The biodistribution of several radiolabelled lipoplex formulation was studied in female 
6-8 week old (18 – 21) g, BALB/c mice (Charles River, Margrate,UK). Groups of 4 
mice were used to study biodistribution of naked DNA and seven liposomal 
formulations (Table 2.2) for each time point and three time points were selected for 
termination of the mice which were 1, 4 and 8 days after the injection. So 3 
experimental groups (12 mice) were used to study each formulation and in total 96 mice 
were used in this study. Mice were housed under conventional conditions (22 °C, 55 % 
humidity, 12 h day/night cycle) in their experimental groups and were given a standard 
diet ad-lib. 
All experimentation undertaken strictly adhered to the 1986 Scientific Procedures Act 
(UK). All protocols have been subject to ethical review and were carried out in a 
designated establishment.  
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                               Table.2.2: Lipoplex specifications of present study 
 
2.11.1. Pontamine blue injection 
Three days before injection of the formulations, 200 µL of sterile filtered (0.2 µm) 
Pontamine blue (0.5 % w/v in PBS) was injected subcutaneously (s.c.) into the neck 
scruff of the mice as a marker for lymph nodes and monocytes (Tilney, 1971b).  
2.11.2. Preparation of radiolabelled vaccines and their injection 
Three days after injection of Pontamine blue, mice were injected a single intramuscular 
(i.m.) injection into the right quadriceps muscle with 50 µL of the plasmid:liposomes 
complex (lipoplex). To be able to investigate the biodistribution of the lipoplexes and 
detect lipid and pDNA in vivo, formulations radiolabelled with dual radiolabelling 
technique (Figure 2.4). Liposomes were radiolabelled by incorporation of [3H]-
Cholesterol to the liposomal bilayer. [3H]-Cholesterol was added to the lipid mixture 
prior to solvent evaporation and the liposomes were prepared by lipid-film hydration 
method detailed in section 2.3. The amount of [3H]-Cholesterol added was based on the 
radioactivity of (3H) and the concentration of cholesterol in the liposomes so that the 
physicochemical properties of the liposomes were not changed. The radioactivity of 
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[3H]-Cholesterol was 37 MBq/mL, which was ideal for this study with a high 
radioactivity and low cholesterol interference in liposomal characteristic parameters. So 
to gain a 150 kBq/dose radioactivity, a weight ratio of 1:10000 [3H]-Cholesterol:lipid 
was used. Plasmid DNA was labelled by the incorporation of [α-32P]-dATP by nick 
translation procedure (Kelly et al., 1970; Rigby et al., 1977). Therefore a Nick 
Translation Kit N5500 (GE Healthcare, Amersham, UK) was used, according to the 
instructions of the supplier and 2 µg of pDNA was labelled with 66 pmole of  [α-32P]-
dATP. After the DNA and [α-32P]-dATP reaction, the free label was removed using 
Illustra Probe Quant G-50 Micro Columns (GE Healthcare, Amersham, UK). The 
appropriate amount of labelled and unlabelled pDNA were mixed to achieve a 150 
KBq/dose activity and the mixture then added to the radiolabelled liposomes to prepare 
the dual radiolabelled lipoplexes (Figure 2.4). The injected dose volume was 50 µL	  containing 150 kBq of [32P] and 150 kBq of [3H]. There was also 50 µg of gWiz 
luciferase plasmid DNA in each dose and the lipid/DNA ratio was +4/1. All mice were 
injected intramuscularly to the right quadriceps muscles. 
2.11.3. Processing of the tissues 
At time points of one day, four days and eight days post injection (p.i.), mice were 
terminated by cervical dislocation and various tissues collected. The collected tissues 
include site of injection (SOI), popliteal lymph node (PLN), liver, kidney, spleen and 
lung. Each tissue was weighted and transferred to scintillation vial and 1.5 mL of 
Solvable™ was added to each vial and incubated for 24 hours at 50 °C to digest the 
tissues completely. To avoid the colour quenching effect on counting of radioactivity of 
the samples, 200 µL of oxygen peroxide was added to each sample and kept at room 
temperature for 8 to 10 hours. 10 mL of Ultima Gold™ scintillation fluid was added to 
the fully bleached samples and made ready to be counted for their radioactivity. 
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2.11.4. Quantification of the proportion of vaccine components in 
tissues 
The activity of [32P] and [3H] of the samples were counted on a Packard Tri-Carb liquid 
scintillation counter (LSC), GMI Inc. using separate standard detection protocols for 
[32P] and [3H]. The data are expressed as percentage of the injected dose per tissue 
(%ID). Also for investigating doses at the PLN, the data was expressed as percentage of 
the injected dose per milligram of the PLN. To calculate the dose percentage for each 
formulation, triplicate samples of the original dose were processed the same as tissue 
processing and were counted at each time point.  
It has been reported (Carstens et al., 2011; Zamecnik et al., 1982) that 32P energy 
spectrum overlap with the 3H spectrum; therefore to determine the radioactive count of 
each radionuclide a standard curve was plotted. In a range of 20 cpms to 150 kBq, 
triplicate samples of 32P were prepared and counted on scintillation counter by both 32P 
and 3H protocols. A plot of the 32P values (x-axis) was made against the cpm values 
derived from 3H (y-axis) and the line of best fit and equation derived for samples below 
50,000 cpm and those above 50,000 cpm. These two equations were used to calculate 
out the effect of 32P on the 3H values.  
2.12. Immunisation studies in mice 
2.12.1. Immunisation plan and vaccine formulations  
Female C57BL/5Jico mice (18-20 g) purchased from Charles River, UK, were placed in 
groups of 5, with a total of 16 groups. Vaccination was performed in a heterologous 
DNA prime-protein boost regimen. This was composed of two immunisations with 50 
µg/dose pRc/CMV HBS plasmid DNA (Free pDNA for controls or various pDNA-
liposome complexes) and a third injection with 3 µg/dose HBsAg (ayw subtype) 
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dissolved in PBS, Alhydrogel 2 % or incorporated with liposomes of various 
formulations. For all of the groups, intramuscular (i.m) injection was applied to the 
quadriceps muscle of the right leg of the animal and the volume of each dose was 50 µL. 
Each group of 5 mice (excluding the naïve group) have received this vaccination 
regimen at 2 week intervals.  
Several control groups were designed as follows: a group of five mice that received one 
single free protein injection on day 28 (Boost control, --P), second group received the 
prime control which composed of two injections of free pDNA on days 1 and 14 (DD-) 
and third group received the prime-boost control that includes two free pDNA injections 
on days 1 and 14 followed by injection of free protein on day 28 (DDP). Same schedule 
was applied for DOPE:DSTAP liposomes which formed in sucrose or PBS. To compare 
the effect of aluminium salts on immunisation one group of 5 mice specified for 
receiving of a single injection of HBsAg in alhydrogel 2 %.  
Other liposomal vaccine formulations were injected under prime-boost (DDP) regimen. 
One day before each injection, one week after third injection and three weeks after third 
injection, (days 0, 13, 27, 36 and 49) blood samples were collected from the tail vein.  
Three weeks after the last immunisation mice were terminated and spleen and the site of 
injection (SOI) were collected to analyse the immune response. 
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Figure 2.4: Schematic diagram of dual radiolabelling method to prepare radiolabelled lipoplexes and the biodistribution schedule plan. 
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2.12.2. Antibody analysis 
To perform the antibody enzyme-linked immunosorbent assay (ELISA), blood samples 
were taken by making a small cut in the tail vein and collecting 50 µL of blood sample 
within a capillary tube, which was coated with 1 % heparin. Heparin was dissolved in 
PBS. The collected bloods were transferred to microcentrifuge tube containing 450 µL 
PBS to give a 1/10 dilution. Blood dilutions were centrifuged (Micro Centaur) at 13,000 
g for 5 minutes. The supernatant was collected and stored at -20 °C. If the volume ratio 
of haematocrit is assumed 50 %, consequently the stored serum in each microcentrifuge 
tube was 20 times diluted in PBS.  
As it is shown in Figure 2.5, ELISA plates (flat bottom, high binding) were coated with 
60 µL of 2 µg/mL HBsAg in 0.05 M sodium carbonate (0.318 g Na2CO3 and 0.58 g 
Na2HCO3 in 250 mL ddH2O, pH 9.6) and left overnight at 4 °C. Plates were washed 
three times with PBST buffer to remove any unbound antigen. PBST buffer were made 
by dissolving 40 g NaCl, 1 g KCl, 1 g KH2PO4 and 7.2 g Na2HPO4(2H2O) in 5 litres 
distilled water and with 0.4 mL Tween 20. To remove any non-specific binding antigen, 
the plates were coated with 100 µL of 4 % (w/v) Marvel (dried skimmed milk powder) 
and incubated for 1 hour at 37 °C. Then plates were washed again three times with 
PBST buffer. 190 µL of PBS was added to each well of first row (Row A) of the 96 well 
ELISA plate and 100 µL PBS was added to the rest of the wells in rows B to H. 10 µL of 
the serum sample was taken and added to the specific wells of row A and mixed well. 
Each sample was investigated in duplicate. Then 50 µL of the mixtures in row A were 
taken and added to row B and this procedure repeated to row H to make the serial 
dilution of the serum for each column of the plate. 50 µL was removed from row A and 
H so that the total volume of the serially diluted serum in all the wells was 100 µL. 
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Figure 2.5: Schematic diagram of mouse antibody enzyme-linked immunosorbent assay (ELISA).  
Elisa plates were coated with HBsAg prior to numerous wash stages with PBST and blocking with Malvern 
milk 4 % (w/v). Washing prior to adding serum samples, antibody conjugates and enzyme substrate took 
placed with incubation at 37 °C	  and	  5	  %	  CO2.	  The	  absorbance	  was	  measured	  using	  plate	  reader	  at	  405	  nm.  
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Samples incubated for one hour at 37 °C followed by 5 times wash with PBST. 50 µL of 
diluted isotype specific immunoglobulin (IgG, IgG1 and IgG2b diluted in PBS as 1:500 
for IgG and 1:4000 for IgG1 and IgG2b) were added to the appropriate plates. Then 
they were incubated for one hour at 37 °C followed by five PBST washes. 50 µL 
colouring agent (substrate) added per well. The substrate was made by dissolving of 6 x 
10 mg tablets of 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid in 100 mL of citrate 
buffer (2.3 g citric acid, 4.89 g Na2HPO4 in 250 mL ddH2O) incorporating 10 µL of 
hydrogen peroxide (Figure 2.5). 
The plates were incubated for 20 minutes at 37 °C and the absorbance was measured at 
405 nm using a microplate reader (Bio-Rad, model 680). Previous known positive sera 
and naïve mouse sera were employed as positive and negative controls, respectively, on 
each ELISA plate. The results were expressed as the log10 value of the reciprocal of the 
end point dilution, which gave an optical density (O.D) of 0.2 or above. 
2.12.3. Splenocyte proliferation study 
Mice were terminated on day 49 and their spleens were removed and placed into 5 mL 
ice-cold sterile PBS. Under sterile conditions, each spleen was gently mashed on a fine 
wire mesh to give a suspension of spleen cells and added to 10 mL RPMI 1640 
supplemented with 10 % FBS and 1 % PSG. The cell suspension was left for 5 minutes 
to allow to the cell debris to settle, and then the supernatant was transferred to the sterile 
15 mL falcon tubes and centrifuged at 1200 rpm for 10 minutes, at 15 °C. After 
centrifugation the supernatant was carefully removed and the pellet was resuspended to 
10 mL with fresh supplemented RPMI, after which this cell suspension was again 
centrifuged at 1200 rpm for 10 minutes, at 15 °C. The supernatant was carefully 
removed and the pellet was resuspended to 5 mL with fresh RPMI. The cells were 
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counted as described in section 2.10.1.3 and the cell number was adjusted to 1 x 
107cells/mL.  
100 µL of serially diluted HBsAg (0.05, 0.5 and 5 µg/mL) in RPMI, was added to the 
sterile 96 well plate. The negative control wells contained medium only, and positive 
control was 5 µg/mL dilution of concanavalin A (Con A) in RPMI. 100 µL of 
splenocytes (1 x 107cells/mL) were added to the wells and the plates were incubated for 
72 hours in a sterile incubator with 37 °C and 5 % CO2 and 95 % humidity. After 
incubation, 40 µL of 18.5 kBq [3H]-thymidine within sterile supplemented RMPI was 
added to each well of a 96-well plate and incubated for further 24 hours under the same 
conditions. Cells were harvested onto a quartz filter mats using a cell harvester 
(Titertek). For harvesting well contents were aspirated onto the quartz filter mat and 
kept to dry.  The discs representing each well were punched from the filter mats into 15 
mL plastic scintillation vial followed by addition of 5 mL Ultima Gold™ scintillation 
fluid. The radioactivity of each sample was counted on a Packard Tri-Carb liquid 
scintillation counter (LSC), GMI Inc. by 3H scintillation counting protocol. 
2.12.4. Cytokine analysis from in vitro restimulated splenocytes 
Restimulated splenocytes with HBsAg or Con A and cells were prepared as outlined in 
section 2.12.3. Dilutions of 5 µg/mL HBsAg in RPMI were made and 100 µL was 
added per well of a sterile 96 well plate. Negative and positive controls were again 
medium only and 5 µg/mL Con A respectively. To have enough supernatant, 12 wells 
of each plate were used for each condition. 100 µL of splenocytes (1 x 107cells/mL) 
were added to the wells and the plates were incubated for 48 hours at a sterile incubator 
with 37 °C and 5 % CO2 and 95 % humidity. The supernatants were then removed and 
added to the microcentrifuge tubes and frozen at -70 °C until use.
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 Cytokine levels of IL-2, IL-5, IL-6, IL-10 and IFN-γ in the cell culture supernatants 
were quantified using the DuoSet® capture ELISA. The protocol was taken from the 
manufacturer catalogue (R&D Systems, Abingdon, UK). The ELISA plates were coated 
with 100 µL capture antibody (1 µg/mL for IL-2 and IL-5, 2 µg/mL for IL-6 and IL-10, 
4 µg/mL for IFN-γ, all in PBS) and incubated at room temperature overnight. Plates 
were then washed three times with PBST buffer and blocked by 300 µL block buffer. 
Block buffer for IL-2 and IFN-γ was 1 % BSA in PBS with 0.05 % NaN3 and for IL-5, 
IL-6 and IL-10 was their reagent diluent which was 1 % BSA (in PBS, pH 7.2-7.4). 
Plates were then incubated for 1 hour at room temperature, followed by three washes 
with PBST buffer. 100 µL of samples added to each well. At this stage standards were 
also diluted in reagent diluent and pipetted into the plate. For IL-2 and IFN-γ reagent 
diluent was, 0.1 % BSA, 0.05 % Tween 20 in Tris-buffer Saline (20 mM Trizma base, 
150 mM NaCl) pH 7.2-7.4. After incubation, plates were washed three times with PBST 
buffer. The cytokine standards were 2-fold serial dilutions of the supplied cytokine 
diluted in 0.2 µm sterile filtered reagent diluent. Each standard was diluted 6 times and 
included a 0 pg/mL control. The samples were added without any dilution. After 
incubation 100 µL detection antibody for the corresponding cytokine was added to each 
well and the plates were covered by new microplate slip and incubated for 2 hours at 
room temperature. Plates were once again washed three times with PBST buffer. 100 µL 
of working dilution of Streptavidin-HRP (horseradish peroxidase) was added per well, 
after which the plates were incubated at room temperature for 20 minutes, and be 
avoided from the direct light. Plates were washed three times with PBST buffer and 100 
µL of substrate solution was added per well. Substrate solution was a 1:1 mixture of 
colour reagent A (H2O2) and colour reagent B (tetramethylbenzidine (TMB) agent (1 mg 
tablets), with 1 tablet dissolved in 1 mL DMSO and 9 mL of phosphate citrate buffer 
(0.05 M, pH 5)). Plates were then incubated at room temperature for 20 minutes while 
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was avoided from the direct light. Then by adding 50 µL of stop solution (2N H2SO4) 
the reaction stopped and the blue light indicating the reaction changes to golden yellow. 
The optical density of each well was measured immediately using a microplate reader 
(Bio-Rad, model 680) set to 450 nm. 
2.12.5. Cytokine analysis from in vitro restimulated cells from the 
site of injection 
The production of IL-1β at the site of injection (SOI) was investigated by the method 
described by Sharp et al. (2009). Muscle from the SOI was excised 3 weeks after the 
final injection and flushed freeze by liquid Nitrogen and kept frozen at -70 °C. On the 
day of experiment, leg was defrosted and the quadriceps muscle was removed and 
separated from the bone. After weighing the muscle using a manual homogenisation 
tube (Figure 2.6), each leg’s muscle homogenised on ice in 2.5 mL of homogenisation 
buffer (500 mM NaCl/50 mM Hepes, pH 7.4, containing 0.1 % Triton X-100, Sigma 
protease inhibition mixture and 0.02 % NaN3).  
 
 
 
 
                                       Figure 2.6: Teflon homogenisation tube to homogenise the leg muscle. 
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Samples were sonicated and centrifuged (6000 x g, 20 minutes, 4 °C) prior to detection 
of IL-1β in supernatants. After centrifugation, three layers were separated from up to 
down of the 15 mL Falcon tube which were fat layer, supernatant or cells and at the 
bottom of the tube there was debris and hair. The supernatant was removed carefully 
from the tube and pooled into the microcentrifuge tubes and kept in -20 °C until use. 
The same method, which used for splenocytes in section 2.12.4 was used to figure out 
the production level of IL-1β at the site of injection. Results were shown as pg of IL-1β 
per milligram of each muscle. 
2.13. Statistics 
Means and standard deviation were calculated for all experiments. The one-way 
analysis of variance (ANOVA) was performed on all data to determine statistical 
significance. The statistical significance determined to 0.05 confidence intervals 
(P<0.05). To compare the difference of significance of different conditions, Tukey’s post 
hoc test was performed. 
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3.1. Introduction 
Cationic liposomes have been widely investigated as a non-viral delivery system for 
gene delivery (Bedi et al., 2011; Gjetting et al., 2011; Gregoriadis et al., 2002; Perrie et 
al., 2003; Wang et al., 2012b; Zabner, 1997) and the electrostatic interaction between 
positive charge of cationic liposomes and negative charge of DNA make a complex of 
cationic liposome-DNA generally referred to as lipoplexes (McNeil et al., 2010). 
To develop lipoplexes with high transfection and low toxicity, several parameters should 
be taken into account such as: size, lipid/DNA charge ratio, net positive charge of the 
lipoplex, chemical structure of cationic lipid and helper lipid, and finally the structure of 
the complex itself (Congiu et al., 2004). However, given the dynamic nature of these 
structures, many factors, in addition to those already listed, can contribute to the 
resultant physico-chemical attributes of the lipoplexes, including the rate of mixing of 
the various components, the temperatures used and even the presence of electrolytes in 
the buffers used (Congiu et al., 2004; McNeil and Perrie, 2006, 2007). Indeed, research 
has shown that the presence of electrolyte within the aqueous media can influence both 
the physicochemical properties and the in vivo efficacy of lipoplexes, with the authors 
demonstrating that the addition of low concentrations of sodium chloride to cationic 
liposomes during complex formation lead to an improved vaccine adjuvant action (Yan 
and Huang, 2009).  
Thus, the aim of the work in this chapter was to investigate the molecular interactions of 
lipids and the resultant lipoplexes properties and to attempt to correlate these with the 
transfection attributes of the system in a controlled in vitro environment. Therefore, lipid 
monolayers were studied by Langmuir-Blodgett trough, as such monolayers can be 
considered as building blocks for bilayer vesicles, consequently, studying these 
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monolayers in an aqueous media (dH2O or PBS) at air/water interface, in combination 
with the lipid attributes, may give insights into bilayer lipid packaging configuration and 
liposomes stability which could influence transfection (Ali et al., 2010; Christensen et 
al., 2008). Cationic liposomes were prepared in dH2O or the commonly used phosphate 
buffered saline (PBS) and the liposome physicochemical characteristics considered, such 
that the effect of electrolytes could be considered, and correlated with the Langmuir 
studies. Of the cationic liposome systems tested, the combination of the fusogenic lipid 
DOPE (Figure 3.1) with the cationic lipid DOTAP, is a frequently used composition 
due to its high in vitro transfection efficiency and optimal immune response (Ciani et al., 
2007; Guo and Lee, 2000; Li et al., 2010; Liu, 2003; McNeil et al., 2010; Perrie et al., 
2001).  
 
Figure 3.1: Molecular structure of used anionic lipids (DOPG and DSPG), fusogenic lipids (DOPE and 
DSPE) and cationic lipids (DOTAP and DSTAP). 
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Therefore, this formulation was chosen for further investigation. To consider the effect 
of lipid acyl chains on their molecular packaging and lipoplex characteristics, DOPE 
and DOTAP were also systematically compared with their disteroyl equivalents (DSPE 
and DSTAP). To investigate if the finding from these studies were cationic lipid specific, 
or if it was achievable by anionic lipids, two anionic lipids (DOPG and DSPG) were 
also studied (Figure 3.1).  
3.2 Liposome preparation: Initial studies 
3.2.1. The effect of buffer concentration on zeta potential 
Prior to performance of characterisation studies on liposomes, the effect of different PBS 
concentrations on zeta potential was measured. First, multilamellar vesicles (MLV) of a 
model cationic liposome formulation (DOPE:DC-Chol) was prepared with PBS as the 
hydration phase. Then a serial dilution of PBS at concentrations of [0.0001, 0.001, 0.01, 
1, 10 mM] was prepared (Figure 3.2).  
For measuring the zeta potential, 100 µL of the liposome suspension was diluted in 3 
mL of the above concentrations. Liposomes diluted in dH2O were also tested. Results 
show an initial increase in zeta potential (≈ 55 mV) by using PBS even at very low 
concentrations (0.01 mM) comparing to distilled water (≈ 30 mV), however, as the PBS 
concentration increases the zeta potential decreases to ≈ 40 mV (Figure 3.2). 
Electrolytes are known to influence the electrical double layer which surrounds charged 
particles and interfaces (Florence and Attwood, 2006); this also leads to changes in the 
zeta potential. It is reported that increasing electrolyte concentration can condense the 
electrical double layer and thus reduce the zeta potential on a charged surface and this 
may explain the reduction in zeta potential at higher PBS concentrations (Florence and 
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Attwood, 2006). However, it was also shown there is no significant difference in the 
zeta potential of liposomes suspended in PBS at 1 mM and 10 mM (P>0.05) suggesting 
that 1 mM PBS can be used for characterisation studies (Perrie and Gregoriadis, 2000).  
 
Figure 3.2: The effect of electrolyte concentration on the zeta potential of cationic liposomes. Results 
represent mean ± SD from 3 independent batches.  
3.2.2. Optimisation of sonication time in SUV preparation 
Whilst it is common to reduce the size of MLV via probe sonication, it has previously 
been reported that prolonged probe sonication can cause an increase in size due to lipid 
damage and particle aggregation; high temperatures produced by sonication were 
reported to be responsible for this (Ferdous et al., 1998). In addition, titanium particles 
from the probe can influence the formulation integrity. To reduce these disadvantages of 
probe sonication, a study was performed to select the shortest and the most efficient 
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time of sonication for the production of SUV. After measuring the size and zeta 
potential of MLV liposomes of DOPE:DOTAP, DOPE:DSTAP, DSPE:DOTAP 
hydrated in distilled water or PBS, the suspension was sonicated for 15 s and size and 
zeta potential were measured at this point. Then, the sonication and measuring of the 
size and zeta potential has continued every 15 s for 2 minutes.  
Results in Figure 3.3A show the mean particle size of MLV for DOPE:DOTAP (8:8 
µmol) hydrated in dH2O was ≈ 540 nm and the size decreases immediately after first 
sonication to ≈ 113 nm. By continued sonication, the size reduced to ≈ 99 nm after 60 s 
sonication, with no further decrease in size or PI (Figure 3.3). Therefore, in further 
experiments with this formulation and concentration, 60 s sonication will be performed 
to make SUV. Measuring the zeta potential of these vesicles during this process also 
demonstrated that their cationic nature remained unaffected by sonication (≈ 39-42 mV; 
Figure 3.3B), as would be expected unless lipid damage occurred.  
Results in Figure 3.3A also demonstrated that sonication of MLV liposomes formed in 
PBS were ≈ 810 nm in size and decreased to ≈ 170 nm after 15 s, with further 
sonication reducing the size of the vesicles slightly (≈ 150 nm) and producing the lowest 
PI, suggesting 60 s sonication as an appropriate time to produce SUV (Figure 3.3A). As 
with the vesicles dispersed in distilled water, the zeta potential of the vesicles remained 
positive and constant (≈42-51mV; Figure 3.3B). Comparing between the formulations 
prepared in the presence/absence of electrolytes show that, whilst MLV prepared in 
PBS were larger in size than those in dH2O, appropraite sonication could produce SUV 
in the same size range in either aqueous media (Figure 3.3A). 
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Figure 3.3: Effect of sonication time on liposomes characteristics. A,C and E show vesicle size and 
polydispersity index for DOPE:DOTAP, DOPE:DSTAP and DSPE:DOTAP respectively.  B, D and F 
demonstrate the zeta potential values for DOPE:DOTAP, DOPE:DSTAP and DSPE:DOTAP respectively. 
All formulations hydrated in both distilled water or PBS and with the molar ratio of (8:8 µmol).	  Results 
represent mean ± SD, from 3 independent batches. 
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When considering the choice of cationic lipid, replacing the unsaturated DOTAP with 
its saturated counterpart DSTAP, shows the mean vesicle size of MLV for 
DOPE:DSTAP hydrated in distilled water was approximately 800 nm, and after 
sonication decreases to ≈ 120 nm after brief sonication, and after 60 s a minimum 
vesicle size of ≈ 97 nm was produced (Figure 3.3C).  
Changing the hydration media to PBS increased the MLV size to ≈ 2 µm, although SUV 
with the size of around 130 nm could be produced with sonication (Figure 3.3C), which 
is comparable to previous studies looking at these formulations hydrated in NaCl (0.85 
% W/V) where the vesicle size is about 120 nm (Filion and Phillips, 1997), and is 
slightly smaller than other research reporting DOPE:DSTAP vesicle sizes of ≈ 160 nm 
(Regelin et al., 2000). Therefore, whilst the DSTAP MLV were significantly larger in 
size (P<0.05) than DOTAP MLV, comparably sized SUV could be produced with either 
cationic lipid. Zeta potential measurements for the DOPE:DOTAP formulation (Figure 
3.3D) show zeta potential for the liposomes which are hydrated in distilled water are in 
a constant range of ≈ 39 to 43 mV, and ≈ 42 to 49 mV for liposomes hydrated in PBS 
(Figure 3.3D). Comparing DOPE:DSTAP to DOPE:DOTAP liposomes shows there is 
no significant difference in zeta potential of these formulations in both rehydration 
phases suggesting that changing in acyl chain of lipid and length of the lipid chain has 
no significant effect on surface charge of the liposomes (P>0.05), as would be expected. 
To consider the role of the fusogenic lipid, DOPE was also replaced with a high 
transition temperature lipid DSPE. The effect of changing chain length and saturation of 
helper lipid in cationic liposomes and in the hydration media of PBS or distilled water 
was investigated. Results (Figure 3.3E) show the DSPE:DOTAP MLV size when 
hydrated in dH2O was ≈ 900 nm and the lowest vesicle size for the liposomes achieved 
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after sonication was ≈ 128 nm with the zeta potential remaining constant (≈ 48 to 54 
mV; Figure 3.3F). 
Comparing DSPE:DOTAP to DOPE:DOTAP shows that neither the vesicle size nor 
the zeta potential were  significantly different, suggesting that saturation of helper lipid 
has no significant effect. Interestingly, DSPE:DOTAP vesicles could not be formulated 
in PBS as the lipid film would not hydrate with PBS. This might be due to the effect of 
salt on critical packaging parameter (CPP) of the lipid. As the DSPE is a saturated form 
of DOPE, it has a longer chain and this can also affect the CPP and consequently 
influence forming of inverted hexagonal phase (HII) of the liposomes leading to 
destabilising the bilayer and aggregation of the lipids in PBS (Regelin et al., 2000; 
Wasungu and Hoekstra, 2006) 
3.2.3. Formulation of DRV and the influence of electrolytes 
This work investigated the effect of salt on characterisation properties of different 
liposomes prepared in the DRV process. For this purpose, DRV liposomes of 
DOPE:DOTAP, DOPE:DSTAP and DSPE:DOTAP were prepared in both aqueous 
phases of distilled water and PBS and their size and zeta potential measured. 
Figure 3.4A show the vesicle size of DOPE:DOTAP formed in dH2O or PBS and in 
different forms of MLV, SUV and DRV. Results show presence of salt in the 
formulation did not effect the vesicle size of the DRV DOPE:DOTAP, as it is ≈ 570 nm 
in both hydration media (Figure 3.4A). The same trend has been shown for 
DOPE:DSTAP, as the vesicle size of DRV remains ≈ 750 nm for the liposome in each 
hydration media. This suggests that presence of salt does not influence on the size of 
DRV liposomes.  
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Figure 3.4: Comparison between MLV,SUV and DRV characteristics of  DOPE:DOTAP(A,B), 
DOPE:DSTAP (C,D) and DSPE:DOTAP (E,F)  in PBS and dH2O: (A,C,E) Particle size vs Polydispersity 
Index, (B,D,F) Zeta potential. Results represent mean ± SD, from 3 independent batches. 
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Results also reveal there is no significant change in the surface charge of liposomes due 
to change of the hydration media (Figure 3.4B and D). The zeta potential for DRV 
DOPE:DOTAP in both hydration media was ≈ 35 mV (Figure 3.4B) while it is 40 and 
35 mV for DRV of DOPE:DSTAP formed in distilled water and PBS respectively 
(Figure 3.4D).  
Investigating the effect of replacing DOTAP by DSTAP revealed that size and zeta 
potential of liposomes, when hydrated in dH2O, has not changed significantly (Figure 
3.4A & C). The same study was performed in the liposomes hydrated in PBS and as 
results in Figure 3.4A & B and Figure 3.4C & D show, there is no significant change in 
size or zeta potential of liposomes. 
Comparison of size and zeta potential of DSPE:DOTAP and DOPE:DOTAP liposomes 
when prepared in distilled water demonstrated there is no significant change in vesicle 
size of MLV and  SUV, although in DRV vesicle size significantly (P<0.05) increased 
from ≈525 nm in DOPE:DOTAP to ≈925 nm in DSPE:DOTAP. Zeta potential has 
decreased for all types of DSPE:DOTAP but it is not significant (Figure 3.4B and F). 
The most notable change, which was observered in all of the studied formulations, was 
the increasing effect of freeze-drying and rehydration on vesicle size of the liposomes. 
This is mostly due to aggregation of the vesicles after rehydration of freeze-dried 
liposomes. The stability of liposomes depends on hydrogen bonds between water 
molecules and polar head groups of the liposomes. The drying phase of  the freeze-
drying process can affect these hydrogen bonds and may lead to vesicle fusion, 
aggregation, and loss of integrity of the liposomes. These all may lead to increasing 
vesicle size (Crowe et al., 1986), although freeze-drying of the liposome can improve 
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stability of the formulation (Darwis and Kellaway, 2001) and it has been shown to be 
more efficient in vivo for DNA delivery than SUV (Gregoriadis et al., 2002; Perrie et al., 
2001). 
3.3. Molecular packaging of lipids: the role of lipid 
structure and electrolytes 
The Langmuir-Blodgett trough was used to investigate single and mixed lipid 
monolayers for their interactions within the monolayer in the aqueous sub-phase of 
either dH2O or PBS, to consider how molecular packaging translates into liposomal 
systems. Pressure-area (π-A) isotherms for cationic liposome components are shown in 
Figure 3.5. The extrapolated (to zero pressure) area per molecule and collapse pressure 
for the individual lipids, in either a water or PBS subphase, and also for 1:1 lipid 
mixtures for all studied lipids are shown in Table 3.1. For the latter, the ideal 
extrapolated area per molecule was calculated based on taking the average area for the 
lipid combination, such that the calculated area could be compared to the actual area 
per molecule of the mixture. Deviations between the experimentally observed and the 
calculated ideal area may be considered as the measure of interactions between the 
mixed components, since the experimentally observed area depends on the 
intermolecular forces between the lipids in the mixed monolayer. Negative deviations 
(where the experimental area is less than the ideal calculated area per molecule) indicate 
attractive interactions occurring between the lipids, whilst positive deviations indicate 
repulsive interactions.  
Considering the single component monolayers formed on dH2O, the extrapolated area 
per molecule for each of the 4 lipids was in the order of 
DOTAP>DOPE>DSTAP>DSPE (Table 3.1), with the cationic lipids (DOTAP and 
Chapter 3: The Effect of Alkyl Chain and Electrolytes on Characteristics of Transfection Agent Lipoplexes 
 
108 
DSTAP) having a larger area per molecule than their comparable zwitterionic 
counterparts (DOPE and DSPE respectively; Table 3.1). The cationic lipids also formed 
liquid-expanded monolayers (Figure 3.5A) with lower collapse pressures than their PE 
counterparts (Table 3.1). Comparison between the saturated and unsaturated lipids, 
show that the saturated lipids are able to pack together closer in a solid monolayer than 
their unsaturated counterparts (Figure 3.5A) with DOTAP having approximately twice 
the measured molecular area compared to DSTAP (104 vs 53 A2/molecule; Table 3.1). 
Due to their closer packaging arrangement, the saturated lipids also display a higher 
collapse pressure and a more rigid monolayer than their unsaturated counterparts (Table 
3.1 and Figure 3.5A). Formation of these monolayers on PBS rather than dH2O made 
no notable difference in the measured area per molecule, however this did result in an 
increased collapse pressure in the case of the cationic lipid monolayers, particularly in 
the case of DOTAP, which increased from 29.5 to 42.1 mN/m (Table 3.1 and Figure 
3.5B). This resulted in their being no significant difference in collapse pressures between 
the cationic and zwitterionic lipid monolayers when formed in PBS (Table 3.1). 
When prepared as mixed monolayers at a 1:1 molar ratio (as is commonly adopted in 
lipoplexes) the extrapolated area per molecule for the combinations was in the order of 
DOPE:DOTAP>DOPE:DSTAP ≈ DSPE:DOTAP>DSPE:DSTAP, with the 
combination of two unsaturated lipids giving the highest mean molecular area, whilst 
the fully saturated mixture (DSPE:DSTAP) had a smaller mean molecular area of 46 A2 
per molecule (Table 3.1), and formed a solid monolayer similar to the individual 
components (Figure 3.5). Of the 4 mixed monolayers, the DSPE:DSTAP monolayer 
also had the highest collapse pressure (52.9±1.3 mN/m; Table 3.1). When the dH2O 
subphase was replaced with PBS, there was a notable increase in the extrapolated area 
per molecule for DSPE:DOTAP, suggesting the presence of buffer salts was inhibiting 
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the packaging of the monolayer, yet the collapse pressures were not influenced by the 
change in subphase (Table 3.1). 
Considering the deviation from ideality (Table 3.1), which can be used to monitor 
molecular interactions between the molecules in the mixed monolayers, for those lipid 
monolayer containing either both saturated (DSPE:DSTAP) or both unsaturated 
(DOPE:DOTAP) lipids the deviation is minimal, irrespective of the choice of subphase 
(Table 3.1), suggesting there was no condensing effect occurring in either type of 
monolayer. In contrast, for the monolayers combining a saturated and an unsaturated 
lipid (DOPE:DSTAP or DSPE:DOTAP) there are large positive deviations from the 
calculated mean area, suggesting the lipids in these mixed monolayers packed in a more 
expanded arrangement than was predicted, particularly when the systems were in PBS 
as the deviation was > 30 % for both DOPE:DSTAP and DSPE:DOTAP (Table 3.1). 
However, these differences do not translate into changes in collapse pressures, with both 
mixed monolayers having the same collapse pressures in dH2O as they did in PBS 
(Table 3.1). 
Saturated long chain lipids often display strong attractive intermolecular interactions 
and this is supported by the small molecular area and high collapse pressure of the 
saturated monolayer and this might suggest that the DSPE:DSTAP combination could 
give a strong low permeability liposome system, as has previously been shown with 
water soluble drugs entrapped within vesicles (Hac-Wydro and Wydro, 2007; Hac-
Wydro et al., 2004; Hac-Wydro et al., 2007). However, in the case of unsaturated lipids, 
these lipids are more bulky (as shown by their larger molecular area; Table 3.1) with a 
less densely packed arrangement, that can cause a more permeable liposome bilayer 
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with higher release profile of entrapped drug compared to saturated monolayers (Ali et 
al., 2010) 
 
Figure 3.5: Compression isotherm studies of the single and mixture of lipid monolayers of DOPE:DOTAP, 
DSPE:DOTAP, DOPE:DSTAP and DSPE:DSTAP in deionised water (A and C) or PBS (B and D) at 20 
°C. Results are expressed as the means of three experiments. SD has not shown for clarity. 
From these results, it would suggest that the use of a fully saturated system promotes the 
higher packing density of lipids with high collapse pressure and which may promote a 
more rigid liposome system. In contrast, liposomes formed in PBS from lipid mixtures 
containing unsaturated lipid(s) in the mixture (either the helper lipid or the cationic 
lipid) could result in liposomes with less rigid bilayers (Table 3.1 and Figure 3.5). 
However, given lipoplexes require both stability on storage and fusogenic properties, the 
consideration of how such monolayer attributes translate into liposome formulation and 
transfection attributes was considered. In addition, this study was performed on 
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monolayers of the single and mixed lipids of DOPG and DSPG on dH2O as a subphase. 
As with the cationic lipids, the molecular area of the saturated single lipid of DSPG is 
almost half of the molecular area for the unsaturated DOPG (44.9 Vs 80.1 
A2/Molecule; Table 3.1).  Interestingly, the trend for collapse pressure of the anionic 
lipid monolayers follows the cationic lipids as saturated lipid of DSPG shows higher 
collapse pressure (52.8 mN/m) than unsaturated DOPG with the collapse pressure of 39 
mN/m (Figure 3.6B and Table 3.1).   
Table 3.1: The experimental extrapolated area and area compressibility of mixed and single monolayers  
at the air/aq media interface at 20 °C in dH2O or PBS as sub-phase. Results denote mean ± SD, n=3. 
 
Lipid 
Extrapolated Area 
(A2/Molecule) 
Ideal Extrapolated 
Area (A2/Molecule) 
Deviation from 
Ideality (%) 
Collapse Pressure 
(mN/m) 
dH2O PBS dH2O PBS dH2O PBS dH2O PBS 
DOPE 71.9±6.0 70.6±7.7 - - - - 42.3±0.4 42.2±2.6 
DOTAP 104.3±12.9 93.4±10.1 - - - - 29.5±1.5 42.1±0.9 
DOPG 80.1±2.2 - - - - - 39.0±0.4 - 
DSPE 47.6±0.5 45.7±2.3 - - - - 55.7±0.5 53.5±1.0 
DSTAP 53.2±2.5 53.0±2.1 - - - - 50.3±3.1 55.9±0.8 
DSPG 44.9±1.6 - - - - - 52.8±1.4 - 
DOPE:DOTAP 89.7±6.5 81.3±5.3 88.1 82.0 +1.8 -0.9 38.4±1.5 42.7±0.9 
DOPE:DSTAP 81.6±0.6 87.4±1.6 62.6 61.8 +30.5 +41.4 38.8±2.3 36.1±2.4 
DSPE:DOTAP 80.6±1.5 91.7±1.4 75.9 69.5 +6.1 +31.9 37.7±0.3 34.5±0.7 
DSPE:DSTAP 46.4±0.7 48.6±0.2 50.4 49.3 -7.9 -1.5 52.9±1.3 54.4±1.2 
DOPE:DOPG 92.8±1.8 - 76.0 - +18.1 - 45±0.14 - 
DSPE:DSPG 54.6±1.2 - 46.3 - +15.2 - 54.1±0.1 - 
As it is shown in Figure 3.6C, the collapse pressure of the mixture of unsaturated lipids 
(DOPE:DOPG) are significantly lower (P<0.05) than saturated DSPE:DSPG and, as 
the cationic lipids, the molecular area of the mixture of unsaturated lipids 
(DOPE:DOPG) is nearly double the area for saturated lipid monolayers (92.8 
A2/Molecule Vs 54.6 A2/Molecule; Table 3.1).   
These results also show that irrespective of the charge of the lipid (anionic vs cationic), 
saturated lipids have a condensed structure with highly attractive intermolecular 
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interactions causing their small molecular area and high collapse pressure compared to 
the unsaturated lipids. However, in contrary to the mixture of fusogenic and cationic 
lipids, there is high positive deviation for DOPE:DOPG and DSPE:DSPG (+18 and 
+15 respectively), showing that in the case of anionic lipid, the helper lipid has more 
effect in changing the molecular packaging of the monolayers compared to the cationic 
lipids, making the monolayers more expanded rather than condensed. This may explain 
why it is possible to form vesicles from the DSPE:DSPG combination (Table 3.2) but 
not from DSPE:DSTAP (Section 3.2.2). 
 
Figure 3.6: Compression isotherm studies of the (A) single neutral lipids of DOPE and DSPE, (B) single 
anionic lipids of DOPG and DSPG, and (C) mixture of lipid monolayers of DOPE:DOPG, DSPE:DSPG 
at 20 °C. Results are expressed as the means of three experiments. SD has not shown for clarity. 
 
Table 3.2: Characteristic properties of the anionic liposomes of DOPE:DOPG and DSPE:DSPG both 
hydrated in distilled water and with the lipid ratio of (8:8 µmol). 
Formulations Vesicle size (nm) Polydispersity Index Zeta potential (mV) 
DOPE:DOPG 80.9 ± 5.5 0.243 ± 0.007 -57.0 ± 2.55 
DSPE:DSPG 88.8 ± 17.3 0.283 ± 0.034 -39.3 ± 14.9 
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3.4. The effect of alkyl chain and electrolytes on the 
characteristics of lipoplexes  
To investigate the lipid properties on the lipoplex attributes, SUV liposomes prepared 
from DOPE:DOTAP, DOPE:DSTAP, DSPE:DOTAP and DSPE:DSTAP (all 
equimolar) and DRV liposomes of DOPE:DOTAP and DOPE:DSTAP (both 
equimolar) were formulated in distilled water or PBS and mixed with plasmid DNA 
(gWizTM Luciferase) at a range of concentrations (2.5, 25, 50, 100, 200 and 1600 µg) for 
SUV liposomes and (2.5, 50, 200 and 1600 µg) for DRV liposomes.  
As previously noted, of the four combinations, it was not possible to formulate 
liposomes from the combination of DSPE:DSTAP, suggesting that whilst this 
combination can form a closely packaged solid monolayer, this could not be translated 
into a liposomal bilayer. Similarly DSPE:DOTAP liposomes could only be formed in 
dH2O and not in PBS. As mentioned, saturated lipids often display strong attractive 
intermolecular forces, which can make hydration and dispersion in water difficult 
(Regelin et al., 2000; Wasungu and Hoekstra, 2006), hence the difficulty in formulating 
liposomes form DSPE:DSTAP. The introduction of double bonds into the lipid tail (i.e. 
replacement of DSPE with DOPE or DSTAP with DOTAP) results in a less compact 
system, which is easier to disperse in water (Wasungu and Hoekstra, 2006). The 
inability of DSPE:DOTAP to form vesicles in PBS may be due to the effect of salt on 
critical packaging parameter (CPP) of the lipid which is dependent on length of 
hydrocarbon chain, volume of hydrophobic part and the surface area per molecule 
(Israelachvili and Mitchell, 1975; Israelachvili et al., 1977). Dispersion of lipid 
molecules in the water can lead to different structures such as micelles, inverted 
micelles, hexagonal, lamellar or cubic phase as well as liquid crystalline with CPP being 
a useful predictor of the structures formed. The desired CPP shape for lipids to form 
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liposomes is a truncated cone shape (a CPP of between ½ and 1); however, studies show 
that liposomes can form from lipids which individually do not have the truncated cone 
shape, but when combined are able to appropriately pack (Israelachvili and Mitchell, 
1975; Israelachvili et al., 1977). In the case of DSPE:DOTAP, in water the molecular 
shape of DOTAP (with its large tail area and cationic head-group) may be able to 
compensate for the smaller DSPE molecular volume, however in the presence of buffer 
this can reduce the electrostatic nature of the DOTAP headgroup (Wasungu and 
Hoekstra, 2006), therefore changing the ‘shape’ of the molecule, which means it is not 
able to compensate for DSPE, thus prohibiting the formation of liposomes.  
3.4.1. Characterisation studies of lipoplexes 
In all formulations, vesicle size increased with increasing DNA concentration (Figure 
3.7 and 3.8) suggesting aggregation of the system due to what has previously been 
attributed to a bridging effect (Ciani et al., 2004) and/or a re-organisation of the system 
(Elouahabi and Ruysschaert, 2005; Huebner et al., 1999; Tarahovsky et al., 2004; 
Weisman et al., 2004), which is highly dependent on the +/- charge ratio (Zuhorn et al., 
2007) to larger sized constructs. 
With the SUV DOPE:DOTAP formulation, the presence of the buffer salts in PBS 
made no significant difference in vesicle size, except for the highest DNA concentration 
tested; lipoplexes were around 300 nm if formulated in water compared to ~1800 nm 
when prepared in PBS (Figure 3.7A). In the case of the SUV DOPE:DSTAP lipoplexes, 
the presence of PBS was shown to significantly (p < 0.05) increase the size of the 
lipoplexes at all DNA concentrations and of the 4 SUV formulations, DOPE:DSTAP in 
PBS gave the largest lipoplexes (Figure 3.8B). Previous studies have also shown the size 
of the liposomes can increase to double the size in the presence of PBS, as the phosphate 
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group of the PBS can act as a glue and increase the vesicle size by bridging the cationic 
polar heads of the lipid (Ciani et al., 2007). Another study reveals cationic liposomes 
have a higher tendency to aggregate when there is salt in the formulation, due to the 
reduced electrostatic interactions between systems and consequently more aggregation 
and larger vesicles formed (Wasan et al., 1999). The difference in size between the 
formulations may be again due to the molecular packaging of the lipids, as more rigid 
assemblies, such as those formed from saturated cationic lipids, have been shown to 
preclude efficient re-organisation of this system, causing aggregation of large particles to 
form with lower transfection efficacy presumably due to reduced internalisation 
(Wasungu and Hoekstra, 2006). The same trend of results has been seen for DRV 
lipoplexes, where presence of salt in formulations caused a significant increase in the 
vesicle size of the lipoplexes at the highest DNA concentrations for both 
DOPE:DOTAP and DOPE:DSTAP (Figure 3.8A & B). Zeta potential studies of the 
systems were used to estimate the level of interaction between negative charges of DNA 
and positive charges of cationic lipid (Ma et al., 2007). As this electrostatic interaction is 
one of the basic components of DNA complexation, and the net charge of lipoplexes is 
important for overcoming cell barriers (Uyechi-O'Brien and Szoka, 2003; Wasungu and 
Hoekstra, 2006), zeta potential studies were performed to determine the surface charge 
of the lipoplexes.  
Results illustrate that increasing the amount of DNA over the range used had little effect 
on the cationic nature of the lipoplexes when formulated in dH2O, presumably due to 
the high cationic/anionic charge ratio (Figure 3.7 and 3.8). However, in PBS, the 
neutralising effect of the buffer electrolytes on the zeta potential can be seen, particularly 
for SUV DOPE:DSTAP, where the zeta potential reduces from ≈ 60 mV in distilled 
water formulations to ≈ 30 mV and less in PBS formulations (Figure 3.7E). For DRV 
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lipoplexes, zeta potential did not change significantly under the PBS effect or by having 
extra DNA in the formulation (Figure 3.8C & D).  
The electrostatic interaction between positive charges of the cationic liposomes and 
negative charges of phosphate groups of DNA are reported as the main interaction in 
formation of lipoplexes (Ciani et al., 2007; Ciani et al., 2004). Some other researchers 
have added that packing properties of the lipids used in the formulation of lipoplexes 
may also play a role in condensation of the nucleic acid (Akao et al., 1996; Bennett et 
al., 1998). However, as it has been shown in Figure 3.7 and previously by Ciani et al. 
(2004) that the zeta potential of the lipoplexes are close to the zeta potential value of the 
pure liposomes at lower DNA concentrations, it can be concluded that half of cationic 
molecules of the liposomes are involved in the electrostatic interaction. These molecules 
are external lipids, which are located on the surface of the liposomes, and when the 
liposomes have been wrapped by DNA, the internal cationic lipids remain intact (Ciani 
et al., 2004). The effect of the buffer electrolytes in reducing the cationic charge of the 
lipoplexes can be due to the additional effect of phosphate polyanion in PBS, which 
reduces the positive charge of cationic lipids and in some cases results in their 
precipitation (Li and Hui, 1997), however a reduction in surface charge may be 
beneficial to allow appropriate DNA dissociation from the lipoplex after cellular uptake 
to allow the DNA to reach to the nucleus (Zhdanov et al., 2002). 
All five of the liposome formulations gave high DNA complexation across the DNA 
concentration range tested (Figure 3.7G-I and 3.8E & F) with % DNA association being 
> 95 % in all cases, showing all systems were able to electrostatically interact with the 
DNA as would be expected. However, the effect this complexation had on the formed 
lipoplexes was dependent on the lipid combination and the choice of aqueous buffer 
(Figure 3.7 and 3.8). 
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Figure 3.7: A,B and C demonstrate vesicle size and polydispersity index, D, E and F represent zeta potential and G, H and I show DNA association within SUV lipoplexes of 
DOPE:DOTAP, DOPE:DSTAP and DSPE:DOTAP hydrated in either dH2O or PBS respectively. Results denote mean ± SD, from 3 independent batches. 
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Figure 3.8: Characterisation studies of DRV lipoplexes of DOPE:DOTAP and DOPE:DSTAP in dH2O or 
PBS.A,C and E demonstrate vesicle size and Polydispersity index, zeta potential and DNA association 
within DRV of DOPE:DOTAP lipoplexes respectively.  Graphs B, D and F show the same information for 
DRV DOPE:DSTAP. Results denote mean ± SD, from 3 independent batches. 
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3.5. Conclusions  
Whilst effectively considering only half a bilayer in a flat rather than curved structure, 
Langmuir-Blodgett monolayer studies on lipid mixtures have shown to offer a variety of 
applications to support our continued appreciation of (nano)mechanical properties of 
liposomes and further underpin our understanding of liposomal drug delivery systems. 
Investigating the effect of lipid structure on liposome characteristics revealed that using 
two saturated lipids, such as DSPE and DSTAP, failed to form a liposome due to their 
highly compact molecular packaging. Monolayer studies on single lipids as well as 
mixture of lipids showed that saturated lipids have closer packaging arrangements than 
their unsaturated counterparts; whilst the use of lipids that form condensed monolayers 
may be beneficial in formulating low permeability bilayers, lipid combinations that form 
highly compact monolayers are not a suitable choice for the formulation of liposomes. 
Molecular packaging of the lipids also effects the size as the liposomes composed of 
saturated cationic lipids, which are more rigid, have been shown to cause aggregation of 
large particles and increase the vesicle size of the formulation. 
Studying the effect of the hydration buffer on liposomal characteristics demonstrated 
that presence of salt in the hydration buffer might increase the vesicle size of the 
lipoplex, especially for SUV lipoplexes and in their higher DNA concentrations. This 
can be due to the reduced electrostatic interactions between systems. Also, the 
phosphate group of the PBS increases the vesicle size as it initiates the bridging of the 
cationic polar heads of the lipid. Moreover, presence of salt in the formulation, 
prevented DSPE:DOTAP to form a liposome as salt can reduce the electrostatic nature 
of DOTAP headgroup and change the critical packaging parameter of the lipid, which 
prohibits the formation of liposomes.  
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4.1. Introduction 
Although it has been known for some time that direct injection of ‘naked’ DNA allows 
transgene expression in muscle (Vassaux et al., 2006), in most of the cases ‘naked’ DNA 
molecules are not able to enter cells efficiently due to their large size, negative charge 
and nuclease mediated degradation in vivo (Al-Dosari and Gao, 2009). Whilst this route 
of DNA delivery has been explored as a potential for DNA vaccination, the immune 
responses generated are low, as only a fraction of DNA is taken up by cells (McNeil et 
al., 2010). Therefore, a delivery vehicle (vector) must be used to carry the gene into the 
target cell to increase the gene transfection, and consequently increase immune 
responses to the DNA-encoded antigen. To achieve this, there are a range of possible 
vectors available, and within the non-viral systems, cationic liposomes have been 
heavily explored as a delivery vehicle due to their ability to protect DNA, and promote 
higher cell transfection (Gregoriadis, 1990).  
It is clear there are many factors which contribute to the efficacy of such systems 
(McNeil et al., 2010); to develop liposome-DNA complexes with high transfection and 
low toxicity, several parameters should be taken into account such as: size, lipid/DNA 
ratio, the net positive charge of the lipoplexes, the chemical structure of cationic lipid 
and helper lipid, and finally the structure of the complex itself (Congiu et al., 2004; 
McNeil et al., 2010). However, given the dynamic nature of these structures, many 
factors, in addition to those already listed, can contribute to the resultant 
physicochemical attributes of the lipoplexes including the rate of mixing of the various 
components, the temperatures used and even the presence of electrolytes in the buffers 
used (Congiu et al., 2004; McNeil and Perrie, 2007). Whilst many of these factors have 
now been investigated in detail, the influence of electrolytes has received little attention, 
despite reports of its influence on cationic-DNA formulations efficacy both in vitro and 
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in vivo (Zhou and Huang, 1994b). Therefore, the aim of this chapter was to investigate 
the role of electrolytes in the in vitro activity of a commonly employed cationic liposome 
transfection agent (DOPE:DOTAP). To achieve this, the impact of the presence of 
electrolytes, in addition to the choice of cationic lipid and the type of liposome 
construct, on the liposomal-DNA formulation characteristics and their transfection 
efficiency were investigated.  
4.2. Formulations investigated. 
To investigate the characterisation and transfection efficiency of different lipoplexes, 
SUV and DRV lipoplexes containing 16 µmole	  lipid	  and	  1.6 mg DNA were prepared, as 
previously outlined and discussed in Chapter 3. However, for reference, the data is 
summarised again in in	  Table	  4.1,	  with	  specific	  reference	  to	  the	  DNA/lipid	  ratio	  used	  in	  the	  forthcoming	  studies.	  
Table 4.1: Characterisation study results including vesicle size, Polydispersity index, zeta potential, and 
loading efficiencies of SUV and DRV lipoplexes. Results denote mean±SD	   and	   n	   =	   3 for three 
independently prepared batches.	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As noted in Chapter 3, the formulation of the liposomal-DNA constructs in PBS, rather 
than distilled water, resulted in larger constructs that are less cationic, presumably due 
to the condensing of the electrical double layer around the vesicles, resulting from the 
increased concentration of electrolytes present. However, this did not impact on the 
DNA loading of the vesicles, as would be expected; electrolytes do not impact on the 
surface potential of the vesicles, so would not necessarily hinder the binding of DNA to 
the cationic lipid head-groups, unless the degree of ionisation of the lipids was 
influenced, which would not occur in the pH range these formulations are in. 
4.3. Considering the spatial location of DNA within 
various liposomal constructs. 
Given that SUV are commonly considered to adsorb DNA to their surface, whilst DRV 
formulations have been reported to incorporate DNA within the vesicles (Gregoriadis et 
al., 2000; Perrie et al., 2001; Perrie and Gregoriadis, 2000), the spatial localisation of 
DNA within the cationic SUV and DRV lipoplexes was initially investigated by 
subjecting the formulations to gel electrophoresis in the presence of sodium dodecyl 
sulphate (SDS) at 0.05 % concentration, below the critical micelle concentration of the 
surfactant. It was expected that the anionic SDS would be able to interact with the outer 
monolayer of the lipoplexes, electrostatically compete with DNA bound to the cationic 
surface charge and displace it from the surface of the vesicles, releasing the DNA into 
the medium (Perrie and Gregoriadis, 2000). The effect of electrolytes on the packaging 
of these liposomal DNA systems was also considered by preparing the formulations in 
either distilled water or phosphate buffered saline (PBS).  
However, initial optimisation studies showed that having 0.05 % SDS in loading buffer 
was not enough to displace the DNA at the DNA/lipid ratios used (data not shown), 
Chapter 4: In Vitro Characterisation of  DNA Liposomes                                                                D 
 
124 
therefore 1.2% SDS was used for the main gel electrophoresis studies. Figure 4.1A 
shows that, on gel electrophoresis of SUV (1-5) and DRV (6-9) lipoplexes in the absence 
of anionic molecules, DNA remains within the well of the gel, bound to the cationic 
liposomes. In contrast, following electrophoresis in the presence of SDS, displaced 
DNA is seen to migrate towards the cathode (Figure 4.1B).  Figure 4.1B also shows that 
more DNA was displaced from SUV lipoplexes rather than DRV preparations. 
Considering the lipid composition of the formulations, amongst the SUV lipoplexes, 
formulations that have DOTAP as their cationic lipid (Figure 4.1B Lanes 1-3) show 
more DNA loss compared to those containing DSTAP. However, comparison between 
liposomes of the same lipid composition, but hydrated in PBS instead of dH2O, showed 
no notable difference in DNA retention in either 4.1A or B. 
 
Figure 4.1: A) Gel electrophoresis of SUV lipoplexes of 1)DOPE:DOTAP+dH2O, 2)DOPE:DOTAP+PBS, 
3)DSPE:DOTAP+dH2O, 4)DOPE:DSTAP+dH2O, 5)DOPE:DSTAP+PBS, and DRV lipoplexes of 
6)DOPE:DOAP+dH2O, 7)DOPE:DOTAP+PBS, 8)DOPE:DSTAP+dH2O and 9)DOPE:DSTAP+PBS. 
Lane (L) represents the DNA ladder and (C) shows the ‘naked’ DNA. B) As in A, but in the presence of 1.2 
% SDS. 
Having more displaced DNA for SUV liposomes, compared to DRV liposomes, in the 
presence of the anionic molecules of SDS suggests that most of the associated DNA 
with SUV lipoplexes are absorbed on the surface of the liposomes. However, for DRV 
lipoplexes, more DNA may be incorporated within closed bilayers and probably bound 
to the inner cationic charges of the liposomes, such that it is not accessible for 
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displacement by SDS. These observations are similar to those previously shown with 
SUV and DRV lipoplexes formed by DOTAP and DC-Cholesterol (Perrie et al., 2004; 
Perrie and Gregoriadis, 2000). 
However, spatial location of the DNA was not the only controlling factor in these DNA 
retention studies; SUV formulations composed of DOPE:DSTAP lipoplexes (Figure 
4.1B lanes 4,5) show reduced DNA displacement compared to DOPE:DOTAP and 
DSPE:DOTAP formulations (Figure 4.1B lanes 1-3). Previously, Perrie et al. showed 
PC:DOPE:DOTAP lipoplexes have more DNA displacement than PC:DOPE:DC-
Cholesterol lipoplexes in the presence of anionic molecules of SDS (Perrie et al., 2004). 
This could be due to the fact that DOPE causes some disability to the formulations, as it 
promotes membrane fusion to change the packing parameter of the liposomes (Farhood 
et al., 1995; Wrobel and Collins, 1995). Therefore, the bilayer system made from the 
combination of DOPE and DOTAP may be less resistant to the destabilisation 
compared to the lipoplexes containing DSTAP  (Figure 4.1B) or DC-Cholesterol (Perrie 
et al., 2004).  
Given that the two hydration media tested showed no notable effect on DNA 
displacement, this suggests that this parameter may not affect DNA release or 
transfection efficacy for formulations under investigation. Based on this information, it 
can be predicted DRV formulations may be better placed to deliver higher DNA loads 
to cells compared to their SUV counterparts and that DOPE:DSTAP (with both 
hydration media) formulations may be preferable compared to the lower transition 
temperature DOTAP formulations. This will be discussed more in section 4.5.  
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4.4. DNA protection from extracellular enzymes 
As mentioned earlier, injection of ‘naked’ DNA would not cause high cell transfection 
due to DNA degradation by nucleases such as deoxyribonuclease I (DNase I), so 
delivery systems such as cationic liposomes are required to protect DNA from 
hydrolysis and degradation (Gregoriadis et al., 2002; Gregoriadis et al., 1996; Patil et 
al., 2005). Previously, Gregoriadis et al. (1996) have shown liposomes can protect DNA 
from degradation by entrapping the plasmid DNA within the liposomes and, as a result, 
degrading enzymes such as DNase I do not have access to the DNA, so the plasmid 
DNA would be protected from the enzymes and can perform its therapeutic duty 
(Gregoriadis et al., 2000; Gregoriadis et al., 1997; Gregoriadis et al., 1996).  
To investigate the ability of studied SUV and DRV liposomes to protect the plasmid 
DNA from degradation by digestive enzymes, as explained in section 2.8, plasmid DNA 
was incubated with DNase I as either ‘naked’ (Figure 4.2A-D Lane C) or entrapped 
within cationic liposomes (Figure 4.2A-D lane 1-9) followed by agarose gel 
electrophoresis to test DNA integrity of the preparations. Figure 4.2 shows ‘naked’ 
DNA, which was not exposed to the DNase I (Figure 4.2 A and B, lane ‘C’) and the 
digested ‘naked’ DNA (Figure 4.2 C and D, lane ‘C’). The band of migrated anionic 
DNA towards the cathode is demonstrated for undigested ‘naked’ DNA in absence 
(Figure 4.2A, lane C) and presence of SDS (Figure 4.2B, lane C). However, when 
‘naked’ DNA exposed to the DNase I, there is no visible band on the agarose gel 
(Figure 4.2C and D lane C) showing the ‘naked’ DNA was digested by DNase I.  
For all the liposomes formulations tested, in the absence of SDS (Figure 4.2A lane 1-9 
and Figure 4.2C, lane 1-9), DNA migration is not seen as plasmid DNA remains 
associated with the liposomes and is retained within the wells of the gel. In the presence 
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of the competitive anionic molecules of SDS, the liposomes can be disrupted and the 
plasmid DNA released (Figure 4.2B, lane 1-9). With the liposomes that were exposed to 
DNase I (Figure 4.2D, lane 1-9), plasmid DNA can still be seen, demonstrating that 
both the SUV and DRV liposomes were able to protect the DNA from degradation (in 
contrast to the ‘naked’ DNA, which is rapidly digested). This is in line with previous 
studies of different groups (Fenske et al., 2002; Gregoriadis et al., 1996; Wong et al., 
2001).   
 
Figure 4.2: Gel electrophoresis of free and liposome entrapped plasmid DNA before and after exposure to 
digestive enzyme, DNase I. A) Gel electrophoresis of 1) SUV DOPE:DOTAP+dH2O, 2) SUV 
DOPE:DOTAP+PBS, 3) SUV DSPE:DOTAP+dH2O, 4) SUV DOPE:DSTAP+dH2O, 5) SUV 
DOPE:DSTAP+PBS, 6) DRV DOPE:DOAP+dH2O, 7) DRV DOPE:DOTAP+PBS, 8) DRV 
DOPE:DSTAP+dH2O and 9) DRV DOPE:DSTAP+PBS before exposure to DNase I with no SDS, B) 
same as A but in the presence of 2.5% SDS (rather than 1.2 % as in Figure 4.1), C) same as A but after 
exposure to DNase I with no SDS, D) Same as C but in the presence of 2.5% SDS. Lane (L) represents the 
DNA ladder and lane (C) represents ‘naked’ DNA. 
As it is shown by Figure 4.2D, this protection role is similar for SUV (lane 1-5) and 
DRV (lane 6-9) liposomes. In addition, differences in physicochemical characteristics of 
the lipoplexes such as size, charge, hydration media and the transition temperature of 
the cationic lipids, are not seen to have an impact on DNA protection from DNase I 
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digestion. This is a result of the electrostatic interactions of the cationic headgroups of 
the liposomes interacting with the anionic plasmid DNA, resulting in its condensation 
(Gregoriadis et al., 2002). This in turn blocks the ability of DNase I to interact with the 
plasmid and digest it, therefore, in terms of protection, there is no notable difference 
between surface adsorbed and entrapped formulations. 
4.5. In vitro DNA release 
The release of DNA from different cationic liposomes was investigated in PBS, pH 7.4, 
37 °C over an 8 day period (192 hours). Figure 4.3 shows the release profile for SUV 
(Figure 4.3A) and DRV (Figure 4.3B) formulations. Results show an initial burst release 
of 30% (of total entrapped DNA) after 4 hours for SUV lipoplexes of DOPE:DOTAP 
and DOPE:DSTAP in both hydration media. After 48 hours, the amount of released 
DNA reached to ≈55% for DOTAP SUV lipoplexes, and ≈65% for DSTAP SUV 
lipoplexes. Beyond this point, DNA release from the lipoplexes appeared to plateau out, 
with no further significant increase in release. In terms of total release over the time 
period, DOPE:DSTAP gave an overall higher release than DOPE:DOTAP, and those 
formulated in dH2O tended to have lower release rates	  (Figure	  4.3A).	  In contrast, with 
SUV lipoplexes, which had a burst release as soon as 4 hours, the DRV formulations 
showed a more sustained release profile: Figure 4.3B shows the DNA release for all 
DRV formulations after 24 hours was ≈20% (of total entrapped DNA) and their burst 
release occurred after 48 hours, with ≈55% of DNA for DRV DOPE:DOTAP lipoplexes 
(in both hydration media) and DRV DOPE:DSTAP formed in dH2O being released. 
Again, comparing between the formulations there was no notable differences in the 
choice of lipid composition used to prepare the liposomes, however the trend was 
similar to that of SUV (i.e. DSTAP>DOTAP and PBS>dH2O), in terms of total release 
(Figure 4.3B). 	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Figure 4.3: DNA release of A) SUV lipoplexes of DOPE:DOTAP, DOPE:DSTAP both hydrated in dH2O or PBS and DSPE:DOTAP in dH2O and B) DRV lipoplexes of 
DOPE:DOTAP and DOPE:DSTAP in dH2O or PBS, pH 7.4; at 37 °C at time points of 2, 4, 24, 48, 96 and 192 hours. Results represent percentage release initially loaded DNA 
expressed as mean±SD,	  n=3 for three independently prepared batches. 
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The difference in release profiles between the SUV and DRV could be due to the fact 
that DNA will be entrapped within the bilayers for DRV formulations, however, for 
SUV lipoplexes, DNA molecules are likely to be adsorbed on the surface of the 
liposomes and easier to be detached from the liposomes, therefore the DNA release 
occurs sooner for SUV lipoplexes. In terms of the differences between the lipid 
composition, whilst it might be expected that the higher transition temperature DSTAP 
formulations would have lower release rates (Gregoriadis, 1990), monolayer studies 
(Section 3.3) showed that having saturated lipids in the formulation makes the bilayer 
structure more rigid, which may actually reduce liposome-DNA interactions, resulting 
in higher release rates (Zuhorn et al., 2002) as seen in Figure 4.3.  
4.6. In vitro transfection efficiency 
To investigate the transfection efficiency of different lipoplexes, SUV and DRV 
lipoplexes containing 16 µmole lipid and 1.6 mg DNA were prepared as outlined in 
Table 4.1. Performing luciferase assay transfection efficiency of each formulation on 
COS-7 cell line was compared to the transfection produced by the marketed transfection 
reagent Lipofectin™.  
Figure 4.4A shows the transfection efficiency of each formulation compared to the 
‘naked’ DNA and Lipofectin™ with SUV lipoplexes of DOPE:DSTAP in PBS showing 
the highest transfection levels. Transfection efficiency of SUV lipoplexes formulated in 
water were in the order of DOPE:DSTAP > DOPE:DOTAP ≈ DSPE:DOTAP and 
DOPE:DSTAP > DOPE:DOTAP when formulated in PBS. Among DRV liposomes, 
DSTAP based formulations in each hydration media have higher transfection efficiency 
than DOTAP lipoplexes of similar hydration media (Figure 4.4A). All of the lipoplexes 
have given higher transfection efficiency than Lipofectin™. Cell viability of all 
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lipoplexes was performed using MTS assay and the cells were exposed to the lipoplexes 
for 24 hours. Results show the cell viability for all lipoplexes was high and at the 
concentrations tested there was no significant difference between the formulations 
(Figure 4.4B). 
Among SUV liposomes, DOPE:DSTAP formulated in distilled water produces 
transfection levels 25 times higher than Lipofectin™ and 21  times higher than 
DOPE:DOTAP+dH2O. When DOPE:DSTAP was hydrated in PBS rather than 
distilled water, transfection efficiency was reduced but was still 15 times higher than 
Lipofectin™ and 6 times higher than DOPE:DOTAP+PBS (Figure 4.4A).  
Considering DRV lipoplexes, DOPE:DSTAP formulated in dH2O produced 7 fold 
higher transfection than DOPE:DOTAP formed in dH2O. The same trend has been 
shown for DRV lipoplexes formulated in PBS (Figure 4.4A). These results demonstrate 
that DSTAP lipoplexes no matter if formulated as a SUV or DRV, and in distilled water 
or PBS, have higher transfection efficiency than the other formulations tested.  
Comparing the transfection efficacy of SUV lipoplexes to DRV formulations show there 
is not an obvious trend for all of the formulations. Transfection levels of 
DOPE:DOTAP+dH2O as a SUV lipoplex is significantly lower (P<0.05) and almost 
half of its DRV formulation. However, when DOPE:DOTAP formed in PBS, there is 
no significant difference in their transfection efficiencies (Figure 4.4A). In contrast, for 
DSTAP formulations and in both hydration media, SUV lipoplex show more 
transfection than DRV (Figure 4.4A). In general, decreasing the hydrocarbon chain 
length has been reported to increase transfection efficiency (McNeil et al., 2010; Writer 
et al., 2006). However, given both lipids have the same carbon chain length, this case 
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cannot be a reason for the variation in transfection efficiency between DOTAP and 
DSTAP liposomes. 
Equally, the size, charge and cationic lipid/DNA ratio have all been attributed to play a 
role in controlling transfection (Aljaberi et al., 2007; Caracciolo et al., 2007). However, 
in the case of DSTAP and DOTAP SUV, neither the size nor the charge of the system 
seem to correlate to its higher transfection efficacy, given it is neither notably different in 
size (e.g., DOPE:DOTAP and DOPE:DSTAP in dH2O are similar in size (Table 4.1) 
but have large differences in transfection efficacy), nor cationic nature than the other 
formulations. Similarly, both systems contain the fusogenic lipid DOPE that may 
enhance intracellular delivery of DNA (Farhood et al., 1995; Israelachvili and Mitchell, 
1975; Israelachvili et al., 1977). The theory of using helper lipid comes from the original 
research of Felgner et al., (1987). The authors demonstrated that the transfection activity 
of DOTMA when formulated with DOPE is more than when is formulated with DOPC 
and it has been proposed the ability of DOPE to promote the transition from lamellar 
phase to an inverted hexagonal phase (Uyechi-O'Brien and Szoka, 2003) thereby 
promoting the conversion of the lamellar lipoplex phase into a non-lamellar structure 
due to the inverted cone-shaped structure of DOPE (Aljaberi et al., 2007; Caracciolo et 
al., 2007; McNeil and Perrie, 2007; McNeil et al., 2010). After endosomal uptake of the 
lipoplexes, the presence of DOPE in the formulation is suggested to aid disruption of 
endosomal membrane, allowing the release of the DNA from the endosome and the 
lipoplex, leaving it free to enter the nucleus (Ciani et al., 2004; McNeil et al., 2010). 
However, in this study, lipoplexes formulated with DOPE:DOTAP and DSPE:DOTAP 
showed no significant difference in transfection levels, suggesting that DSPE may be 
equally suitable as a helper lipid for unsaturated cationic lipids but not useful when 
combined with saturated lipids. 
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Figure 4.4. A) Comparison of transfection efficiency of five SUV lipoplexes and four DRV lipoplexes on 
COS-7 cell line by applying luciferase assay. Positive control is Lipofectin™ and negative control is ‘naked’ 
DNA. B)Comparison of cell viability of five SUV lipoplexes and four DRV lipoplexes on COS-7 cell line 
and by applying MTS assay. Results denote mean±SD and n = 3 for three independently prepared batches. 
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It has been reported that saturated cationic lipids make rigid and packed bilayers 
(Maurer et al., 2001; Ulrich, 2002), and hence show lower transfection efficiency than 
their unsaturated analogues (Kudsiova et al., 2011; Wasungu and Hoekstra, 2006). 
However, in this current study, saturated DSTAP has been shown to produce higher 
transfection efficiency compared to unsaturated DOTAP. Equally, in another study 
considering cellular uptake of lipoplexes by macrophage cells, DOPE:DSTAP uptake 
was shown to be higher than DOPE:DOTAP (Filion and Phillips, 1997). As discussed 
earlier, all the characteristic properties studied for DOTAP and DSTAP based 
lipoplexes for this study were shown to be similar. In terms of their thermodynamic 
nature, a previous study (Lobo et al., 2002) has shown that although DSTAP bilayers 
are rigid and closely packed, addition of DNA to the bilayers, increases their fluidity 
while decreasing their stability. This may mean that, whilst DSTAP formulations would 
form more rigid structures, the addition of plasmid DNA may fluidise these bilayers, 
again mitigating this attribute. Adding the fusogenic effect of DOPE to the system also 
makes the bilayers more fluidic, allowing the bilayers to be instable enough to be able to 
produce a comparable in vitro transfection. Indeed, Regelin et al., (Regelin et al., 2000) 
have shown DOPE:DSTAP lipoplexes are highly unstable compared to 
DOPE:DOTAP. This suggests that, although DSTAP monolayer studies (Section 3.3, 
Chapter 3) show a high rigidity as a result of their high transition temperature (Lobo et 
al., 2002; Regelin et al., 2000), addition of DNA could make the lipoplex structure 
flexible enough to promote high transfection efficiency.  
Correlation between monolayer studies and transfection efficiencies of cationic 
liposomes has been reported earlier (Savva et al., 2005). Moreover, monolayer studies in 
this lab revealed that the mixture of DOPE:DSTAP in either of subphases (PBS or 
dH2O) produced a significantly (P<0.001) higher positive deviation compared to 
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DOPE:DOTAP monolayers (Section 3.3, Chapter 3). It has been reported that positive 
deviation is related to the less attractive interactions between film-forming molecules 
(Hac-Wydro and Wydro, 2007; Hac-Wydro et al., 2007), which offers instability to the 
bilayers and enhances their in vitro transfection efficiency. This might explain the higher 
transfection efficiency of DSTAP-based lipoplexes as shown in Figure 4.4 and also 
previous research which has shown that lipoplexes formulated with the saturated 
cationic lipid DPTAP in lipoplex formulation created stronger transfection compared to 
unsaturated DOTAP (McNeil et al., 2010).  
In this current study, considering the effect of presence of salt in the lipoplex 
formulations did not show an obvious trend for all of the formulations. Previous studies 
have shown that the impact on transfection of electrolytes present in lipoplex 
suspensions, is an outcome of the liposomes size, which is influenced by electrolytes, as 
formation of DNA lipoplex under physiological salt concentration formed large (1 µm) 
vesicles and liposomes with these large salt-induced aggregates, induced 10-100 fold 
higher in vitro transfection efficiency (Ogris et al., 1998). It has also been shown that 
increases in vesicle size can enhance transfection efficiency of liposomes (Eastman et al., 
1997; McNeil et al., 2010).  The correlation of particle size versus transfection in this 
study have been considered and are shown in Figure 4.5, which demonstrated a very 
low R2 equal to 0.015 showing a very poor correlation between vesicle size and 
transfection efficiency of the formulations. 
Among the DOTAP-based SUV formulations, presence of salt in the liposomes 
hydration media caused an increase in transfection efficiencies of SUV DOPE:DOTAP 
(Figure 4.4). This is line with the above findings as PBS significantly increased the 
vesicle size of SUV DOPE:DOTAP  (Table 4.1).  In contrast, for DRV DOPE:DOTAP, 
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the presence of salt did not have impact on vesicle size and, as a result, the transfection 
efficiency of both formulations are similar (Figure 4.4A). This trend is not detectable for 
DSTAP formulations, as presence of salt caused increase in vesicle size of the liposomes 
(Table 4.1) but this not only did not increase the transfection of the liposomes but also 
significantly decreased their transfection efficiency (Figure 4.4A). This shows the vesicle 
size is not the only decisive parameter and biological or biophysical properties such as 
mechanism of action for the lipoplexes on their endosmal release may have a role in 
their transfection efficiencies.  
 
 
Figure 4.5: Correlation between vesicle size and luciferase activity percentage of tested formulations. 
Results denote mean±SD and n = 3 for three independently prepared batches. 
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4.7. Conclusion 
Previously in chapter 3, the monolayer studies revealed saturated lipids such as DSTAP 
would make a condensed monolayer and using this type of lipid may lead to having a 
bilayer with low permeability. The effect of molecular arrangements on the 
physicochemical properties of the liposomes was also considered. In theory, it would be 
expected that monolayer studies along with characterisation studies could help to show 
correlation with transfection efficacy of the liposomes. However, in terms of transfection 
efficacy, neither considering the molecular packaging of the lipids with DNA-liposome 
constructs, nor their basic physicochemical attributes (size, cationic nature, DNA 
release profiles), have been shown to correlate with transfection efficacy with several 
general assumptions being shown to be misleading in our studies. Similarly, the role of 
electrolytes in lipoplex formulations is shown to be dependent on the formulation, with 
PBS diminishing the transfection of DSTAP systems yet enhancing DOTAP based 
lipoplexes. Therefore, there remains no clear physicochemical screening that can be 
adopted to predict in vitro efficacy. Combining this with the lack of in vitro and in vivo 
efficacy that plagues non-viral delivery systems suggests that for the continued 
development of non-viral transfection agents, new tools are needed to rationalise these 
differences. 
Therefore, whilst there is not clear link between characterisation and in vitro 
performance, formulations to progress as potential DNA delivery systems in vivo had to 
be selected. Thus, based on in vitro studies, the formulations which were shown to be 
more effective were selected. SUV DOPE:DOTAP and SUV DOPE:DSTAP in both 
hydration media were chosen, along with the most efficient DRV, which was 
DOPE:DSTAP+dH2O, to investigate their potential as delivery systems for DNA 
vaccines.
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5.1. Introduction 
Vaccination remains one of the most effective ways of supporting the health of a 
population, with several effective vaccines playing a key role in global healthcare. 
Indeed the WHO vaccination campaign against Smallpox, initiated in 1967 (Fenner, 
1993) ensured the complete eradication of this disease. However, there remains a 
pressing need for the development of vaccines for new diseases e.g. tumour associated 
diseases, and older-poorly controlled diseases e.g. HIV, TB and malaria.  
In terms of options for vaccines, live vaccines generally offer the strongest protection; 
however, they tend to have higher adverse events associated with them. In contrast, sub-
unit vaccines tend to have a good safety profile, but are generally only weakly 
immunogenic. DNA vaccines are also being investigated as a potential option: DNA 
vaccines can be designed to encode bacterial, viral or tumour antigens and may offer 
several advantages, as they are easy to produce, potentially more stable than subunit 
vaccines (e.g. heat stability), easy to manipulate and can mimic viral infections, yet 
there is no risk of reversion to pathogenicity (Gregoriadis, 1998; Henke, 2002). Like 
protein subunit vaccines, DNA vaccines are considered to be both safe and cost effective 
(Henriksen-Lacey et al., 2011c), however, both subunit and DNA vaccines suffer from 
poor immunogenicity, rapid clearance from the body and degradation by the host 
immune system (Perrie et al., 2001; Singh and O'Hagan, 2002). Hence, there is an 
urgent need for safe, cost effective and efficient vaccine adjuvants and delivery systems 
to overcome these issues (Gregoriadis et al., 1999; Watson et al., 2012).  
Cationic liposomes have been extensively studied as potential vaccine adjuvants to 
increase the immune response and their role as antigen delivery systems in vaccines is 
well recognised (Henriksen-Lacey et al., 2011c; Kaur et al., 2012a; Watson et al., 2012). 
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Comparing to other vaccine adjuvants, liposomal adjuvant systems have several 
advantages: they are safe, relatively easy to produce and show low reactogenicity 
(Herzog et al., 2009; Watson et al., 2012). In addition, any type of antigen such as 
proteins, peptides, nucleic acids, carbohydrates and small molecule haptens can be 
incorporated in to the liposomes due to their versatility. For example, cationic 
liposomes can electrostatically interact with anionic proteins and nucleic acid allowing 
these antigens to be absorbed onto the surface of cationic liposomes and be carried to 
the antigen presenting cells (APCs) (Kaur et al., 2012a; Watson et al., 2012). In contrast, 
although microspheres have also been described as potential adjuvants for antigens 
producing both humoural (O'Hagan et al., 1991) and cellular immunity (Audran et al., 
2003), they have failed to initiate immune responses at comparative levels to the 
liposomes due to the difference in their characteristic parameters (Kirby et al., 2008). 
Given the ability of cationic lipids/liposomes to protect plasmid DNA against 
degradation and promote gene expression, it is not surprising that these systems have 
been applied for the delivery of DNA vaccines, with cationic liposome systems having 
been shown to effectively induce humoural and cellular immune responses against 
antigen-encoding plasmid DNA (Jiao et al., 2003; Lay et al., 2009; Morrey et al., 2011; 
Perrie et al., 2001). In general, these studies have considered the choice of the 
lipid/liposome construct in a bid to enhance immune responses. However, a study by 
Yan and Huang (2009) also investigated the effect of salt on the physicochemical and 
immunogenicity of the protein based vaccines formulated in cationic lipids. This study 
reported that presence of small amounts of salt (30 mM) within cationic liposome 
formulations could enhance immune performance of the vaccine. This was attributed to 
the interference of salt with the electrostatic interactions between the cationic lipid and 
the antigen, which facilitates the antigen release from the carrier and at the same time 
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activates the antigen presenting cells. Therefore, within this chapter, the aim of the work 
was to consider the application of the liposomal formulations developed within Chapter 
3 as possible DNA vaccine delivery systems. From the in vitro studies carried out in 
chapter 4, a select few liposome formulations were chosen for further investigation as 
possible vaccine delivery systems. Since there was no significant difference in 
transfection efficiencies of SUV and DRV liposomes, the in vivo study will focus on the 
SUV lipoplexes prepared from DOPE:DOTAP and DOPE:DSTAP lipoplexes in both 
hydration media. However, the best DRV liposome in terms of in vitro transfection 
efficiency (Chapter 4) was also selected (DRV DOPE:DSTAP with no electrolyte in its 
hydration media). 
When developing vaccines, immunisation strategies have commonly been based on 
homologous regimens, which involves giving the same vaccines multiple times. 
However, some studies (Carstens et al., 2011; Yang et al., 2008) suggest that prime-
boost strategies, which use a combination of DNA-encoded antigen as a primer 
immunisation and subunit vaccines of the same antigen as a booster, can enhance 
humoural and cellular immune responses. Indeed, studies investigating different 
sequences of prime and boost injections have shown that two prime immunisations of 
plasmid DNA, following by one boost injection of protein (DDP), is more effective than 
a DNA (D), protein (P), protein combination or homologous injections of DD or P only 
(Deshmukh et al., 2007; Yang et al., 2008). Therefore, based on these finding, within 
this current study the DDP regimen has been adopted. 
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5.2. Physicochemical characteristics of DNA lipoplexes 
and protein-liposome complexes. 
5.2.1. Radio-labelling of protein antigen 
As explained in details in section 2.6.2, for entrapment studies, HBsAg was 
radiolabelled with the radioisotope Iodine-125 (125I). The labelled protein was separated 
from the free, unincorporated 125I via Sephadex G-75 gel chromatography. 0.25 mL 
aliquots were collected and the radioactivity of 125I and the absorbance (A280) for protein 
content within each aliquot was determined. As shown in Figure 5.1A, both high levels 
of 125I and protein content are found in samples 11 and 12, with protein content in these 
samples being confirmed by the BCA assay (Figure 5.1B).  From Figure 5.1A it can also 
be seen that the second peak in radioactivity does not have associated protein content, 
and is typical of free iodine (Figure 5.1A). 
5.2.2. Liposomal delivery systems for DNA or sub-unit antigens 
Given that previous studies have shown the presence of electrolytes within the aqueous 
media of cationic liposome suspensions can impact the vesicle characteristics (Section 
3.4, Chapter 3), the impact of electrolytes on liposomal-protein antigen system was also 
briefly investigated, as these formulations would be used as the ‘booster’ for the in vivo 
vaccine studies. Therefore, initially the two cationic lipid formulations containing the 
fusogenic lipid DOPE, combined with either DOTAP or DSTAP, were formulated in 
either a high electrolyte buffer (PBS) or non-electrolyte (sucrose 10%) aqueous media 
(Table 5.1).  
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Figure 5.1: A) Determination of radioactivity for iodine labelled HBsAg samples eluted through Sephadex 
column, as well as their absorbance at 560 nm. B) Confirmatory BCA assay results for protein labelled 
samples. A colour change from green to purple indicated the presence of protein for samples 11 and 12. 
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Results in Table 5.1 show that both formulations, when complexed with plasmid DNA 
showed a significant increase (p<0.05) in vesicle size and significant reduction (p<0.05) 
in zeta potential, when formulated in the presence of electrolytes as previously reported 
in Chapter 4 and summarised in Table 5.1. However, this effect was not specific to 
lipoplexes, with liposomal-subunit complexes also demonstrating a similar outcome 
(Table 5.1). This is to be expected as the drop in zeta potential for the cationic systems is 
attributed to the condensing of the electrical double-layer. The increase in vesicles size 
measured may be attributed to the phosphate groups within PBS bridging the cationic 
polar heads of the lipid, thereby promoting aggregation (Ciani et al., 2007; Wasan et al., 
1999). Therefore, these physicochemical changes would apply to the cationic lipids 
irrespective of what anionic antigen was adsorbed (DNA or protein) (Table 5.1).  
Table 5.1: Characteristics of cationic liposomes. Size and zeta potential measured by Malvern Zetasizer 
Nano-ZS. Results represent mean±SD of triplicate independent experiments. 
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5.3. Investigating the depot-formation of cationic 
liposome-based DNA vaccines 
To investigate how the electrolyte-induced changes in physicochemical characteristics 
translated to in vivo performance, the ability of these lipoplexes to carry and deliver 
DNA-encoded antigen after intramuscular injection was investigated. It has been 
previously reported that cationic liposomes can induce a depot effect at the site of 
injection (Henriksen-Lacey et al., 2010c), causing a prolonged deposition of the antigen 
and adjuvant at the site of injection, and this may be responsible for the enhanced 
immune responses promoted by some cationic formulations. Since cationic liposomes 
are retained for a longer period at the site of injection, the adsorbed antigen (DNA or 
protein) will also have longer retention time leading to an increase exposure of the 
antigen presenting cells (APC) to antigen at the site of injection. This is shown to be 
beneficial for induction of Th1 immune responses, since this increases the production of 
IFN-γ (Christensen et al., 2012; Henriksen-Lacey et al., 2010c). Therefore, the 
biodistribution of both lipid compositions and their associated DNA, formulated in the 
presence and absence of electrolytes was investigated after intramuscular injection.  
5.3.1. Monocyte influx to the site of injection 
Given the ability of pontamine blue to be taken up by macrophages in vivo (Tilney, 
1971a) it can be applied to identify the lymph nodes and give an indication to the ability 
of liposomes to induce innate immune cell influx to the injection site (Henriksen-Lacey 
et al., 2010b). However, given that it is also known that inflammation can occur at the 
site of injection, due to the tissue damage caused by injection and the inflammatory 
mediators potentially promoted by cationic lipids (Filion and Phillips, 1997), 
visualisation of monocyte influx can be tracked by pre-injecting mice with pontamine 
blue. Therefore, to determine the level of infiltrated immune cells to the site of injection, 
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pontamine blue dye was injected subcutaneously 3 days prior to the start of the 
biodistribution study.  
Figure 5.2A shows the monocyte influx to the site of injection on day 8 p.i for SUV 
formulations and ‘naked’ DNA. Prior to the intramuscular injection of these 
formulations, and at early time-points, no staining was noted at the site of injection 
(data not shown). However, as time progressed an increase level of blue staining was 
noted at the injection site for mice injected with the liposomal DNA formulations, with 
high levels shown at day 8 (Figure 5.2A; samples 1 to 4), yet this was not the case with 
mice injected with the DNA alone where no staining was noted over the period of the 
study (Figure 5.2A; leg 5). Whilst not quantitative, these results suggest that cationic 
liposomes are able to enhance recruitment of circulating monocyte to the injection site 
whilst DNA alone does not. 
5.3.2. Determination of vaccine components at the injection site. 
The concentration of the liposomal carrier, and the DNA antigen was measured at site 
of injection (SOI), the local draining lymph node (PLN), liver, kidney, spleen and lung 
were investigated at day 1, 4 and 8, post injection (p.i.); of these sites, only the site of 
injection and the PLN had detectable levels of liposomes and/or DNA and therefore 
only this data is presented (Figure 5.2).  
From these results, it can be seen that plasmid DNA injected without a liposomal carrier 
was quickly cleared, with only 10% of DNA detected at the site of injection 24 h after 
administration. This reduced significantly (p < 0.05) to 3% on day 4 and to less than 1% 
on day 8 p.i (Figure 5.2B). In contrast, DNA associated with any of the tested liposome 
formulations gave enhanced retention at the injection site, with approximately 40 to 
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60% of the liposome-associated DNA remaining at the injection site after 24 h (Figure 
5.2B). Whilst the choice of cationic lipid (DOTAP vs DSTAP) made no significant 
impact on retention rates after 24 h, the higher transition DSTAP based lipoplexes 
promoted significantly (p<0.05) higher DNA retention at the injection site over the 
longer periods (Figure 5.2B) with DNA retention on day 8 p.i for DOPE:DSTAP 
formed in sucrose being double compared with DOPE:DOTAP hydrated in same 
medium. The same trend was shown for the formulations made in PBS with DNA 
retention for the DSTAP based lipoplex being 30%, compared with less than 3 % for 
DOPE:DOTAP formed in PBS (Figure 5.2B; day 8). This was mirrored by movement 
of the liposomes, with no significant differences being noted at day 1 and 4, however by 
day 8 the DOPE:DSTAP formulations tended to show higher levels at the injection site 
after 8 days compared to the DOTAP formulations (Figure 5.2C). 
Interestingly, despite the presence of electrolytes making a significant impact on the 
vesicle characteristics prior to injection, this did not translate to measurable differences 
in either DNA or liposome movement from the injection site (Figure 5.2B & C); for 
DOPE:DOTAP formulated in either sucrose or PBS there was no significant difference 
in DNA (Figure 5.2B) or liposome retention (Figure 5.2C) at the site of injection despite 
the vesicles being twice the size when formulated in PBS (Table 5.1). This was also 
reflected with the DOPE:DSTAP formulations, with the difference in vesicle size and 
zeta potential having no impact on clearance rates (Figure 5.2B,C). However, it is 
important to consider that whilst differences in vesicle size are noted prior to injection, it 
is likely that on injection vesicle aggregation will occur due to the presence of interstitial 
proteins, which would negate any difference in vesicle sizes prior to injection. This can 
be supported by recent work by Kaur et al (Kaur et al., 2012b), which demonstrated that  
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Figure 5.2: A) Pontamine blue staining on day 8 p.i of the injection site (quadriceps muscle) after i.m. 
injection with pDNA lipoplexes of 1)DOPE:DOTAP+Sucrose, 2)DOPE:DOTAP+PBS, 
3)DOPE:DSTAP+Sucrose, 4)DOPE:DSTAP+PBS and 5)free DNA. B-C) pDNA and liposome detection 
at the site of injection and D-E) draining lymph nodes (PLN) following i.m. injection. pDNA and liposome 
quantification were determined at days 1,4 and 8 p.i. using radiolabel counting methods. Data represents 
mean ± SD of 4 mice and is presented % dose at the SOI (B,C) or the % dose per mg PLN harvested (D,E). 
Significance measured by one-way ANOVA and Tukey’s post test, it is shown by *p<0.05, and ***P<0.001.  
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pegylation of cationic vesicles, which was able to block aggregation of vesicles, 
promoted enhance drainage from the injection site. 
Tracking the distribution of vaccine to the draining PLN (Figure 5.2D and E) indicates 
that the amount of detectable DNA and lipid in all of the formulations at the PLN 
increased over the time. DNA and lipid retention at PLN did not show any significant 
difference between different formulations and therefore was not influenced by size nor 
liposome composition. However, all four liposome formulations gave significantly 
(p<0.05) high DNA delivery to the PLN compared to ‘naked’ plasmid DNA.  
To investigate the effect of different vesicle types, SUV and DRV of DOPE:DSTAP 
were also compared. Figure 5.3A shows the comparison between the two different 
liposome preparations of the DSTAP formulation (DRV vs SUV), with no difference on 
monocyte infiltration between these two liposome preparations being notable. 
Considering the distribution of the liposomal formulation and the plasmid DNA, there 
was no significant difference between DNA retention of SUV 8 days after 
immunisation, with approximately 30% of DNA dose retention at the injection site 
compared with ~20% for the DRV formulation (Figure 5.3B).  In terms of liposome 
retention at the injection site, the choice of liposome preparation made no significant 
difference (Figure 5.3C).  
Measuring the DNA and lipid content at the draining PLN shows the amount of 
drained DNA and lipid increased over the time, however generally there was no notable 
difference between the SUV and DRV formulation (Figure 5.3D and E). 
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Figure 5.3: A) Pontamine blue staining at day 8 p.i of the injection site (quadriceps muscle) after i.m. 
injection with pDNA lipoplexes of 1) SUV DOPE:DSTAP+Sucrose, 2) DRV DOPE:DSTAP+Sucrose and 
3)free DNA. B-C) pDNA and liposome detection at the site of injection and D-E) draining lymph nodes 
(PLN) following i.m. injection. pDNA and liposome quantification were determined at days 1,4 and 8 p.i. 
using radiolabel counting methods. Data represents mean ± SD of 4 mice and is presented % dose at the 
SOI (B,C) or the % dose per mg PLN harvested (D,E).  Significance measured by one-way ANOVA and 
Tukey’s post test, it is shown by *p<0.05, **p<0.01, and ***P<0.001. 
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These results (Figure 5.2 and 5.3) suggest that the key feature in the clearance rate of 
these vesicles, and their loaded DNA, from the site of injection may be the transition 
temperature of the cationic lipid used rather than vesicle size and antigen location; 
DSTAP, with its higher transition temperature, presents as a more rigid bilayer vesicle 
(Lobo et al., 2002; Regelin et al., 2000) compared to DOTAP formulations, whose more 
fluid bilayers allows more lipid clearance from the injection site (Christensen et al., 
2012; Henriksen-Lacey et al., 2011a). 
Monolayer studies showed that, compared to DOTAP, the cationic lipid of DSTAP has 
a more rigid structure due to its saturated alkyl chain and higher Tc; however, 
incorporation of DOPE to the DSTAP reduced the rigidity of the DSTAP and both 
DOPE:DOTAP and DOPE:DSTAP monolayers had similar monolayer properties 
(Section 3.3, Chapter 3). From another perspective, differential scanning calorimetry 
(DSC) studies (Regelin et al., 2000) reported a higher transition temperature for DSTAP 
and showed that although incorporation of helper lipid DOPE within DSTAP in an 
equimolar ratio decreased the  transition temperature, it was still high enough to make 
rigid bilayers.  
Considering the cationic liposomes as adjuvant systems, they are able to form a depot 
effect at the injection site, and are then taken up by the infiltrating antigen presenting 
cells (APCs) and move slowly to the lymph nodes and consequently promote more 
antibody production (Henriksen-Lacey et al., 2010b; Richards et al., 2004). Recent 
studies have suggested that the more rigid the liposome formulations are, the more 
depot they form at the site of injection (Christensen et al., 2012; Henriksen-Lacey et al., 
2011a), which is in line with results of this study. Henriksen-Lacey et al, compared the 
depot formation of DDA, DC-Chol and DOTAP-based liposomes and reported that 
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more rigid DDA and DC-Chol-based liposomes showed significantly higher antigen 
localisation at the site of injection compared to fluidic DOTAP-based liposomes 
(Henriksen-Lacey et al., 2011a). Furthermore, it has been reported that upon i.v, s.c or 
i.m injection of liposomal vaccines, formulations with rigid bilayers show more 
localisation (for s.c and i.m) and improved circulation (i.v) and ultimately show stronger 
immune responses (Frezard, 1999; Storm and Crommelin, 1998; Yasuda et al., 1977). 
5.4. Investigating the immunogenicity of cationic 
liposomes 
To consider the potential of these various liposome systems as vaccine delivery systems, 
formulations including SUV liposomes of DOPE:DOTAP and DOPE:DSTAP 
formulated in either sucrose or PBS were investigated and the effect of presence of 
electrolytes, as well as the impact of the transition temperature of the cationic lipid on 
immunogenicity of the formulations were studied. Separately, the ability of DRV 
formulations of DOPE:DSTAP to immunise the mice were compared with SUV 
liposomes of DOPE:DSTAP. Based on a study performed by Yang et al. (2008), the 
chosen immunisation strategy for this study was a heterologous prime-prime-boost, 
which included two i.m immunisations of liposomal-pDNA (DD), followed by one i.m 
immunisation of liposomal-subunit antigen (P) injected at two week intervals (combined 
to DDP; Figure 5.4).  
The immunogenicity of heterologous DDP immunisation was compared to the 
homologous vaccination regimens of DNA only (DD-) and sub-unit protein only (--P) 
using DOPE:DSTAP liposomes, to allow the measurement of the impact of the two 
plasmid DNA immunisations and the additional impact of the boost with protein. Table 
5.2 shows the immunisation plan for this study. With regards to the heterologous 
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immunisation regimen, several sequences for the injection of the prime and booster have 
been proposed. Most of reviewed studies show 3 injections including 2 DNA and 1 
protein injection (DDP) (Carstens et al., 2011; Yang et al., 2008). However, the 
sequences of DP (Wang et al., 2008), DDDP (Wierzbicki et al., 2002) and DDDPP 
(Vaine et al., 2010) have also been reported. Some studies have investigated different 
sequences of prime and boost injections and showed that DDP is more effective 
compared to DPP or homologous injections of DD or P only (Deshmukh et al., 2007; 
Yang et al., 2008). Also, it has been reported that no synergy has been seen upon 
injection in the sequence of PDD (Yang et al., 2008). 
 
 
Figure 5.4: Schematic diagram of immunisation plan for the prime-boost heterologous vaccination study.  
Two prime liposome-pDNA complex i.m injections followed by a liposome-protein complex i.m injection 
on a two week intervals. One day before each injection and one week and three weeks after last injection 
tail bleed was performed on groups of 5 female C57BL/6Jico mice. Mice were terminated on day 49 post 
first injection and the spleen and site of injection was dissected and processed for immunological studies. 
 
Chapter 5: In Vivo Studies on DNA Vaccine Formulations                                                              D 
 
154 
Table.5.2: Immunisation plan for DNA vaccine study. 
 
5.4.1. Exploring the effect of vaccine formulation on antibody 
responses against HBsAg in a heterologous immunisation schedule 
Considering first the responses from groups that received the heterologous 
immunisation schedule (1st and 2nd immunisation with DNA, third with sub-unit 
protein; groups 1,4,7 and 8) using SUV as delivery systems the ability of 
DOPE:DOTAP and DOPE:DSTAP liposomes to induce IgG (total), IgG1 and IgG2 
antibody isotypes was studied using ELISAs. As explained in section 2.12.2 and shown 
in Figure 5.4 blood was collected on days 0, 13, 28, 36 and 49 and mice were injected 
with vaccines on days 1, 14 and 29.  
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5.4.1.1. Investigating the effect of electrolyte and transition temperature on antibody 
responses 
Investigating the total IgG levels produced by cationic liposomes (Figure 5.5A) shows 
only liposomes formulated from DOPE:DOTAP (Group 1; Figure 5.5A) and 
DOPE:DSTAP (Group 3; Figure 5.5A) suspended in sucrose, were able to induce the 
antibody production on day 36, and additionally were able to induce significantly 
(p<0.01) higher levels of IgG relative to free DDP (Group 10; Figure 5.5A) on day 49. 
However, DOPE:DOTAP (Group 2; Figure 5.5A) and DOPE:DSTAP (Group 6; 
Figure 5.5A) formed in PBS, showed levels of IgG equal to free DDP (Group 10; Figure 
5.5A), ‘naked’ HBsAg subunit antigen (Group 11; Figure 5.5A), and alum-HBsAg 
(Group 13; Figure 5.5A) on day 49. Indeed, free DNA (Group 12; Figure 5.5A) showed 
backgrounds levels of IgG similar to the naïve group (Group 14; Figure 5.5A) and 
remarkably lower than other immunisation groups (Figure 5.5A).  
Comparing between the two cationic lipids, replacing DOTAP (Group 1 and 2; Figure 
5.5A) with DSTAP (Group 3 and 6; Figure 5.5A) in the liposome formulations showed 
no significant change in total IgG levels by day 49. However, the impact of the presence 
of electrolyte in the formulation, antigen-specific IgG production was significantly 
(P<0.05) lower for DOPE:DOTAP and DOPE:DSTAP when formed in PBS (Group 2 
and 6 respectively; Figure 5.5A) compared to sucrose (Group 1 and 3 respectively; 
Figure 5.5A). This trend was also seen in Th2 responses of mice that were immunised 
with formulations prepared in PBS rather than sucrose; however, in contrast, Th1 
responses were significantly higher (P<0.05) in mice immunised with DOPE:DSTAP 
formulated in PBS (Group 6) compared with all other liposome systems (Figure 5.5B). 
This adds to the previous knowledge that liposomes containing DOTAP promote lower 
Th1 responses compared to other cationic lipids (Henriksen-Lacey et al., 2011a).  
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As controls, a series of options were considered: free DDP (Group 10), free sub-unit 
protein (group 11), free DNA (Group 12) and a sub-unit protein formulated with Alum 
(Group 13). Despite the free DDP and sub-unit group formulations promoting total IgG 
and IgG1 levels similar to liposomal formulations, alum and free DNA could not induce 
any detectable level of IgG2b at this stage (Figure 5.5B). Alum is one of the oldest 
vaccine adjuvants, despite its inability to produce cellular responses (Davidsen et al., 
2005). This explains the failure of the alhydrogel to induce detectable levels of IgG2b. In 
addition, this shows the ability of the cationic liposomes to induce high levels of both 
humoural and cellular immune responses (Figure 5.5B).  
Results show that, compared to free DDP group, which is composed of two free DNA 
and one free subunit antigen injections, liposomal vaccines can induce significantly 
higher (P<0.05) levels of IgG and IgG1 (Figure 5.5). However, the free DDP group, is 
the only non-liposomal group showing detectable levels of IgG2b (Figure 5.5B). This 
might be the effect of prime-boost immunisation, which will be discussed later in section 
5.4.1.3. HBsAg is known to be a moderately strong immunogen, as it contains both T 
and B cell epitopes (Schirmbeck et al., 1994a; Schirmbeck et al., 1994b); however, its 
injection as a free subunit antigen does not induce high antibody response (Group 12, 
Figure 5.5). Previous studies also demonstrated that giving free HBsAg as a booster after 
prime injections of plasmid DNA increases the IgG production significantly; however, 
upon encapsulation of HBsAg protein within liposomes, further (3 times higher, 
P<0.01) enhancement was observed (Yang et al., 2008). This demonstrates the adjuvant 
effect of cationic liposomes, which is in line with the findings of this current study.  
The influence of cationic lipid content within the liposome formulation on antibody 
production, may be explained by the impact of liposomal depot effect at the site of 
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injection, and hence draining of the plasmid DNA into the PLN, on antibody 
production. It has been reported that upon entrance of the antigens to the lymph node, 
antigen presenting cells (APCs), such as dendritic cells (DCs), will present the antigen to 
the MHC class II molecules which activate CD4+ T cells and induce antibody 
production (Bramwell and Perrie, 2005a; McCullough and Summerfield, 2005; 
Medzhitov, 2007). Biodistribution results (Figure 5.2, Section 5.3.2) showed that, 
although DSTAP-based formulations show more localisation at the injection site, DNA 
drainage rate is similar for both kinds of DOTAP and DSTAP liposomes. This was 
followed by similar IgG and IgG1 production levels for all formulations, emphasising 
the effect of DNA drainage to the PLN on humoural immune response and antibody 
production. In contrast, lower IgG2b levels produced by DOTAP formulations reflects 
the difference in intracellular pathways, which leads to induction of either Th1 or Th2 
responses. Given that IgG2b production is related to Th1 responses implies that 
DOTAP based formulations show less Th1 responses when they are compared to 
DSTAP liposomes.  
Having a more rigid structure due to the higher transition temperature, DSTAP 
liposomes have been shown to produce more depot effect at the site of injection. Their 
rigid structure may have caused slower localisation of DNA to the local draining lymph 
nodes and this gives more opportunity to APCs to be in contact with the plasmid DNA 
and activate the pathways, which leads to enhanced Th1 activation. This is in line with 
the findings of a previous study (Henriksen-Lacey et al., 2011a), which compared the 
effect of different cationic lipids on immunogenicity of the liposomes and demonstrated 
that cationic lipids of DDA and DC-chol, which have a more rigid structure, produce 
higher Th1 response compared to DOTAP with fluidic bilayer structure. The difference 
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in structures of the DOTAP and DSTAP has previously been discussed in details in 
chapter 3 (Section 3.3). 
 
 
Figure 5.5: HBsAg specific antibody titres. A) Total IgG for all of the tested formulations in heterologous 
immunisation regimen, serum taken from day 36 and 49, B) IgG1(light blue bars) and IgG2b(dark blue bars) 
for all of the tested formulations in heterologous immunisation regimen, serum taken from day 49. Results 
show the mean ± SD reciprocal endpoint dilution (log10) of 5 mice. Significance measured by one-way 
ANOVA and Tukey’s post test, it is shown by *p<0.05, **p<0.01 and ***P<0.001.  
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5.4.1.2. Comparing the ability of SUV and DRV liposomal vaccines to induce 
antibody responses 
Figure 5.6 compares the antibody production in mice immunised with the heterologous 
strategy using SUV and DRV liposomes of DOPE:DSTAP, so to consider if entrapping 
the antigen with the system could further boost the immune responses.  
Results demonstrate SUV liposomes induce significantly (P<0.05) higher IgG (Figure 
5.6A) and IgG1 responses (Figure 5.6B) than DRV, while IgG2b levels are similar for 
both SUV and DRV formulations (Figure 5.6B). Given the similar depot effect for both 
formulations, higher humoural response of SUV formulations could be due to the 
smaller vesicle size compared to DRV. Characterisation studies (Table 5.1) showed 
DRV formulations own significantly larger vesicles than SUV liposomes. Moreover, in 
vitro transfection studies demonstrate significantly higher cell transfection for SUV 
DOPE:DSTAP+dH2O compared to DRV of the same formulation (Section 3.4, Chapter 
3). These data imply that having smaller size, SUV formulations have more chance than 
DRV to be uptaken by APCs and hence they induce stronger humoural immunity. In 
agreement to this, another study (Carstens et al., 2011) showed that although larger 
vesicles produce stronger depot effect at the injection site, the induced immune response 
of smaller cationic liposomes was significantly stronger and suggested that liposomal 
DNA vaccines do not benefit from strong depot effect and other factors such as vesicle 
size have a role in immune performance of the vaccine. 
These results are in line with the results of a recent study (Milicic et al., 2012) which has 
compared the immune response of MLV, SUV and DRV of DDA:TDB liposomes and 
showed total IgG production of SUV formulation was higher than MLV and DRV 
formulations.  
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Figure 5.6: HBsAg specific antibody titres A) Total IgG for SUV and DRV of DOPE:DSTAP+Sucrose, 
serum taken from day 36 and 49, B) IgG1(light blue bars) and IgG2b(dark blue bars) for SUV and DRV of 
DOPE:DSTAP+Sucrose, serum taken from day 49. Results show the mean ± SD reciprocal endpoint 
dilution (log10) of 5 mice. Significance measured by one-way ANOVA and Tukey’s post test, it is shown by 
**p<0.01 and ***P<0.001. 
5.4.1.3. Considering the immunisation regimen on antibody production levels 
induced by DOPE:DSTAP liposomes 
Given DSTAP based formulations elicit high antibody levels for all three studied 
antibodies (Figure 5.5), SUV liposomes of DOPE:DSTAP were studied to show the 
effect of immunisation regimen on their ability to induce antibody (Figure 5.7); 
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therefore, two homologous and one heterologous vaccination strategies were tested 
using DOPE:DSTAP hydrated in sucrose or PBS.  
Results show no detectable levels of HBsAg-specific antibodies found in the serum when 
mice received two immunisations of liposomal-DNA vaccines (Group 4 and 7; Prime-
Prime (DD-); Figure 5.7), whilst mice that received a single liposomal-sub-unit antigen 
dose (Group 5 and 8; Boost (--P); Figure 5.7) gave measurable responses on day 49 for 
all antibodies tested.  
The heterologous strategy (prime-prime-boost; DDP), promoted high antibody 
responses from both formulations (Group 3 and 6; Figure 5.7) and comparing to the --P 
regimen demonstrated significantly (P<0.05) higher levels of total IgG and IgG1 for 
DOPE:DSTAP when formulated in sucrose (Figure 5.7). In contrast, for IgG2b there 
was no significant change between DDP and --P immunisation strategies (Figure 5.7B). 
Comparing the single immunisation of liposomally formulated sub-unit antigen, the 
formulation in PBS versus sucrose made no significant difference. These results suggest 
that the two liposomal DNA prime immunisations were unable to elicit antigen-specific 
humoural antibody responses, and that the addition of a protein booster immunisation 
was required. Furthermore, the DDP strategy was not significantly better than a single 
liposomal-protein immunisation in terms of Th1 responses (Figure 5.7B).  
Given the low immunogenicity of DNA vaccines (Li et al., 2012), several studies have 
shown that  DNA vaccines have the ability to prime the immune system for responses to 
other vaccines which are known as boost (Lu, 2009; Park et al., 2003; Richmond et al., 
1998; Robinson et al., 1999). 
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Figure 5.7: HBsAg specific antibody titres. A) Total IgG to compare heterologous and homologous 
immunisation of DOPE:DSTAP formed in sucrose or PBS, serum taken from day 36 and 49, B) IgG1(light 
blue bars) and IgG2b(dark blue bars) to compare heterologous and homologous immunisation of 
DOPE:DSTAP formed in sucrose or PBS, serum taken from day 49 Results show the mean ± SD reciprocal 
endpoint dilution (log10) of 5 mice. Significance measured by one-way ANOVA and Tukey’s post test, it is 
shown by **P<0.01 ***P<0.001 
It is also shown that when the contents of prime and boost immunisations are different, 
which is called heterologous immunisation, the immune response is remarkably higher 
than using the same vaccine different times (homologous immunisation) (Lu, 2009; 
Mazumder et al., 2011). Although the mechanism of this technology is still unknown 
(Li et al., 2012; Liu, 2011), it is believed that as DNA vaccines only encode and present 
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the antigen of interest, this makes it easier for initial immune responses to only focus on 
the key antigen during the prime immunisation (De Mare et al., 2008). Furthermore, the 
lower antigen expression by DNA vaccines compared to protein subunit vaccines, may 
prime T helper cell responses and subsequently humoural response will be boosted by 
the protein boost immunisation, so the antibody production level in prime boost 
regimen will be higher than when it is seen with DNA alone (Otten et al., 2005; 
Stambas et al., 2005). Particularly, Yang et al. (2008) showed that immunisation of 
C57BL/6 mice with heterologous prime/boost immunisation of HBsAg as either free 
antigen or liposomal vaccines induced the antibody production. These findings are in 
line with the results of this study and explain why (DDP) antibody responses for all 
antigens are significantly higher than (DD-) immunisation (Figure 5.7). 
5.4.2. Investigating the ability of cationic liposomal vaccines to 
promote cytokine production in response to heterologous 
immunisations with HBsAg 
In order to further examine the role of different cationic liposomal vaccines on both cell 
mediated and humoural immune responses following immunisation, supernatants from 
HBsAg restimulated splenocyte cultures were removed and cytokine levels (IL-2, IL-5, 
IL-6, IL-10 and IFN-γ) determined using ELISA.  
Furthermore, tissue from the SOI was excised, digested and analysed for the presence of 
the pro-inflammatory cytokine IL-1ß. Production of IL-1ß has been related to uptake of 
particulate adjuvants by dendritic cells (Henriksen-Lacey et al., 2011b; Sharp et al., 
2009) and will therefore be useful to see how vesicular vaccine adjuvants promote 
antigen uptake at the SOI. 
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5.4.2.1. Studying the effect of bilayer composition of liposomal vaccines on their 
cytokine production efficiency 
Figures 5.8 and 5.9 show the cytokine production level for all studied formulations in 
the presence of media alone (negative control) and 5µg/mL	  Con A (positive control), 
respectively. Media results show the background levels of cytokine production were low 
(Figure 5.8) and Con A results show Con A simulated splenocytes produced relatively 
high levels of cytokines measured, confirming the viability of the model (Figure 5.9).  
Figure 5.8A shows the production of IL-2 from splenocytes in the absence of a 
stimulant, which is in a range between 20 to 60 pg/mL for all the immunisation groups. 
Upon re-stimulation of splenocytes with HBsAg there were significant increases in IL-2 
production for all the groups except naïve and free antigens and alum groups that 
showed the baseline levels (Figure 5.10A). Between the liposome injected groups, there 
was no notable trend; for DOTAP based liposomes (Group 1 and 2), liposomes formed 
in sucrose (Group 1; Figure 5.10A) show a significantly (P<0.05) higher IL-2 
production (with 700 pg/mL) compared to the DOPE:DOTAP formulated in PBS (with 
350 pg/mL) (Group 2; Figure 5.10A). In contrast, for DSTAP based liposomes (Group 
3 and 6), the vaccine formulations formed in PBS (Group 6; Figure 5.10A) show 
significantly (P<0.05) higher cytokine production with approximately 900 pg/mL 
compared to 550 pg/mL IL-2 produced under the effect of DOPE:DSTAP hydrated in 
sucrose (Group 3; Figure 5.10A).  In addition, replacing DOTAP with DSTAP does not 
result in a significant difference in cytokine responses for the liposomes made in sucrose. 
However, DOPE:DSTAP+PBS (Group 6; Figure 5.10A) produced significantly higher 
levels of IL-2 compared to its DOTAP analogue (Group 2; Figure 5.10A). 
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Figure 5.8: Cytokine production showing IL-2 (A), IL-5 (B), IL-6 (C), IL-10 (D), IFN-γ (E) from 
unrestimulated splenocytes derived from immunised mice or naïve group. Cytokines were measured from 
splenocyte or muscle supernatants using sandwich ELISAs. 
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Figure 5.9: Cytokine production showing IL-2 (A), IL-5 (B), IL-6 (C), IL-10 (D), IFN-γ (E) from 
restimulated splenocytes with 5µg/mL Con A derived from immunised mice or naïve group. Cytokines 
were measured from splenocyte or muscle supernatants using sandwich ELISAs. 
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IL-2 is known as a growth and expansion factor for T helper cells and influences the 
production of T-cell derived cytokines. Its major function is to promote proliferation of 
both CD4+ and CD8+ T-cells and promotes production of NK-derived cytokines such as 
TNF-α and IFN-γ (Gaffen and Liu, 2004). It is known as a Th1 mediating cytokine and 
plays a role in cellular immune response (Christensen et al., 2012; Henriksen-Lacey et 
al., 2011a). Considering IL-2 as a Th1 indicator cytokine, the low IL-2 production of 
alum proves the poor ability of this adjuvant, which only induces Th2 responses, to 
present HBsAg to the T cells.  
Figure 5.8B shows IL-5 production from splenocytes in the absence of a stimulant; these 
results show background levels in a range between 10 to 60 pg/mL. In the presence of 
HBsAg the IL-5 production level increased significantly (P<0.05) for the liposomes 
formed in sucrose (Group 1 and 3; Figure 5.10B); however, the presence of electrolytes 
in the liposomes caused a lower IL-5 production for DOTAP and DSTAP liposomes 
(Group 2 and 6; Figure 5.10B). Cytokine levels for alhydrogel (Group 13; Figure 5.10B) 
increased significantly (P<0.05) from 10 pg/mL (Figure 5.8B) to 60 pg/mL when it is 
restimulated with HBsAg (Figure 5.10B). Con A stimulation induced higher IL-5 
production from splenocytes derived from all liposome injected groups and alum group 
in a range between 200 to 250 pg/mL (Figure 5.9B). IL-5 is known as a Th2 indicator 
(Christensen et al., 2009; Kaur et al., 2012b), which promotes B cell proliferation and 
explains the reason alum has higher cytokine production than DOTAP and DSTAP 
liposomes formed in PBS (Group 3 and 6; Figure 5.10B). IL-5 production levels suggest, 
regardless of the transition temperature of the cationic lipids, liposomes when 
formulated in PBS show lower antibody production as Th2 cells induce humoural 
immune responses, which are responsible for antibody production.  
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Figure 5.10: IL-2, IL-5, IL-6, IL-10 and IFN-γ cytokine production from splenocytes (A–E) and IL-1β 
production from excised leg muscle from the SOI (F) derived from mice immunised with DOPE:DOTAP 
or DOPE:DSTAP pDNA-lipoplex or subunit protein liposome formed in sucrose or PBS and in 
heterologous prime boost strategy. Splenocytes and muscle from the SOI were obtained 3 weeks post the 
final immunisation. Splenocytes were restimulated for 48 h in the presence of HBsAg (5 µg/ml). Leg muscle 
was excised, digested and homogenised. Cytokines were measured from splenocyte or muscle supernatants 
using sandwich ELISAs. Significance measured by one-way ANOVA and Tukey’s post test, it is shown by 
*p<0.05, **p<0.01 and ***P<0.001. 
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 IL-6 is another cytokine which represents Th2 responses, however this cytokine also 
promotes differentiation of Th17 cells with production of IL-17 (Dienz and Rincon, 
2009). This cytokine has been reported to detect both cellular and humoural responses 
(Diehl and Rincon, 2002; Henriksen-Lacey et al., 2011b). Non-stimulated splenocyte 
IL-6 production was between 20-80 pg/mL with no significant difference between 
immunisation groups (Figure 5.8C). These background levels remained for free DNA 
and Naïve group when restimulated with HBsAg; however, alum and free antigen 
groups showed significant increase when restimulated with HBsAg (Figure 5.10C). 
Considering the liposome injected groups, whilst no trend was noted between the 
liposomal groups, all groups responded to HBsAg restimulation, producing levels of IL-
6 approximately 4 to 6 fold (P<0.05) higher than free DDP and alum group (Group 10 
and 13 respectvely; Figure 5.10C). Results show no significant difference between IL-6 
production levels of liposomal groups when restimulated by HBsAg (Figure 5.10C) or 
Con A (Figure 5.9C).  
Figure 5.8D demonstrates IL-10 production from splenocytes from unstimulated 
immunisation groups, which is in a range of 30 to 70 pg/mL showing no trend or 
significant difference between vaccination groups. Restimulation of the immunisation 
groups with HBsAg led to a significantly higher IL-10 production level for alum group 
(Group 13; Figure 5.10D) compared to any liposomally dosed group. Amongst the 
liposomally immunised groups, a similar trend to IL-5 production was seen, since the 
liposomes formed in sucrose (Group 1 and 3; Figure 5.1D) show higher IL-10 
production levels than those mice which received the liposomes with electrolyte in their 
hydration media (Group 2 and 6; Figure 5.10D).  The use of Con A as a positive control 
resulted in IL-10 production of 1000 to 1400 pg/mL for all the injected groups except 
from naïve groups with 400 pg/mL IL-10 production (Figure 5.9A). IL-10 is known to 
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be a Th2 indicator (Henriksen-Lacey et al., 2011b) same as IL-5 and this explains high 
IL-10 production of alum as it tends to induce humoural immune response.  
The next cytokine investigated was IFN-γ, which is critical for innate and acquired 
immune systems. IFN-γ is produced by natural killer (NK) cells and CD4 Th1 cells and 
is indicative of cell mediated immune response (Henriksen-Lacey et al., 2011b; 
Trinchieri, 1997). Figure 5.8E displays IFN-γ production from unstimulated splenocytes 
derived from all immunised groups, which is between 20 to 40 pg/mL. Exposure of 
HBsAg to naïve, free DNA and alum groups also showed background levels of IFN-γ, 
while free HBsAg group as well as all liposomal groups show high IFN-γ production 
levels (Figure 5.10E). It should be noted that all liposomal groups produce significantly 
(P<0.05) higher IFN-γ than free DDP (Group 10; Figure 5.10E). Similar to IL-2 
production, IFN-γ levels of DOTAP liposomes when formed in sucrose (Group 1; 
Figure 5.10E) are significantly (P<0.05) higher than the group which formed in PBS 
(Group 2; Figure 5.10E); in contrast, presence of electrolyte in the formulation does not 
influence produced IFN-γ levels in response to DSTAP based liposomes (Group 3 and 
6; Figure 5.10E) and both of the DSTAP formulations show high IFN-γ production near 
to 2000 pg/mL. Con A restimulation produced higher levels of IFN-γ in a range 5000 to 
7000 pg/mL (Figure 5.9E). 
The last studied cytokine was IL-1ß. It is a potent proinflammatory cytokine whose 
production is related to the uptake of particulate adjuvants by dendritic cells (DCs) 
(Henriksen-Lacey et al., 2011b; Sharp et al., 2009); hence, as liposomal vaccines 
promote antigen uptake at the SOI, it would be of interest to investigate the production 
levels of IL-1ß at the injection site. Figure 5.10F shows that not only the liposome 
formulations (Group 1, 2, 3 and 6), but also DDP (Group 10), free subunit antigen 
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(Group 11), free plasmid DNA (Group 12) and alum (Group 13), are able to activate 
dendritic cells to induce the innate immune response; however, the level which is shown 
by liposomal groups is significantly (P<0.05) higher than non-liposomal injected groups 
(Groups 10-13; Figure 5.10F). Results also display that there is no significant difference 
between the liposomal formulations, as they all of them produce high levels of IL-1ß in 
a range between 4000 to 5000 pg/mg of the injection site (Figure 5.10F). 
Considering Th1 cell mediated immune responses, DOPE:DOTAP+Sucrose and 
DOPE:DSTAP+PBS induce the highest cytokine (IL-2 and IFN-γ) levels (Figure 5.10A 
and E). Investigating the effect of electrolytes in the formulation, this does not give any 
convincing conclusion; DOPE:DOTAP incorporating PBS caused significant (P<0.01) 
decrease in the cytokine production level for both IL-2 and IFN-γ. Even though for 
DOPE:DSTAP, the presence of electrolyte in the formulation has led to an increase in 
cytokine production (Figure 5.10A and E). Furthermore, replacing the cationic lipid 
DOTAP with DSTAP caused no notable difference in Th1 response when sucrose was 
used for hydration of the lipid film. In contrast, DOPE:DOTAP+PBS liposomes 
showed significantly (P<0.001) lower IL-2 and IFN-γ production comparing to 
DOPE:DSTAP+PBS (Figure 5.10A and E), showing that DSTAP formulations induce 
high cell mediated immune response without being limited by nature of hydration 
media.  
Alhydrogel formulation is an aluminium salt and is known to be predominate activator 
of Th2 biased immunity (Davidsen et al., 2005). This is clearly shown in the results as 
the level of alhydrogel in IL-5 and IL-10 is comparable with tested liposomes and 
particularly the IL-10 level of alhydrogel significantly higher (P<0.001) than any of the 
four liposomes in this study (Figure 5.10D). However, the level of produced IL-2 and 
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IFN-γ by alum is similar to the naïve group results (Figure 5.10A and E), showing that 
alum is not able to produce cell mediated immune responses.  
Considering humoural immune responses, it is shown that liposomes formulated in 
sucrose give the highest Th2 response, as both DOPE:DOTAP (Group 1; Figure 5.10B 
and D) and DOPE:DSTAP (Group 3; Figure 5.10B and D) formed in sucrose give 100 
pg/mL and 110 pg/mL for IL-5 and IL-10, respectively (Figure 5.10B and D). It is also 
shown that IL-5 and IL-10 production level for DOPE:DOTAP+PBS (Group 2; Figure 
5.10B and D) are significantly (P<0.05) lower than the same formulation hydrated in 
sucrose (Group 1; Figure 5.10B and D). The same trend has been seen for 
DOPE:DSTAP, however, the difference is not significant (Group 3 and 6; Figure 5.10B 
and D).  
From these results, it appears that both DOTAP and DSTAP liposomal vaccines are 
able to induce comparable levels of Th1 and Th2 responses; however, DSTAP 
formulations showed more stability in inducing immune response in both hydration 
media and for all studied cytokines. Previously in section 5.4.1.1., the impact of these 
formulations on antibody production was described and it was concluded that both 
DOTAP and DSTAP formulations show similar IgG and IgG1 production levels due to 
their similar levels of DNA drainage to the local draining lymph nodes at the site of 
injection. The results also showed higher IgG2 production for DSTAP-based vaccines, 
which was as a result of higher transition temperature of DSTAP. With regards to the 
Th1 and Th2 antibody responses, both formulations show similar levels of Th2 
responses and DSTAP liposomes show higher Th1 responses.  Considering the results 
from cytokine study, the results show the same trend as DSTAP-based liposomes with 
higher cellular immune responses compared to DOTAP formulations, while both 
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formulations show similar innate (based on IL-1ß results) and humoural immune 
responses. This shows the higher transition temperature and more rigidity of 
DOPE:DSTAP structure, which caused higher in vitro transfection efficiency for this 
formulation compared to DOTAP liposomes (Section 4.6, Chapter 4 of this thesis), is 
the key factor in higher Th1 immune response. 
Previous studies (Henriksen-Lacey et al., 2011a) have also compared the 
immunogenicity of different cationic lipids and demonstrated that lipids with higher 
transition temperature like DDA and DC-Chol show higher cellular immune response 
than DOTAP, which has a Tc below room temperature, and its bilayer structure is 
fluidic. They suggest that the higher transition temperature caused more antigen 
retention at the site of injection resulting in stronger antigen recall and consequently 
higher IFN-γ production level, which indicates DDA and Dc-chol liposomes, induce 
higher cell mediated responses. In addition, a recent study (Christensen et al., 2012) 
compared saturated DDA to its unsaturated analogue DODA, and results showed more 
antigen retention at the injection site for DDA resulted in higher expression of co-
stimulatory molecules CD40 and CD86 and this led to higher cellular immune response 
for DDA-based liposomes.  
These results are in agreement with the findings of this current study, suggesting a 
similar mechanism caused higher IL-2 and IFN-γ production for saturated DSTAP 
liposomes compared to unsaturated and fluidic DOTAP formulations. Finally, this 
study suggests that bilayer composition has a major role in induced immune response by 
liposomal vaccines. 
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5.4.2.2. Exploring the effect of vesicle morphology on cytokine production levels of 
cationic liposomal vaccines in a heterologous immunisation schedule 
The impact of the liposomal vaccine type (DRV vs SUV) on cytokine production was 
investigated using DOPE:DSTAP. Results (Figure 5.11) show no significant difference 
in producing Th1 response, with both SUV and DRV inducing similar cytokine 
production for IL-2 (Figure 5.11A) and IFN-γ (Figure 5.11E). IL-6 production also 
followed the same trend, although, it is shown that IL-5 and IL-10 production levels of 
SUV formulations are higher than their DRV analogue (Figure 5.11B and D). This 
shows SUV liposomes may be better at inducing humoural immune responses 
compared to DRV liposomal vaccines.  
In vitro transfection results (Section 4.6, Chapter 4) showed significantly (P<0.05) higher 
transfection efficiency for SUV DSTAP based liposomes compared to DRV 
formulations when they formed in the absence of electrolytes. However, biodistribution 
investigations revealed no notable differences between the two types of liposomes 
(Section 5.3.2; Figure 5.3), yet antibody production was reduced when DRV liposomes 
were used (Section 5.4.1.2; Figure 5.6). This could also explain the significantly 
(P<0.05) lower IL-5 levels for DRV liposomes; IL-5 is characteristic of humoural 
responses. A recent study of Milicic et al (Milicic et al., 2012) demonstrated that SUV 
liposomal vaccines of DDA:TDB induced higher IgG levels than DRV formulations. 
This study also demonstrates that SUV liposomes induce stronger CD4+ and CD8+ T 
cell responses as well as antibody production compared to DRV. More activation of 
CD4+ T cells by MHC II class molecules may have caused higher humoural response 
for SUV liposomes, which is in line with the results of this current study and according 
to Carstens et al., it might be due to the smaller vesicle size of the SUV liposomes than 
DRV formulations and consequently higher APC uptake of SUV (Carstens et al., 2011). 
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Figure 5.11: IL-2, -5, -6, -10 and IFN-γ cytokine production from splenocytes (A–E) and IL-1β production 
from excised leg muscle from the SOI (F) derived from mice immunised with SUV DOPE:DSTAP or DRV 
DOPE:DSTAP pDNA-lipoplex or subunit protein liposome formed in sucrose and in heterologous prime 
boost strategy. Splenocytes and muscle from the SOI were obtained 3 weeks post the final immunisation. 
Splenocytes were restimulated for 48 h in the presence of HBsAg (5 µg/mL). Leg muscle was excised, 
digested and homogenised. Cytokines were measured from splenocyte or muscle supernatants using 
sandwich ELISAs. Significance measured by one-way ANOVA and Tukey’s post test, it is shown by 
**p<0.01.  
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5.4.2.3. Studying the impact of heterologous vaccination strategy on cytokine 
production of DOPE:DSTAP liposomal vaccines 
Although both DOTAP and DSTAP based liposomes showed the ability of producing 
high levels of cytokine and inducing both humoural and cell mediated immune 
responses, SUV DOPE:DSTAP promoted higher responses in both hydration media for 
all of the cytokines. Hence DOPE:DSTAP were investigated to compare the cytokine 
responses for prime-boost vaccination (DDP) compared to the homologous 
immunisations of two DNA primes (DD-) or protein boost only (--P) (Figure 5.12).  
As it is shown in figure 5.12, DDP immunisation caused a significantly (P<0.001) 
higher cytokine response in splenocytes compared to prime only immunisation (DD-). 
However, it was slightly different when the heterologous immunisation was compared 
to the homologous boost only (--P) immunisation. In many formulations there was not a 
significant difference between cytokine production levels in response to these 
immunisation strategies. This was not limited to one hydration media and was seen 
with both sucrose and PBS formed liposomes. For IL-2 and IL-6 cytokines the prime-
boost immunisations responses to the DOPE:DSTAP+sucrose are higher than their 
boost immunisation responses, but the difference is not significant (Figure 5.12A and C, 
orange bars). Similar results have been seen in IL-5, IL-6 and IL-10 for 
DOPE:DSTAP+PBS (Figure 5.12B,C and D, dark blue bars). However, IFN-γ 
responses to both DOPE:DSTAP liposomes that are formulated in sucrose or PBS show 
the prime boost immunisation induces significantly higher (P<0.05) cytokine production 
than boost only immunisation (Figure 5.12E). Overall, considering the Th1 and Th2 
responses, the results show both cellular and humoural responses were enhanced by the 
effect of heterologous immunisation. 
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Tissue excised from the injection site of mice immunised with three different 
immunisation strategies show no significant difference between the vaccination 
regimens in both hydration media (Figure 5.12F), as all of the responses were near to 
(5000 ng/mg tissue) suggesting that any kind of liposomal immunisation has the ability 
to stimulate pro-inflammatory responses. 
 
Figure 5.12: IL-2, IL-5, IL-6, IL-10 and IFN-γ cytokine production from splenocytes (A–E) and IL-1β 
production from excised leg muscle from the SOI (F) derived from mice immunised with SUV 
DOPE:DSTAP pDNA-lipoplex or subunit protein liposome formed in sucrose (orange bars) or PBS (dark 
blue bars). Immunisation strategies varied between heterologous prime-boost, homologous pDNA prime 
and homologous protein boost. Splenocytes and muscle from the SOI were obtained 3 weeks post the final 
immunisation. Splenocytes were restimulated for 48 h in the presence of HBsAg (5 µg/mL). Leg muscle 
was excised, digested and homogenised. Cytokines were measured from splenocyte or muscle supernatants 
using sandwich ELISAs. Significance measured by one-way ANOVA and Tukey’s post test, it is shown by 
*p<0.05, **p<0.01 and ***P<0.001. 
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Taken together, this data (Figure 5.12) suggests that the subunit protein vaccination (--P) 
provides immunisation responses similar to the produced levels by prime-boost 
vaccination composed of two DNA vaccines and one subunit protein vaccine (DDP). 
A similar study by Yang et al (Yang et al., 2008), showed prime-boost immunisation 
induces higher humoural immune responses and also increases the CD8+ T cell activity. 
This caused an increased IFN-γ production suggesting that heterologous immunisation 
can induce stronger cell mediated immune responses. Their results show the synergic 
effect of prime-boost immunisation has caused a significantly higher Th1 and Th2 
responses compared to homologous immunisations; however, in this current study, 
heterologous immunisation of DOPE:DSTAP vaccines did not produce significantly 
higher response than single i.m injection of DOPE:DSTAP-subunit.  Comparing these 
two studies shows the only major difference is in the route of the administration of 
protein boost immunisation. Yang et al. (2008) study included 2 i.m injection of DNA-
liposomes and a single i.n. injection of boost HBsAg; however in this study all the 
injections were applied as an i.m injection. This indicates the higher synergic effect of 
heterologous immunisation could be as a result of mucosal immune response, which 
was activated by the i.n. injection.  
5.4.3. Splenocyte proliferation 
In addition to the cytokine study, liposomal vaccines were investigated for their ability 
to initiate antigen specific spleen cell proliferation (Figure 5.13-5.16). Splenocytes were 
restimulated with 0.05, 0.5 and 5 µg/mL HBsAg antigen, in addition to the positive 
control stimuli Con A (5 µg/mL). Figure 5.13 shows the proliferative ability of 
splenocytes of all immunised groups in response to Con A; all the groups showed 
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response to Con A as the 3H-thymidine uptake was shown to be between 30000 to 40000 
CPM (Figure 5.13).  
 
 
Figure 5.13: Splenocyte proliferation of each immunisation group and naïve group in response to 
stimulation with 5 µg/mL Con A. Splenocytes were derived on day 49 of the study and restimulated ex vivo 
with Con A as a positive control. After a further 24 hrs cells were harvested and the proportion of 3H-
thymidine incorporated in the cells measured using standard scintillation counting. 
Studying the splenocytes, when exposed to HBsAg antigen, shows that increasing the 
amount of HBsAg concentration increased the splenocyte proliferation in all of the 
immunised groups tested with the exception of groups 10, 11, 12 and 14 (Figure 5.14).  
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Figure 5.14: Splenocyte proliferation of DOPE:DOTAP and DOPE:DSTAP both hydrated in sucrose or 
PBS and injected under heterologous regimen, Alum, free antigen, free pDNA and naïve group. 
Splenocytes were derived on day 49 of the study and restimulated ex vivo with range of 0 to 5 µg/mL HBsAg 
.After a further 24 hrs cells were harvested and the proportion of 3H-thymidine incorporated in the cells 
measured using standard scintillation counting.  Significance measured by one-way ANOVA and Tukey’s 
post test, it is shown by **p<0.01. 
Comparing to the naïve group, all other groups show a significantly (P<0.05) higher 
proliferation for all concentrations of HBsAg. Considering the effect of presence of 
electrolytes in the formulation, results show both liposomes where formulated with PBS 
showed lower proliferation compared to the liposomes hydrated in sucrose (Groups 2 vs 
1 and 4 vs 3 respectively; Figure 5.14). It is also shown in antigen concentrations below 
5 µg/mL there is no significant difference in proliferation of mice immunised with 
DOTAP or DSTAP liposomes and the only notable change is in 5 µg/mL concentration 
of HBsAg, where mice immunised with DOPE:DSTAP+sucrose (Group 3) show a 
significantly (P<0.05) higher splenocyte proliferation than any other formulation 
(Figure 5.14). In the mice immunised with alum (Group 13; Figure 5.14), proliferation 
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was shown to be similar to mice receiving the liposome formulations and higher than 
free antigens, with only the group which received DOPE:DSTAP/sucrose (Group 3; 
Figure 5.14) giving significantly ( p<0.05) higher responses. 
Figure 5.15 shows the comparison between SUV and DRV liposomes of DOPE:DSTAP 
in splenocyte proliferation and it demonstrates that SUV liposomes show significantly 
(P<0.05) higher cell proliferation than DRV liposomes in all of HBsAg concentrations 
(Figure 5.15).  
 
 
Figure 5.15: Comparing splenocyte proliferation of SUV DOPE:DSTAP and DRV DOPE:DSTAP both 
formed in sucrose. Splenocytes were derived on day 49 of the study and restimulated ex vivo with range of 0 
to 5 µg/mL HBsAg .After a further 24 hrs cells were harvested and the proportion of 3H-thymidine 
incorporated in the cells measured using standard scintillation counting.  Significance measured by one-way 
ANOVA and Tukey’s post test, it is shown by **p<0.01. 
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Comparing the impact of different immunisation strategies on splenocyte proliferation 
shows the heterologous prime-boost immunisation of DOPE:DSTAP+sucrose has the 
highest proliferation level, which is significantly higher (P<0.001) than homologous 
immunisations at the 5 µg/mL concentration of HBsAg (Figure 5.16). However, there is 
no significant difference between heterologous and homologous immunisations of 
DOPE:DSTAP+PBS.  
 
Figure 5.16: Comparing splenocyte proliferation of heterologous prime boost immunisation to homologous 
pDNA prime and protein boost for DOPE:DSTAP+Sucrose and DOPE:DSTAP+PBS. Splenocytes were 
derived on day 49 of the study and restimulated ex vivo with range of 0 to 5 µg/mL HBsAg .After a further 
24 hrs cells were harvested and the proportion of 3H-thymidine incorporated in the cells measured using 
standard scintillation counting.  Significance measured by one-way ANOVA and Tukey’s post test, it is 
shown by ***p<0.001. 
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Taken together, these results show that, apart from DSTAP formulations when made in 
sucrose, other liposomal vaccines show a similar splenocyte proliferation rate regardless 
of their cationic lipid, hydration media or immunisation strategy. 
5.5. Conclusion 
The studies in this chapter aimed to investigate the ability of liposomal formulations as 
possible DNA vaccine delivery systems and to consider the impact of their 
physicochemical properties on their immunogenicity. Furthermore, induced immune 
responses resulting from a heterologous immunisation schedule were compared to two 
different homologous vaccinations. 
In general, all liposomal formulations tested showed significantly higher cellular and 
humoural immune response compared to the all free antigens and naïve group, as 
expected (Gregoriadis, 1990; Gregoriadis et al., 1997; Henriksen-Lacey et al., 2011c; 
Morrey et al., 2011; Perrie et al., 2001; Yang et al., 2008). Although Alum, an old and 
well-known adjuvant for subunit protein vaccines, showed comparable humoural 
responses to the liposomal systems, it failed to produce cell mediated responses, as 
expected (Brunel et al., 1999; Davidsen et al., 2005; Rosenkrands et al., 2005).  
Overall, in terms of immune responses promoted by the tested liposomal formulations, 
DOPE:DSTAP, when formed in sucrose and injected under heterologous prime-boost 
(DDP) immunisation regimen, showed the highest response. DOPE:DSTAP hydrated 
in PBS showed similar results, with comparable cellular immune responses but lower 
humoural responses. The higher immune responses of DSTAP-based liposomes can be 
related to the higher transition temperature of cationic lipid of DSTAP, which makes 
the bilayer more rigid, compared to the more fluidic DOTAP-based liposomes. 
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Biodistribution study showed that having a more rigid bilayer caused stronger depot 
effect at the site of injection, therefore promoting a more sustained drainage into the 
local draining lymph nodes where dendritic cells (DCs) interact with the antigen and 
present the antigens to the MHC class II molecules and T cells, which result in 
induction of the humoural and cell mediated immune responses. Several studies have 
shown the same trend, showing the effect of bilayer composition on enhancement of 
immune response (Christensen et al., 2012; Henriksen-Lacey et al., 2011a).  
Investigating the impact of incorporating electrolytes in the formulation showed 
formulations which were hydrated in sucrose induce stronger immune responses 
compared to the formulations made in PBS. Characterisation studies showed the 
presence of salt in the liposome formulation can cause aggregation, which may hinder 
uptake of the liposomal-antigen by DCs infiltrating the site of injection or residing at the 
local lymph nodes, which leads to the reduction in immune response. In agreement to 
this result, Henriksen-Lacey et al. (2011b) compared the effect of vesicle size of the 
liposomes on immune response and for this reason formulated DDA:TDB liposomes in 
PBS to reach to an extra large vesicle size. The study demonstrated a poor immune 
response for the formulation when formed in PBS compared to other formulations and 
suggested that the unexpectedly poor immunogenicity of this formulation may not be 
solely size induced, but could be as a result of presence of salt. However, another study 
(Yan and Huang, 2009) has shown presence of small amount of salt in the formulation 
enhances the development of immune response by the liposomes. Therefore, the ability 
to exploit electrolytes to enhance immunes responses remains unclear.  
Comparing SUV and DRV of DOPE:DSTAP formulated in sucrose showed that, in 
terms of humoural immune responses, SUV formulations induce significantly stronger 
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total IgG and IgG1 responses for SUV compared to DRV. However, results 
demonstrate no significant difference between SUV and DRV formulation in enhancing 
cellular mediated responses, where amongst all the cytokines tested, only IL-5 
production was shown to be significantly higher for SUV, which could be due to the 
smaller vesicle size of SUV. This is in line with the study (Carstens et al., 2011) that 
shows smaller liposomal DNA vaccines with low depot effect induce strong humoural 
immune response, suggesting that liposomal DNA vaccines do not benefit from strong 
depot effect and other characteristic parameters of the formulation can have an 
important role in activation of immune system. It has been established through in vitro 
studies that the optimal size for APC uptake is below 500 nm (Foged et al., 2005). 
Moreover, Singh et al. (2000) have demonstrated an enhanced immunogenicity for 
particulate-based DNA vaccine with the size of 300 nm over 1 µm size particles. 
Furthermore, a recent (Milicic et al., 2012) study compared three different types of 
liposomes in terms of humoural and cellular immune responses; these studies showed 
that SUV liposomes of DDA:TDB complexed with OVA induce higher IgG production 
and consequently stronger humoural immune response compared to MLV and DRV 
types of the formulation. In contrast, it is shown by Kaur et al. (2012a, b) that DRV 
liposomal vaccines of DDA:TDB- Ag85B-ESAT-6 provide stronger immunity 
compared to SUV liposomes. This suggests that the chosen antigen in the formulation 
may also have an impact. 
Finally, to study the impact of different immunisation strategies on immune response, 
heterologous prime-boost and (DDP) immunisation for DOPE:DSTAP, formed in both 
hydration media has compared to two homologous vaccination regimens including 
prime DNA(DD-) and boost (--P) regimens. The results from these studies illustrate 
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that, compared to the homologous DNA-liposome regimen, heterologous immunisation 
can stimulate significantly higher antibody and cytokine production in response to 
HBsAg. Showing a synergistic immune response by the heterologous regimen implies 
that DDP strategy provides higher immune responses than single i.m injection of 
liposomal subunit antigen (--P); however, the difference between two strategies is not 
notably different and potentially a PPP regimen would give higher responses. This 
indicates that, although numerous studies (Carstens et al., 2011; Liu, 2011; Lu, 2009; 
O'Hagan et al., 2004; Otten et al., 2005; Stambas et al., 2005; Yang et al., 2008) show 
promising results for heterologous immunisation, more studies are needed to improve 
this technology to a level that justifies the cost of this type of vaccination. 
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6.1. Introduction 
To date, there are at least eight liposome-based adjuvant formulations which are 
approved or going through clinical trial phases (Watson et al., 2012): for example, there 
are virosomes such as Infexal® V (Herzog et al., 2009) and Epaxal® (Bovier, 2008), 
which are in the market, and  DNA vaccines like Vaxfectin (Sullivan et al., 2010; 
Veselenak et al., 2012) and JVRS-100 (Dong et al., 2012), which are in Phase II clinical 
trials. Among the subunit protein vaccines, there is a liposome formulation, which is 
composed of cationic lipid dimethyl dioctadecyl ammonium (DDA) and the 
immunomodulating glycolipid trehalose dibehenate (TDB). DDA:TDB (known as 
Cationic Adjuvant Formulation 01 or CAF01) has recently completed phase I clinical 
trials in combination with the tuberculosis (TB) vaccine antigen candidate, Ag85B-
ESAT-6 (ClinicalTrials.gov, 2012). This formulation has shown to give strong Th1 
responses (Henriksen-Lacey et al., 2010b; Henriksen-Lacey et al., 2011c) as required for 
TB immunisation and its mechanism of action has been extensively investigated; for 
example, recent studies on DDA:TDB formulations have revealed that immunisation of 
this formulation produces a strong depot effect at the injection site and induces a high 
cellular and humoural immune responses against Ag85B-ESAT-6 (Davidsen et al., 
2005; Henriksen-Lacey et al., 2010b; Holten-Andersen et al., 2004).  
DDA itself has long been recognised to have adjuvant properties (Gall, 1966) and has 
been shown to enhance both cellular and humoural responses for a range of antigens 
(Vangala et al., 2007). DDA is a quaternary ammonium lipid with two saturated 18-
carbon hydrophobic tails (Figure 6.1A). The adjuvant action of DDA based liposomes 
has been described to be related to the ability of DDA to protect and deliver antigen to 
the antigen presenting cells (APCs), and to form the depot effect at the site of injection, 
causing the antigens to retain for a prolonged time period and hence enhance antigen 
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uptake and subsequent presentation of antigen material to T cells (Korsholm et al., 
2007).  
DDA-based liposomes, like other cationic liposomes, are able to convert the antigens 
into a particulate form and thus enhance their immunogenicity. This is due to the 
cationic surface charge of DDA and its ability to electrostatically bind anionic antigens 
(Christensen et al., 2009; Hilgers et al., 1985) and recent studies have confirmed this; by 
replacing the cationic DDA with the neutral lipid 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), the biodistribution behaviour of the vaccine adjuvant was 
changed and dramatically decreased immune responses (Henriksen-Lacey et al., 2010c; 
Kaur et al., 2011). 
 
Figure 6.1: Chemical structure of A) the cationic lipid DDA and B) the immunostimulant TDB. 
TDB (Figure 6.1B), the second component of DDA:TDB liposomal adjuvant, is a 
synthetic analogue of trehalose 6,6’-dimycolate (TDM), which is known as cord factor 
and is an immunostimulatory component in mycobacterial cell wall (Lemaire et al., 
1986; Pimm et al., 1979). The advantage of TDB over TDM is that it is less toxic due to 
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its shorter fatty acid chains, whilst it shows the same immunostimulatory effect as TDM 
(Olds et al., 1980; Pimm et al., 1979).  
As a liposomal adjuvant system, DDA:TDB is able to initiate intracellular activation 
pathways. Amongst the different classes of signals initiating immune responses, it has 
been reported that liposomes may enhance signal 1 by providing effective delivery of 
antigen to secondary lymphoid organs (Perrie et al., 2008; Zinkernagel et al., 1997). 
Given the high depot effect of DDA:TDB at the injection site, and the consequent slow 
draining of the incorporated antigen to the local lymph node (Henriksen-Lacey et al., 
2010b), suggests that DDA:TDB is able to induce immune responses through signal 1 of 
the signalling pathways. It has also been shown that induction of immune responses 
depends upon antigens being available in lymphoid organs, since if an antigen does not 
reach lymphoid organs it is ignored by immune cells (Zinkernagel et al., 1997). Having 
antigen in the T cell region of lymph nodes can stimulate Toll-like receptors (TLRs), 
which activate important mediators of innate and adaptive immunity (Perrie et al., 
2008). TLRs transduce signals via the intracellular MyD88 pathways and enhance 
cellular (Th1) and humoural (Th2) immune responses (Christensen et al., 2009; Milicic 
et al., 2012).  
DDA:TDB was first introduced in 2004 by Holten-Andersen et al. as an efficient 
adjuvant for TB subunit vaccines (Holten-Andersen et al., 2004), initiating high IFN-γ 
response considered to be the key cytokine for induction of a Th1 immune response. 
Since then, DDA:TDB has been extensively studied and optimised with regards to the 
ratio of components, adjuvant dose and stability of the formulation (Davidsen et al., 
2005), resulting in the production of a MLV of DDA:TDB with the weight ratio of 5:1. 
Differential scanning calorimetry (DSC) studies revealed that during incorporation of 
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TDB into DDA vesicles, the acyl chains of the TDB might be incorporated into the 
hydrophobic core of the DDA lipid bilayers, which makes the DDA bilayers more stable 
(Davidsen et al., 2005).  
In a comparative study, the ability of DDA:TDB as a protein subunit vaccine for HBV 
was studied by incorporating Hepatitis B surface antigen (HBsAg) into the liposome 
formulation. Similar to DDA:TDB with H1, the HB vaccine produced high levels of 
Th1 and Th2 responses (Vangala et al., 2007; Vangala et al., 2006). These previous 
studies have been performed using a homologous immunisation regimen. However, 
given previous reports (Carstens et al., 2011; Yang et al., 2008) and the results from 
Chapter 5, which suggest that by applying heterologous prime-boost immunisation, 
using plasmid DNA and protein subunit of the same antigen, enhances both cellular and 
humoural immune responses, the purpose of this current study was to consider the use 
of DDA:TDB in a prime-boost immunisation strategy.  
It has been mentioned earlier that DDA as a cationic lipid can be used as a liposomal 
adjuvant system (Gall, 1966). In addition, there are several cationic lipids such as 
DOTAP and DC-cholesterol, with immunogenic properties which have been used in 
liposomal vaccines (Gregoriadis et al., 2002; Henriksen-Lacey et al., 2011a; McNeil et 
al., 2010; Perrie et al., 2001; Perrie et al., 2002). These studies and those in chapters 3 to 
5, have revealed that, to make an efficient liposomal vaccine, an equimolar ratio of 
helper lipid such as DOPE or cholesterol is needed to be incorporated into the cationic 
lipid. Hence, in this current study, in addition to DDA:TDB, equimolar ratio of 
fusogenic lipid DOPE is added to the DDA to make cationic liposomes of DDA:DOPE.  
Therefore, the aim of this chapter was to evaluate the immunological efficiency of DDA 
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based liposomes as a DNA vaccine and in a heterologous prime boost immunisation 
regimen. To achieve this aim, the overall objectives of the work were to: 
• study the characteristics of DDA:TDB and DDA:DOPE as a DNA lipoplex 
formulation. 
• evaluate the in vitro transfection efficiency of the formulations. 
• investigate the biodistribution of liposomes and their associated DNA and 
attempt to correlate these to their physicochemical properties and 
immunological function. 
• study the immunological efficiencies of the liposomes in a heterologous prime 
boost immunisation study.  
6.2. Molecular packaging of the lipids 
Monolayer studies of DDA:DOPE and DDA:TDB were first investigated to consider 
potential molecular interactions between the two lipids in the mixtures. Previous studies 
have shown that monolayer studies can explain the molecular packaging of the lipids 
and its effect on characteristic properties of the liposomes, as these results could be 
translated into liposomal systems (Section 3.3, Chapter 3).  
Therefore, in this study monolayers of single and mixed lipids were investigated for their 
interactions within the monolayer in the aqueous sub-phase. Pressure-area (π-A) 
isotherms are shown in Figure 6.2. Studying the monolayer of TDB was not possible as 
it is a glycolipid and does not make monolayers on the air/water interface. The collapse 
pressure and extrapolated (to zero pressure) area per molecule for each isotherm are 
shown in Table 6.1. Monolayers of single lipids of DOPE and DDA were studied on 
Langmuir-Blodgett trough individually. Figure 6.2 shows the isotherm of the DOPE 
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monolayer collapses at 42.3 mN/m at a mean molecular area of 43.4 A2. The 
extrapolated area of DOPE monolayer at zero pressure is about 72 A2/Molecule (Table 
6.1). The DDA monolayer seems to have similar molecular packaging arrangements to 
DOPE as its collapse pressure is ≈44 mN/m. The mean molecular area for DDA 
monolayer is slightly smaller than DOPE monolayer (≈ 37 A2), as is its extrapolated 
area per molecule (64 A2/Molecule; Table 6.1).  
 
Figure 6.2: Compression isotherm studies of the single and mixture of lipid monolayers of DDA:DOPE 
and DDA:TDB in deionised water at 20° C. Results are expressed as the means of three experiments. SD 
has not shown for clarity. 
Table 6.1: The experimental extrapolated area and area compressibility of mixed and single monolayers at 
the air/water interface at 20° C. Results denote mean±SD, n=3 for three independently prepared batches. 
Lipid	   Extrapolated	  Area	  (A2/Molecule)	  
Ideal	  Extrapolated	  
Area	  (A2/Molecule)	  
Deviation	  from	  
Ideality	  (%)	  
Collapse	  Pressure	  
(mN/m)	  
DOPE	   71.9	  ±	  6.0	   -­‐	   -­‐	   42.3	  ±	  0.4	  
DDA	   63.8	  ±	  4.7	   -­‐	   -­‐	   43.9	  ±	  0.6	  
DDA:DOPE	   67.4	  ±	  5.1	   67.9	  	   -­‐	  0.7	   42.8	  ±	  0.8	  
DDA:TDB	   114.3	  ±	  7.6	   -­‐	   -­‐	   46.5	  ±	  1.6	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Results show that there is no significant difference between the ideal (67.8 A2/Molecule; 
Table 6.1) and experimental areas for the DDA:DOPE mixture (67.4 A2/Molecule; 
Table 6.1). Deviation from the ideality can be used to monitor molecular interactions 
between the molecules in the mixed monolayers such as a condensing effect, as is seen 
with some phospholipids and cholesterol (Ali et al., 2010).  
The mixture of DDA:TDB monolayer (5:1) w/w was also studied to investigate the 
effect of addition of TDB on DDA monolayer characteristics. As it is shown in Figure 
6.2, the DDA monolayer isotherm shows a transition from liquid-expanded to liquid-
condensed phase. This transition has disappeared in DDA:TDB monolayer. The results 
also show that the addition of TDB increases the collapse pressure (Table 6.1), and the 
extrapolated area at zero pressure for DDA:TDB monolayer  compared with the DDA 
monolayer (114 vs 64 A2/Molecule respectively), suggesting the overall area per 
molecule has increased, which maybe indicative of enhanced liposome stability as 
previously reported (Christensen et al., 2008). Increasing the collapse pressure of DDA 
monolayer by incorporation of TDB suggests that the trehalose head group of TDB has 
stronger interactions with water molecules than the DDA quaternary ammonium head 
groups. Therefore, it can be predicted that incorporation of TDB into the membrane of 
DDA liposomes will increase the hydration of the membrane and prevent dehydration 
of the quaternary ammonium head groups. This decreases charge repulsion between the 
DDA molecules in the bilayer, and reduces aggregation of the liposomes so TDB 
stabilises the DDA liposomes (Christensen et al., 2008). 
6.3. Physicochemical characterisations of the liposomes 
Physicochemical characterisations of pDNA lipoplexes of DDA:DOPE and DDA:TDB 
were studied in terms of their vesicle size, surface charge and antigen loading (Figure 
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6.3). Similar to the previously studied DOPE:DOTAP and DOPE:DSTAP formulations 
(Chapter 3), DDA:DOPE and DDA:TDB lipoplexes vesicle size increased with 
increasing DNA concentration (Figure 6.3A). This is due to the aggregation of the 
system, which occurs as a result of bridging effect (Ciani et al., 2004). The vesicle size 
for DDA:DOPE lipoplexes increased from 60 to 600 nm as the DNA concentration 
increased (Figure 6.3A) and these systems were significantly (P<0.05) smaller than 
DDA:TDB lipoplexes equivalents, which increased in vesicle size from 200 to 800 nm 
(Figure 6.3A). The difference in size between DDA:TDB and DDA:DOPE may be 
indicative of differences in molecular packaging of the different lipids particularly given 
that the DDA:TDB were shown to have more rigid monolayers than DDA:DOPE 
(Table 6.1 and Figure 6.2). Similarly Zantl et al., (Zantl et al., 1999) also showed that 
lipoplexes formed from saturated and more rigid bilayers resulted in larger vesicle sizes 
for the lipoplexes. Furthermore, it is known that different structures exist for the cationic 
liposome-DNA complex including lamellar and inverted hexagonal structures (Ulrich, 
2002) and it is believed that complexation of cationic lipids in the presence of a helper 
lipid such as DOPE or cholesterol, with DNA would be changed from lamellar to the 
inverted hexagonal phase, which is preferable for transfection (McNeil and Perrie, 2006) 
and increases in the fluidity of the bilayer would avoid formation of aggregations 
(Ulrich, 2002). 
Results showed that the zeta potential of any of the studied formulations was constant 
for DNA content of 0 to 200	  µg and was between 60 to 70 mV for both liposomes, but it 
reduced significantly (P<0.05) to ≈50 mV for both DDA:DOPE and DDA:TDB 
lipoplexes at the highest DNA concentration of 1600	  µg, showing that lipid/DNA +/- 
ratio affects zeta potential of the lipoplexes (Figure 6.3B). DNA association of 
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Figure 6.3. A) demonstrates vesicle size and polydispersity index, B) represents zeta potential and C) shows 
DNA association within SUV lipoplexes of DDA:DOPE and DDA:TDB. Results denote mean ± SD, for 
three independently prepared batches. 
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lipoplexes were similar to each other around 90% and was independent from vesicle 
size, as would be expected for such cationic systems (Figure 6.3C). 
6.4. The ability of DDA-based lipoplexes to protect DNA 
from degradation. 
To investigate the DNA protection offered by DDA-based SUV lipoplexes, 
DDA:DOPE and DDA:TDB complexed with DNA (2µg) were subjected to gel 
electrophoresis in the presence of SDS  at 1.2 % concentration as described in sections 
2.7 and 4.2. 
Figure 6.4A shows that, on gel electrophoresis of DDA:DOPE (1) and DDA:TDB (2) in 
the absence of anionic molecules of SDS, DNA remains within the well of the gel, 
bound to the cationic liposomes. In contrast, following electrophoresis in the presence of 
SDS, displaced DNA is seen to migrate towards the cathode (Figure 6.4B). Result 
showed that there is no notable difference in DNA retention between both formulations 
in either 6.4A or B. Having most of DNA displaced for both DDA:DOPE and 
DDA:TDB in the presence of SDS suggests that most of the SUV associated DNA is 
adsorbed on the surface of the lipoplexes and that replacing DOPE with TDB had no 
notable effect on DNA displacement. This confirms that it is choice of cationic lipid, 
and not the presence of the helper lipid, which is the key factor for DNA release. This is 
in line with the results shown in chapter 4 with DOTAP vs DSTAP and in previous 
studies (Perrie et al., 2004), where replacing DOTAP with DC-choelsterol changed the 
DNA displacement profiles.  
Also similar to section 4.3, to investigate the ability of DDA-based lipoplexes to protect 
the plasmid DNA from degradation by digestive enzymes, plasmid DNA was incubated 
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with DNase I as either naked (Figure 6.5A-D, lane ‘C’) or loaded with cationic 
liposomes (Figure 6.5A-D, lane 1-2). Figure 6.5 shows naked DNA, which was not 
exposed to the DNase I (Figure 6.5A and B, lane ‘C’), and the digested naked DNA 
(Figure 6.5C and D, lane ‘C’). The band of migrated anionic DNA towards the cathode 
is shown for undigested naked DNA in the absence (Figure 6.5A, lane ‘C’) and presence 
of SDS (Figure 6.5B, lane ’C’). However, when naked DNA exposed to the DNase I, 
there is no visible band on the agarose gel (Figure 6.5C and D, lance ‘C’) showing the 
naked DNA was digested by DNase I.  
 
Figure 6.4: A) Gel electrophoresis of SUV lipoplexes of 1)DDA:DOPE, and 2)DDA:TDB. Lane (L) 
represents the DNA ladder and (C) shows the naked DNA. B) As in A, but in the presence of 1.2 % SDS.  
For both liposome formulations tested in the absence of SDS (Figure 6.5A, lane 1,2 and 
Figure 6.5C, lane 1,2), DNA migration is not seen, as the plasmid DNA remains 
associated with the liposomes and is retained within the wells of the gel. In the presence 
of the competitive anionic molecules of SDS, the liposomes can be disrupted and the 
plasmid DNA released (Figure 6.5B, lane1,2). With the liposomes that were exposed to 
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DNase I (Figure 6.5D, lane 1,2), plasmid DNA can still be seen, demonstrating that 
both DDA:DOPE and DDA:TDB were able to protect the DNA from degradation 
contrary to the naked DNA, which is rapidly digested.  
 
Figure 6.5: Gel electrophoresis of free and liposome entrapped plasmid DNA before and after exposure to 
digestive enzyme, DNase I. A) Gel electrophoresis of 1) SUV DDA:DOPE, 2) SUV DDA:TDB before 
exposure to DNase I with no SDS, B) same as A but in the presence of SDS, C) same as A but after 
exposure to DNase I with no SDS, D) Same as C but in the presence of SDS. Lane (L) represents the DNA 
ladder and lane (C) represents naked DNA. 
6.5. In vitro DNA release 
The release of DNA from DDA:DOPE and DDA:TDB was investigated in PBS, pH 
7.4, 37 °C. As it is shown in Figure 6.6, there is no significant difference in the DNA 
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release rate between the formulations; and similar to the SUV lipoplexes investigated in 
Chapter 4, there is a burst release after 4 hours, which is 20% of total DNA entrapment 
(Figure 6.6).  After 24 hours the DNA release increased to 30%, and to 40% after 48 
hours again with no significant difference between the formulations. From this point, 
the release rate becomes slower, as after 4 days the release rate for both of the lipoplexes 
were 45% and finally the total DNA release for DDA:DOPE and DDA:TDB reached to ≈ 55% after 8 days (Figure 6.6).  
 
Figure 6.6. DNA release of SUV lipoplexes of DDA:DOPE and DDA:TDB in PBS, pH 7.4 and at 37 °C at 
time points of 2, 4, 24, 48, 96 and 192 hours. Results represent percentage release initially loaded DNA 
expressed as mean±SD, for three independently prepared batches. 
The similarity in release profiles again demonstrates that DDA has the main role in the 
DNA release behaviour, as the electrostatic interactions between anionic DNA and 
cationic DDA is the main interaction involved in complex formation. The presence of 
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DOPE vs TDB makes no impact on the measured characteristics, with the formulations 
having similar zeta potentials (Figure 6.3B), DNA association (Figure 6.3C) and similar 
results for gel electrophoresis studies (Figure 6.4). 
6.6. Studying the in vitro transfection efficiency of DDA-
based lipoplexes 
To investigate the transfection efficacy of the two formulations, the ability of the 
systems to transfect COS-7 cells with plasmid DNA encoding for luciferase was 
measured and compared to the marketed Lipofectin™ which is made of 
DOPE:DOTMA (Felgner et al., 1987) as a control.  In addition, cell viability was 
measured using the MTS assay. 
Cytotoxicity studies show that cell viability was significantly lower (P<0.05) after 
incubation with the DDA:DOPE formulations compared to cells incubated with 
plasmid DNA alone (Figure 6.7A). This is in line with a previous study performed by 
McNeil et al (2010), showing similar results for DDA:DOPE. However, this did not 
translate into transfection efficacy; the DDA:DOPE formulation was able to promote 
transfection, at levels similar to Lipofection, however, DDA:TDB, whilst having less 
impact on cell viability, did not promote transfection (Figure 6.7B).  
Previous studies showed that having cationic charge on the surface of the liposome 
might not be sufficient to initiate high transfection and other parameters might be 
involved on transfection efficacy of the cationic liposomes (McNeil et al., 2010; 
Ramezani et al., 2009). These present results also confirm this, although DDA is a 
cationic lipid, when combined with TDB, the cationic SUV were unable to promote 
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transfection, despite no measured difference in commonly studied physico-chemical 
characteristics. 
 
Figure 6.7. A) Relative cell viability of cationic liposomes. B) Comparison of transfection efficiency of 
cationic liposomes. All results denote mean±SD, for three independently prepared batches.  
Clearly, although studies have demonstrated that DDA:TDB is a promising vaccine 
adjuvant for subunit vaccines and can promote cellular uptake (Henriksen-Lacey et al., 
2011b), it is not an ideal transfection reagent with low luciferase activity of 30% (Figure 
6.7B). Comparing DDA:TDB and DOPE:DDA suggests the effect of helper lipid 
DOPE is required to enhance the transfection efficiency of DDA. Felgner et al., in 1987 
demonstrated that transfection activity of DOTMA increases when is formulated with 
DOPE instead of DOPC (Felgner et al., 1987) and it has been proposed that DOPE has 
the ability of promoting the transition from lamellar phase to an inverted hexagonal 
phase, as the inverted cone shaped structure of DOPE promotes the conversion of the 
lamellar lipoplexes phase into a non-lamellar structure. It has also been suggested that 
after endosomal uptake of the lipoplexes, the presence of DOPE in the formulation 
causes destabilisation of endosomal membrane leading to entrance of free DNA to the 
cytosol (Ciani et al., 2004; Farhood et al., 1995; McNeil et al., 2010). This might explain 
higher transfection efficacy of DOPE:DDA comparing to DDA:TDB.  
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6.7. Biodistribution studies: Vaccine localisation after 
intramuscular immunisation.  
Previous studies reveal that DDA-based subunit vaccines are able to form a high depot 
effect at the injection site (Henriksen-Lacey et al., 2010b), which leads to the prolonged 
and sustained presence of the antigen at the local draining lymph nodes. This is shown 
to be effective for initiating the immune responses, as more antigens will be exposed to 
the APCs and as a result TLRs enhance Th1 and Th2 immune responses (Henriksen-
Lacey et al., 2010b). 
Therefore, to investigate the depot formation abilities of DDA-based DNA vaccines, the 
concentration of the liposomal carrier and the DNA was measured at the site of 
injection, the local draining lymph node (PLN), the liver, spleen, kidney and lungs using 
a dual radiolabelling method (Henriksen-Lacey et al., 2010a). Similar to the results of 
chapter 4 for DOTAP and DSTAP DNA vaccines, only injection site and PLN showed 
detectable levels of lipid and DNA (Figure 6.8) and other organs results were negligible 
(and therefore data not shown).  
DNA associated with both the DDA-formulations, gave enhanced retention at the 
injection site, with approximately 40 % to 60% of the liposome-associated DNA 
remaining at the injection site after 24 h for DDA:DOPE and DDA:TDB, with no 
significant difference (Figure 6.8A). Over time the amount of DNA retained at the 
injection site decreased, and after 8 days levels had fallen to approximately half of those 
on day 1. However, the levels of DNA retained at the injection site was still significantly 
(P<0.05) higher than naked DNA (Figure 6.8A). In terms of lipid retention, a similar 
trend is seen for both formulations, with no significant difference between DDA:DOPE 
and DDA:TDB at each of the time points measured (Figure 6.8A). 
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The distribution of vaccine components to the draining PLN is shown in Figure 6.8B. 
Results show that the amount of detectable DNA and lipid for both formulations at the 
PLN increased over the time. The retained DNA at the PLN on day 1 for the lipoplex 
formulations was less than 0.003% and this amount increased to about 0.005% by day 8 
(Figure 6.8B).  
Overall the retention of the vaccine components at the injection site and PLN did not 
show any significant difference between the two DDA-based liposome formulations 
(Figure 6.8). This suggests that the presence of DOPE vs TDB has no impact on the 
biodistribution of the formulations, which could be an outcome of their similar charge 
and antigen retention. Indeed, previous studies considering DDA:TDB formulations 
suggest that the vesicle size of these highly cationic vesicles made no difference to their 
biodistribution and the primary driving factor for clearance rates is the charge of the 
vesicles (Henriksen-Lacey et al., 2011b). Using pontamine blue as a tracker for 
monocyte influx (Carstens et al., 2011; Henriksen-Lacey et al., 2010b; Tilney, 1971a), 
Figure 6.9 shows that the DDA:TDB promoted much higher levels of monocyte 
recruitment compared to the DDA:DOPE formulation. 
Higher monocyte infiltration for DDA:TDB is believed (Henriksen-Lacey et al., 2010b) 
to be due to the role of immunomodulating molecule of TDB in the activation of the 
innate immune system in the influx of circulating monocytes to the site of injection. 
This is in agreement with the previous study (Henriksen-Lacey et al., 2010b) that 
reported TDB when administered in DDA liposomes activates APCs. The present 
results (Figure 6.8 and 6.9) show that DDA based liposomes are efficiently able to 
promote antigen retention at the injection site, as both systems showed similar retention 
of the lipid and the plasmid DNA at the site of injection and lymph node (Figure 6.8).  
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Figure 6.8. pDNA and liposome detection A) at the site of injection and B) draining lymph nodes (PLN) 
following i.m. injection of DDA:DOPE and DDA:TDB liposomes. pDNA and liposome quantification 
were determined at days 1,4 and 8 p.i. using radiolabel counting methods. Data represents mean ± SD of 4 
mice and is presented % dose at the SOI (B,C) or the % dose per mg PLN harvested (D,E). Naked DNA 
included for comparison.  
 
Given the similar antigen and liposome retention at the site of injection and the local 
draining lymph node (Figure 6.8) and the higher monocyte infiltration at the injection 
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site for DDA:TDB (Figure 6.9) would suggest the necessity of presentation of the 
antigen along with the liposome to the APCs for higher immune response. Previous 
studies have also reported this finding (Christensen et al., 2012; Kamath et al., 2009). 
 
Figure 6.9: Pontamine blue staining on day 8 p.i. of the injection site after i.m injection with DNA 
lipoplexes of DDA:DOPE, DDA:TDB and naked DNA.  
6.8. Immunisation studies 
To investigate the potential of these DDA-based lipoplexes as DNA vaccine adjuvants, 
both the DDA:DOPE and DDA:TDB formulations were considered in a heterologous 
prime-boost vaccination strategy. Previous research on Hepatitis B vaccines have been 
performed in two different homologous immunisation methods; DNA vaccines were 
designed by using plasmid DNA pRc/CMV HBS which encodes the HBsAg protein 
(Bramwell et al., 2002; Gregoriadis et al., 1997; McNeil et al., 2010; Perrie et al., 2001) 
or subunit vaccines using HBsAg antigen (Brunel et al., 1999; Vangala et al., 2007; 
Vangala et al., 2006). DOTAP and DC-Chol were used extensively in DNA vaccine 
studies and DDA:TDB used in subunit vaccine study against HBV. To investigate the 
effect of prime-boost immunisation and compare the effect of this heterologous 
immunisation regimen with previous homologous strategies, in this current study 
DDA:DOPE and DDA:TDB were formulated as prime DNA lipoplex and boost 
subunit-liposome complex as explained in section 2.2 and injected as mentioned in 2.10. 
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The specification and characterisation results of DDA:DOPE and DDA:TDB plasmid 
DNA and subunit protein complex formulations are shown in details in Table 6.2. 
Table 6.2: Characteristics of cationic liposomes od DDA:DOPE and DDA:TDB. Size and zeta potential 
measured by Malvern Zetasizer Nano-ZS. Results represent mean±SD of triplicate experiments. 
 
6.8.1. Antibody production in response to DDA-based vaccines 
HBsAg specific antibody titres were determined by antibody ELISA. For total IgG 
levels, both DDA:DOPE and DDA:TDB were able to induce significantly higher 
(P<0.001) levels of IgG relative to free antigen and alum on days 36 and 49 of the 
immunisation study, however, there was no significant difference between these 
liposome formulations (Figure 6.10A).  
Figure 6.10B demonstrates the IgG1 and IgG2b responses on day 49; for IgG1 levels, 
again both DDA:DOPE and DDA:TDB have similar responses; however, their 
responses are significantly lower (P<0.05) than the alum group which has the highest 
IgG1 responses compared to the liposomes and free DDP. This shows the alum’s 
potency to provide Th2 responses (Brunel et al., 1999; O'Hagan and Valiante, 2003; 
Rosenkrands et al., 2005; Yang and Hayglass, 1993).  
IgG2b antibody isotype immune responses of groups which received formulations show 
DDA:TDB liposomes induce significantly (P<0.01) higher IgG2b production than 
DOPE:DDA. Interestingly, alum and free subunit antigen did not show any detectable 
Chapter 6: DDA-based DNA Vaccine Formulations: From Characterisation to In Vitro & In Vivo Studies D 
 
208 
levels of antibody responses for IgG2b; however, the free DDP group (which is the 
prime boost immunisation of the plasmid DNA and the subunit protein) shows 
detectable amounts of IgG2b production (Figure 6.10B) which could be due to the 
heterologous immunisation as discussed in chapter 5.  
As mentioned above, Alum formulations promote a Th2 bias, which shows a high level 
of humoural immune responses and fail to show cellular responses (Brunel et al., 1999; 
Davidsen et al., 2005; Diminsky et al., 1996; O'Hagan and Valiante, 2003; Rosenkrands 
et al., 2005). Conversely, DDA:TDB induces a high level of IgG2b responses (Figure 
6.10B), suggesting the ability to induce cellular immune responses. This is in line with 
previous studies which showed the high levels of Th1 responses induced by DDA:TDB 
formulations for different antigens (Henriksen-Lacey et al., 2010b; Henriksen-Lacey et 
al., 2011a; Vangala et al., 2007).  
Giving similar levels of total IgG and IgG1 production, both DDA:TDB and 
DDA:DOPE show the adjuvant effect of cationic lipids and, in particular, DDA, which 
induces a significantly (P<0.05) higher humoural immune response compared to free 
antigens. This has been reported by several studies (Henriksen-Lacey et al., 2010b; 
Henriksen-Lacey et al., 2010c; Vangala et al., 2007) with the very first one was shown 
by Gall et al (Gall, 1966).  
This present study also shows that DDA:TDB group induces significantly (P<0.05) 
higher Th1 responses compared to DDA:DOPE group, suggesting that 
immunomodulating TDB has a crucial role in stimulation of Th1 responses and high 
immunogenicity of DDA:TDB formulation.  
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Figure 6.10. HBsAg specific antibody titres. A) Total IgG titre of DDA:DOPE and DDA:TDB, serum 
taken from day 36 and 49, B) IgG1(white bars) and IgG2b(black bars) levels for DOPE:DDA, DDA:TDB, 
serum taken from day 49. Results compared to alhydrogel, free DDP, free subunit antigen, free DNA and 
naïve group. Results show the mean ± SD reciprocal endpoint dilution (log10) of 5 mice. Significance 
measured by one-way ANOVA and Tukey’s post test, it is shown by *p<0.05 and ***P<0.001.   
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6.8.2. Investigating the cytokine production level in response to 
heterologous vaccination by DDA-based liposomes 
The ability of DDA:DOPE and DDA:TDB to elicit cell-mediated as well as humoural 
immune responses was evaluated by measuring endogenous cytokine levels (IL-2, IL-5, 
IL-6, IL-10 and IFN-γ) within spleen homogenates to assess the presence of Th1/Th2 
response.  IL-1ß levels were also studied to see how vesicular vaccine adjuvants promote 
antigen uptake at the SOI.  
To determine the cellular immune responses, IL-2 and IFN-γ levels were determined. 
Results (Figure 6.11) show that DDA:TDB produced significantly (P<0.001) higher 
levels of IL-2 and IFN-γ compared to DDA:DOPE. Induced levels of IL-2 for 
DDA:DOPE was 1000 pg/mL compared with 1800 pg/mL for DDA:TDB (Figure 
6.11A). Similarly IFN-γ levels induced by DDA:TDB were almost 2 fold higher than 
DDA:DOPE (4800 Vs 2500 pg/mL) (Figure 6.11E). In both cases, the liposome 
formulations promoted immune responses significantly higher than those of alum or 
free DDP (Figure 6.11A,E).  
Levels of Th2 indicator cytokines (IL-5, IL-6 and IL-10) were also measured to 
investigate the ability of the mentioned liposomes in induction of humoural immune 
responses. As it is demonstrated in Figure 6.11B and D, the induced levels of IL-5 and 
IL-10 for both liposomal vaccines are similar (80 pg/mL for IL-5 and 100 pg/mL for IL-
10) and significantly (P<0.05) higher than free DDP levels (Figure 6.11B and D).  
Since IL-5 and IL-10 are indicators of humoural immune responses, restimulation of 
alum group splenocytes promoted high levels of IL-5 and IL-10 comparable to 
liposomal groups. Data shows induced IL-5 levels for alum group was 60 pg/mL which 
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was not significantly different from IL-5 levels for DDA:DOPE and DDA:TDB (Figure 
6.11B). 
Alum cytokine production levels for IL-10 is even more interesting with 150 pg/mL, 
which was significantly (P<0.001) higher than DDA:DOPE and DDA:TDB cytokine 
production level (Figure 6.11D). For IL-6, DDA:TDB cytokine levels were above 500 
pg/mL which is significantly (P<0.001) higher than DOPE:DDA with 300 pg/mL 
(Figure 6.11C). Both liposomes produced notably (P<0.05) higher IL-6 than alum and 
free DDP, however alum levels were also higher than background levels (Figure 6.11C). 
This shows an intermediate response for IL-6, which has both Th1 and Th2 parameters. 
IL-6 is known to represent Th2 responses, although this cytokine also promotes 
differentiation of Th17 cells with production of IL-17 and has been reported to detect 
both cellular and humoural responses (Diehl and Rincon, 2002; Dienz and Rincon, 
2009; Henriksen-Lacey et al., 2011b). This explains the specific trend of IL-6 cytokine 
levels that have been achieved in this experiment.  
Studying the amount of produced IL-1ß at the SOI shows that not only the liposome 
formulation, but also alum, free DDP, free subunit antigen and free DNA are able to 
activate dendritic cells to induce the innate immune response; however, DDA:TDB 
levels of IL-1ß are significantly (P<0.001) higher than other immunised groups (Figure 
6.11F). This data supports the results provided by pontamine blue staining (Figure 6.9), 
showing higher stimulation of innate immune system for DDA:TDB.  
Chapter 6: DDA-based DNA Vaccine Formulations: From Characterisation to In Vitro & In Vivo Studies D 
 
212 
 
Figure 6.11. IL-2, IL-5, IL-6, IL-10 and IFN-γ cytokine production from splenocytes (A–E) and IL-1β 
production from excised leg muscle from the SOI (F) derived from mice immunised with DDA:DOPE or 
DDA:TDB pDNA-lipoplex or subunit protein liposome , compared to free DDP, free subunit antigen, free 
DNA, alhydrogel and naïve group. Splenocytes and muscle from the SOI were obtained 3 weeks post the 
final immunisation. Splenocytes were restimulated for 48 h in the presence of HBsAg (5 µg/mL). Leg 
muscle was excised, digested and homogenised. Cytokines were measured from splenocyte or muscle 
supernatants using sandwich ELISAs. 
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Overall, these results (Figures 6.11) demonstrate similar Th2 immune responses for both 
liposomes however the Th1 responses induced by DDA:TDB are higher than those 
promoted by DDA liposomes. As it has been reported earlier (Davidsen et al., 2005; 
Henriksen-Lacey et al., 2010b; Holten-Andersen et al., 2004; Vangala et al., 2007) the 
presence of TDB in the liposomal structure causes more immunogenicity for 
DDA:TDB. Two key factors have been defined as the main reasons that incorporation 
of TDB to DDA induce higher immune responses by DDA:TDB rather than 
DDA:DOPE;  
1- TDB is synthetic version of the glycolipid which is in the cell wall of the 
tuberculosis bacteria and based on this it provides more immunogenicity to the 
liposome formulations (Olds et al., 1980; Pimm et al., 1979).  
2- TDB stabilise the DDA liposomes by inhibiting the fusion between phospholipid 
vesicles due to the relatively large headgroups of trehalose. This would increase 
the hydration of the liposomal surface and prevent the dehydration of the 
quaternary ammonium headgroups so no aggregation would occur. Moreover, 
due to its large headgroup, trehalose might prevent close contact between 
opposing liposome and consequently prevent the aggregation of the liposomes 
(Crowe et al., 1994; Spargo et al., 1991). 
6.8.3. Splenocyte proliferation ex vivo in response to HBsAg 
Using spleens of immunised mice in an ex vivo splenocyte proliferation assay, the ability 
of DDA:DOPE and DDA:TDB liposomes to deliver the antigen to antigen presenting 
cells (APCs) was explored. Therefore splenocytes were restimulated with 0.05, 0.5 and 5 µg/mL HBsAg antigen in addition to the positive control stimuli Con A (5 µg/mL). 
Figure 6.12 shows the proliferative ability of splenocytes of all immunised groups in 
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response to Con A. It is shown that all the groups showed response to Con A as the 3H-
thymidine uptake was shown to be between 30000 to 40000 CPM (Figure 6.12).  
 
Figure 6.12: Splenocyte proliferation of each immunisation group and naïve group in response to 
stimulation with 5 µg/mL Con A. Splenocytes were derived on day 49 of the study and restimulated ex vivo 
with Con A as a positive control. After a further 24 hrs cells were harvested and the proportion of 3H-
thymidine incorporated in the cells measured using standard scintillation counting. 
Figure 6.13 demonstrates that increasing the pooled HBsAg concentration increases the 
splenocyte proliferation of the formulations. Upon restimulation, with DDA:TDB 
immunised group showed the highest level of splenocyte proliferation with 4000 CPM 
at 5 µg/mL of HBsAg.  
The level of splenocyte proliferation for DDA:TDB significantly increased (P<0.05) 
from 1500 to nearly 4000 CPM when the HBsAg concentration increased to 0.5 µg/mL 
of HBsAg  (Figure 6.13). Comparing DDA:TDB to DDA:DOPE shows the splenocyte 
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proliferation levels for DDA:TDB is significantly (P<0.05) higher than DDA:DOPE in 
0.5 and 5 µg/mL of HBsAg; however, in lower concentrations of HBsAg, similar results 
were seen for both formulations. This shows the effect of TDB as an 
immunomodulating agent in inducing higher levels of cell proliferation, which is in line 
with a previous study (Vangala et al., 2007) where it is shown that presence of TDB in 
liposome formulation has a crucial role in increasing the cell proliferation and in total 
initiating the cell mediated immunity compared to other cationic liposomes with no 
TDB in their formulation.  
 
Figure 6.13. Spleen cell proliferation in response to stimulation/re-stimulation with HBsAg antigen. Cell 
proliferation was measured by incorporation of 3H into cultured splenocytes. Splenocyte proliferation of 
DOPE:DDA and DDA:TDB injected under heterologous regimen, compared to free DDP, free subunit 
antigen, free pDNA, alhydrogel and naïve group. ** denotes significantly increased proliferation in 
compare to naïve controls (n=5 p<0.01).  
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Alternatively, although DDA:DOPE showed lower cell proliferations compared to 
DDA:TDB, its level of splenocyte proliferation were significantly higher than alum and 
free antigens (Figure 6.13), suggesting the ability of cationic liposomes to improve 
splenocyte proliferation level and delivering the antigen to the APCs. 
6.9. Conclusion 
The aim of this study was to evaluate the immunogenicity of DDA-based liposomes as 
DNA vaccines and in a heterologous prime boost immunisation regimen. 
From the monolayer studies and characterisation measurements, no notable differences 
in physicochemical characteristics of DDA:DOPE and DDA:TDB were observed, 
however their biological activity has been shown to be significantly different. Although 
DDA is a cationic lipid, lipoplexes of DDA:DOPE and DDA:TDB are not competitive 
transfection reagents compared to formulations including DOTAP and DSTAP (Section 
4.6; Chapter 4). Comparing DDA:DOPE and DDA:TDB shows the presence of TDB 
does not have specific impact on characteristic properties of the lipoplexes, however 
absence of DOPE dramatically reduced the in vitro transfection of DDA:TDB. This can 
be due to the effect of DOPE as a helper lipid to change the liposome structure from 
lamellar to HII inverted hexagonal, which is believed to be more beneficial for in vitro 
transfection efficiency of the lipoplexes (Felgner et al., 1987). The concept of using a 
fusogenic lipid such as DOPE is to mimic attributes of viruses when fuse with the cell 
membrane and delivering their genetic material into the cytosol (McNeil and Perrie, 
2006). It has been reported that incorporation of DOPE into the liposome formulations 
enhances the transfection efficiency of the liposomes (Farhood et al., 1995) and this 
could be the reason of low transfection efficiency of DDA:TDB. 
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Considering the localisation of the DDA:DOPE and DDA:TDB at the injection site and 
drainage of the liposome contents to the local draining lymph node showed no 
significant difference between the two formulations, however pontamine blue staining 
results demonstrated more monocyte influx for DDA:TDB which is known to be due to 
the incorporation of immunostimulant molecule of TDB within the liposome structure. 
These observations are in correlation to what has been observed previously (Henriksen-
Lacey et al., 2010b), suggesting the co-stimulatory effect of the adjuvant and the antigen 
and their presentation to the APCs at the lymph node is essential for stimulation of a 
high immune response (Christensen et al., 2012; Henriksen-Lacey et al., 2010b; Kamath 
et al., 2009). 
Immunisation studies including exploring antibody and cytokine production of 
DDA:DOPE and DDA:TDB reveal that both formulations show a similar humoural 
immune response; however, DDA:TDB liposomal vaccine shows a significantly higher 
cellular immune response compared to DDA:DOPE. Results show similar total IgG 
and IgG1 levels for both liposomes as well as similar IL-5 and IL-10 cytokine levels as a 
result of intramuscular heterologous prime boost immunisation of these formulations, 
show humoural immune system is triggered similarly by both formulations.  In contrast, 
it has been observed that IgG2b levels produced by DDA:TDB were significantly higher 
than DDA:DOPE. Furthermore, results of cytokine study showed the same trend for 
the IL-2 and IFN-γ production levels, suggesting that DDA:TDB induces higher cell 
mediated immune response rather than DDA:DOPE. The results are in agreement with 
previous studies (Henriksen-Lacey et al., 2010b; Holten-Andersen et al., 2004; Vangala 
et al., 2007).  They suggest higher cellular immune response of DDA:TDB is related to 
the incorporation of TDB into the DDA bilayers, which increases the immunogenicity 
of the liposomes as well as stabilising them. 
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7.1. Monolayer studies: lipid packaging configurations 
Lipid monolayer studies have been shown to be able to increase the understanding of 
bilayer structures, hence it can add knowledge into areas such as the bilayer lipid 
packaging configurations (Dynarowicz-Latka and Hac-Wydro, 2004), drug-lipid 
interactions (Sun et al., 2004) and liposome stability (Crowe et al., 1984).  
The aim of monolayer studies in this project was to study molecular lipid packaging and 
interactions, and correlate the results with the physico-chemical properties of the 
liposomes. Studies demonstrated that saturated lipids have closer packaging 
arrangements compared to their unsaturated analogues and this influences the bilayer 
formation as using two saturated lipids, such as DSPE and DSTAP, failed to form 
liposomes. Characterisation studies also showed liposomes containing saturated and 
rigid lipids had a tendency to aggregate with DNA molecules, which caused larger 
vesicle sizes in comparison to liposomes made of unsaturated lipids. Studying the 
mixture of the unsaturated and bulky DOPE with the saturated and rigid DSTAP in 
monolayers showed that presence of DOPE reduces the rigidity of DSTAP, which can 
be translated to the high release profile and high in vitro transfection of DOPE:DSTAP 
lipoplexes.  
For liposomes to be able to transfect cells efficiently, they need to be more fluidic in 
nature so they can destabilise the lipid membrane of the cells, therefore DOPE as a 
fusogenic lipid has been used extensively to enhance the cell transfection. Monolayer 
studies conducted within this thesis have shown that incorporation of DOPE with 
DSTAP reduced the rigidity of DSTAP to a similar level of the DOPE:DOTAP. 
Considering transfection efficiency of DOPE:DOTAP and DOPE:DSTAP, both 
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formulations have higher transfection efficiency than a marketed transfection reagent 
(Lipofectin). 
In conclusion, the monolayer studies were shown to be effective in giving insight into 
the molecular packaging of the lipids, which is helpful for understanding liposomal 
molecular packaging, and hence the liposomal delivery systems.  
7.2. Investigating the effect of electrolyte on liposomal 
vaccine formulations 
It has been reported that presence of small amounts of salt (30 mM) within cationic 
liposomes could enhance immune responses of the vaccine (Yan and Huang, 2009). 
This was due to the interference of salt with the electrostatic interactions between the 
cationic lipid and the antigen, which enhances the antigen release from the liposomes 
and at the same time activates the antigen presenting cells. Therefore, to investigate the 
effect of presence of NaCl within the liposomes on their physicochemical properties, in 
vitro transfection efficiency and immune performances, DOPE:DOTAP and 
DOPE:DSTAP liposomes were hydrated with PBS or dH2O (Sucrose for in vivo studies).  
Characterisation studies showed that the presence of electrolytes within the liposomes 
could lead to increases in the vesicle size of the formulations due to the reduction in 
electrostatic interactions between systems and the effect of the phosphate group of PBS, 
which initiates bridging of the polar headgroups of the lipids. Although no influence was 
observed on DNA association within the lipoplexes as a result of electrolyte existence in 
the formulations, it decreased the cationic surface charge of the lipoplexes, which was 
attributed to the neutralisation effect of buffer electrolytes on zeta potential. These 
results are in line with the previous studies, which shows presence of salts increases the 
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vesicle size (Ciani et al., 2007; Wasan et al., 1999) and reduces the zeta potential (Li and 
Hui, 1997). 
In vitro transfection studies showed no correlation with characterisation results, as the 
presence of electrolytes did not show a trend on transfection efficiency. This suggests 
that the key feature in transfection efficacy could be the lipid composition rather than 
vesicle size or hydration buffer electrolytes. In contrast, previous studies (Ogris	   et	   al.,	  1998) showed that the impact of salt on transfection efficiency is basically due to the 
increase in vesicle size of the systems, which is shown to cause higher transfection 
efficiency	  (Eastman	  et	  al.,	  1997;	  McNeil	  et	  al.,	  2010).  
Similar to the transfection efficiency, the presence of salt within the liposomes did not 
make a significant impact on localisation of the liposomes and plasmid DNA at the 
injection site, showing that not all of the characterisation measurements are translatable 
to in vitro and in vivo studies. In contrast, immunisation studies showed that 
formulations hydrated in sucrose induce higher humoural immunity than the 
formulations which incorporated electrolytes within their system, whilst the cellular 
immune system activity remained similar for both kinds of liposomes. This is in 
agreement with a previous study (Henriksen-Lacey et al., 2011b), which shows the 
presence of PBS in the formulations caused aggregation and this led to a poor immunity 
performance by DDA:TDB formulations. It has been described that aggregation of the 
vesicles at the injection site would slow down and reduce the rate of antigen 
presentation at the lymph node and consequently would decrease the immune response.  
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Overall, it has been shown that the main impact of the presence of salt in the liposomal 
formulation is on its characterisation parameters; particularly increases in the vesicle 
size of the liposomes, which eventually causes a reduction in immune responses.  
7.3. Impact of lipid composition on liposomal vaccines 
The importance of cationic charge and antigen (subunit protein or plasmid DNA) 
adsorption to the lipids for a liposomal vaccine has been established, therefore the role 
of cationic lipid structure was investigated as unsaturated cationic lipid of DOTAP was 
compared to the saturated DSTAP in terms of characterisation studies, in vitro and in 
vivo studies.  
While characterisation studies showed no significant difference in vesicle size, zeta 
potential and DNA association of the liposomes when DOTAP replaced by DSTAP, in 
vitro studies demonstrated significantly higher transfection efficiency for DSTAP-based 
lipoplexes. This is in contrast with previous studies, which have reported more rigid 
bilayers (Kudsiova et al., 2011; Wasungu and Hoekstra, 2006) produce lower 
transfection in cells. Higher transfection efficiency of DSTAP-based lipoplexes is 
believed to be due to the fluidic effect of DNA (Lobo et al., 2002) and DOPE on 
bilayers of DSTAP and the instability of this system compared to DOPE:DOTAP 
(Regelin et al., 2000). In addition, it has been described that high positive deviation from 
ideal extrapolated area of the monolayers can lead to increased instability of the bilayer 
system, and hence facilitating the fusion of the liposome and the cell membrane, and 
higher transfection efficiency of the lipoplexes (Hac-Wydro and Wydro, 2007; Hac-
Wydro et al., 2007).  
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In vivo studies showed higher localisation of lipid and DNA at the site of injection for 
DSTAP-based liposomes, which is attributed to the higher transition temperature, and 
rigidity of DSTAP bilayers. This is in line with previous studies which showed fluidic 
bilayers will be cleared faster compared to the rigid bilayers (Christensen et al., 2012; 
Henriksen-Lacey et al., 2011a). A stronger depot effect for DSTAP-based liposomes can 
cause a higher chance for antigen presentation to APCs, which are located in local 
lymph nodes leading to higher activity of CD8+ T cells via MHC II molecules and 
consequently stronger cellular and humoural immune response for DSTAP 
formulations. Recent studies confirm similar results for DDA:TDB liposomal subunit 
vaccine (Christensen et al., 2012; Henriksen-Lacey et al., 2011a).  
7.4. SUV vs DRV: The effect of liposomal preparation 
method on their in vitro and in vivo attributes  
The dehydration-rehydration method has been shown to be effective in entrapment of 
plasmid DNA within liposomes (Kirby and Gregoriadis, 1984), therefore a comparison 
has been made between SUV and DRV liposomes to see the effect of dehydration-
rehydration method on characteristic properties, as well as in vitro transfection efficiency 
and immune performance of the liposomes.  
The physiochemical characteristics of DRV liposomes composed of DOPE:DOTAP 
and DOPE:DSTAP revealed that in contrast to SUV liposomes, vesicle size and zeta 
potential values did not change significantly in the presence of DNA. This suggests that 
the plasmid DNA was entrapped within bilayers of the cationic DRV liposomes, 
presumably bound to the cationic charge of the inner bilayers when produced by the 
dehydration-rehydration procedure. Gel electrophoresis studies supported these results 
as only minimal amounts of DNA was displaced by SDS molecules for DRV liposomes. 
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However, observation of the higher transfection efficiency of SUV liposomes compared 
to DRV formulations shows having entrapped DNA within the liposomes may not be 
advantageous. This could be attributed to the inability of the entrapped DNA escaping 
the vesicles in the time duration of the experimental protocol. In vivo studies showed 
that whilst localisation of both SUV and DRV liposomes at the injections site were 
similar for both formulations, SUV liposomes induce stronger humoural immunity 
however cell mediated immune response levels for both formulations are similar. This 
implies that there was higher APC uptake for SUV liposomal vaccines, which was 
expected due to higher in vitro transfection efficacy of SUV formulations. This could be 
due to the smaller vesicle size of SUV liposomes compared to DRV formulations. In 
agreement to this finding, it has previously been reported that induction of immune 
response by DNA liposomal vaccines is more related to the higher cell transfection and 
smaller vesicles size of the particles with a optimum size of below 500 nm is desirable 
for APC uptake of the particles (Carstens et al., 2011).  
7.5. How effective are heterologous immunisation 
strategies in providing desirable levels of immune 
response? 
Investigating the effect of immunisation regimens on immune performance of the 
liposomal vaccines, a heterologous vaccination schedule including two injections of 
DNA-liposome vaccines followed by a protein subunit-liposome booster was compared 
to the homologous immunisation strategies composed of either two DNA-liposome 
immunisation or a single protein-liposome vaccination. Results of this study showed the 
occurrence of synergistic response as the activation of immune system in response to the 
heterologous immunisation was higher than each of homologous regimens. Compared 
to prime DNA vaccine administration, heterologous vaccination caused a significantly 
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higher antibody and cytokine production levels. However, the results of prime/boost 
immunisation were not significantly higher than a single injection of liposome-protein. 
Therefore considering the cost and number of injections, subunit protein vaccines seem 
to be more attractive option compared to DNA vaccines or the heterologous vaccination 
strategies.  
7.6. DDA-based liposomal vaccines 
Given a high and solid immune activity for DDA:TDB incorporated with subunit 
antigen of TB; Ag85B-ESAT-6 (Henriksen-Lacey et al., 2010b; Holten-Andersen et al., 
2004) and earlier research which showed the cationic liposomes made from DDA have 
adjuvant properties (Gall, 1966) has led to evaluate DDA-based liposomes as a DNA 
vaccine in a prime/boost immunisation regimen. To investigate the impact of 
immunostimulant TDB molecule on immune response and compare it with fusogenic 
lipid DOPE, which enhances the transfection of the liposomes, DDA:TDB and 
DDA:DOPE formulations were compared in this study.  
While characterisation studies showed larger vesicle size for DDA:TDB compared to 
DDA:DOPE (which can be as a result of more rigidity and aggregation of DDA:TDB 
upon its complexation with DNA) zeta potential and DNA entrapment for the 
formulations did not show significant difference. In vitro transfection efficiency of 
DDA:TDB has been shown to be significantly lower than DDA:DOPE and 
Lipofectin™.	   This	   was	   suggested	   to	   be	   due	   to	   the	   effect	   of	   DOPE,	   which	   acts	   as	   a	  fusogenic	  lipid	  and	  enhances	  the	  destabilisation	  of	  cell	  membrane	  by	  conversion	  of	  the	  DDA:DOPE	  structure	  to	   inverted	  hexagonal	  HII	  structure,	  which	  has	  been	  shown	  to	  be	  ideal	   for	   transfection.	   Biodistribution	   studies	   showed	   no	   significant	   difference	   in	   the	  localisation	  and	  movement	  of	   the	   liposomes	  and	   their	  associated	  plasmid	  DNA	  at	   the	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injection	  site;	  however,	  by	  applying	  pontamine	  blue	  staining	  technique,	  results	  showed	  significantly	  higher	  monocyte	  infiltration	  at	  the	  site	  of	  injection	  upon	  administration	  of	  DDA:TDB	   compared	   to	   DDA:DOPE.	   This	   was	   attributed	   to	   the	   immunostimulatory	  effect	  of	  TDB	  molecule,	  which	  activated	  the	  innate	  immune	  response.	  This	  was	  followed	  by	  the	  immunisation	  studies	  which	  showed	  higher	  cell	  mediated	  immunity	  of	  DDA:TDB	  in	   comparison	   to	   DDA:DOPE	   while	   both	   formulations	   showed	   similar	   levels	   of	  humoural	   immune	  activity.	   In	   agreement	   to	  previous	   studies	   (Henriksen-Lacey et al., 
2010b; Holten-Andersen et al., 2004; Vangala et al., 2007), higher cellular immune 
responses of DDA:TDB is related to the immunostimulatory effects of TDB molecule.  
It is believed that DNA vaccines need high cell transfection to be able to enter to the 
nucleus of the cell, encode the antigen and start the immune activity. However, low 
transfection efficiency of DDA:TDB suggests that strong immune activity of this 
formulation is more attributed to the subunit vaccine injection rather than two DNA 
vaccine immunisations of this heterologous vaccination, and DNA prime injections are 
not necessary to induce immune response for this formulation.  
7.7. Final conclusions 
In summary, investigation of a range of cationic liposome formulations as DNA 
vaccines showed that: 
Ø Monolayer studies can be useful in giving more insight about the bilayer 
structure and molecular packaging of the bilayers, which can be translated to the 
characteristic properties of the liposomes. 
Ø It is known that physicochemical characteristic parameters of cationic liposomes 
have an impact on their in vitro and in vivo behaviours and this study showed 
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lipid composition had the most influence on in vitro transfection and in vivo 
biodistribution of the formulations, as well as their immune performances.  
Ø Applying saturated lipids enhances cell transfection and promotes immune 
responses of the liposomal DNA vaccines. 
Ø Liposomal DNA vaccines induce remarkably stronger cellular and humoural 
immune responses compared to the free DNA administration. 
Ø Although heterologous prime/boost immunisation produces higher immunity 
than homologous vaccination, yet more studies need to be performed to improve 
this technology.  
7.8. Future work 
Further studies can be conducted in continuation of this work. Monolayer studies could 
include investigating the effect of presence of DNA in the subphase on monolayer 
properties of the lipids. This might open new windows to our understanding about lipid-
DNA interactions in bilayer systems. Differential scanning calorimetry (DSC) study can 
be performed on tested lipids and their combination to see the effect of DOPE on 
lowering the transition temperature of saturated lipid such as DSTAP. Also impact of 
incorporation of DNA to the bilayer molecular packaging could be investigated using 
DSC. Microscopic imaging could be conducted showing the size, morphology and 
antigen entrapment within liposomes and possible aggregations. Transmission electron 
microscopy (TEM) would be the method of choice due to nano scale size of the vesicles. 
In vitro transfection studies could include comparing different periods of transfection for 
the liposomes, specially to see the difference in optimum transfection time for SUV and 
DRV liposomes.  
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To perform the biodistribution of the formulations and localisation of the lipid at 
different organs, advanced in vivo imaging instruments such as Spectrum CT and 
VECTor/CT can be used to show a real time data about the localisation of the 
formulation at different time points. This will eliminate need of different groups of 
animals for each time point. 
With regards to the immunisation studies, flow cytometry analysis could be performed 
to give more knowledge about the induced immune responses and the stage of T cell 
differentiation based on cytokine production. Moreover, the immunisation studies could 
be carried on with a challenge study and investigate the effect of the liposomal vaccines 
to protect the animal form the pathogens. Finally, the ability of studied cationic 
liposomes in delivery of nucleic acids can be further investigated by using these delivery 
systems to deliver siRNA to down-regulate the genes which control cancer cells.  
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1- PicoGreen® dsDNA quantification assay 
Quant-iT™ PicoGreen® dsDNA reagent is an ultrasensitive fluorescent nucleic acid 
stain which has been used for quantitating double-stranded DNA (dsDNA) in solution. 
It helps researchers to selectively detect as little as 25 pg/mL of dsDNA with a standard 
spectroflurometer and fluorescein excitation and emission wavelengths. The assay is 
linear over their orders of magnitude and has little sequence dependence, allowing you 
to accurately measure DNA from many sources including genomic DNA, viral DNA, 
miniprep DNA, or PCR amplification products. All graphs and figures shown below 
were obtained from www.invitrogen.com. 
Figure.1 Dynamic range and sensitivity of the Quant-iT™ PicoGreen® dsDNA assay 
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Figure.2 Fluorescence enhancement of the PicoGreen® Quantitiation Reagent upon biding dsDNA, 
ssDNA and RNA. 
 
Figure.3 Fluorescence excitation and emission spectra of PicoGreen® dsDNA Quantitation reagent bound 
to DNA (adapted from Singer et al., 1997) 
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2. Calibration curves used for DNA association calculations 
 
Figure. 4 Low range calibration curve for DNA using PicoGreen assay. Results denote mean ± SD, from 3 
independent patches. 
 
 
Figure.5 Low range calibration curve for DNA using PicoGreen assay. Results denote mean ± SD, from 3 
independent patches. 
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3. Calibration curve for calculation the 3H and 32P in biodistribution study. 
 
 
 
